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ABSTRACT OF DISSERTATION

DESIGN, SYNTHESIS, AND PHARMACOLOGICAL EVALUATION OF THREE
SERIES OF LOBELANE ANALOGS AS INHIBITORS OF THE VESICULAR
MONOAMINE TRANSPORTER (VMAT2)

Methamphetamine (METH) abuse is a serious problem in the United States and
worldwide. The reward experienced by METH users is due to the increase in
extracellular dopamine (DA) concentrations caused by an interaction between METH and
the DA transporter (DAT) as well as the Vesicular Monoamine Transporter-2
(VMAT2). The reward felt by users of METH leads to further use of the drug and
subsequent abuse. The current project examined the ability of three novel series of
lobelane analogs to interact with a binding site on the Vesicular Monoamine Transporter2 (VMAT2) in an attempt to inhibit the effects of METH. Lobelane is a defunctionalized
analog of Lobeline, a natural product found in Lobelia inflata which has been shown to
bind to VMAT2 and inhibit its function. Rational drug design methodology and organic
synthesis was used to generate a library of three series of lobelane analogs. In total, 107
compounds were synthesized and examined. Compounds were assayed for affinity in a
high-throughput [3H] dihydrotetrabenazine (DTBZ) radioligand binding screen as well as
for function in a [3H] DA uptake assay. Several compounds were identified which
possess affinity as well as selectivity for the DTBZ binding site on VMAT2 [JPC-077
(Ki=0.19 µM), JPC-094 (Ki=0.15 µM), JPC-096 (Ki=0.19 µM), and JPC-106 (Ki=0.19
µM)]. The same four compounds exhibited inhibition of [3H]DA uptake [JPC-077
(Ki=9.3 nM), JPC-094 (Ki=13 nM), JPC-096 (Ki=20 nM), and JPC-106 (Ki=83 nM)].
With the assay data generated from the library of compounds, several structure activity
relationship (SAR) based ligand based pharmacophore models were developed to guide
future ligand design.
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Chapter 1
Goals of the study and literature review
1.1 Hypotheses
This study involved three central hypotheses. One hypothesis of this work was
that structural analogs of lobelane that maintain the 2,6-diphenethylpiperidine scaffold
but introduce preferred moieties into the phenyl rings present in lobelane can be designed
and synthesized that increase binding affinity for the vesicular monoamine transporter-2
(VMAT2), and that these analogs will increase the functional inhibition of VMAT2 and
modify the effects of Methamphetamine (METH) on VMAT2. A second hypothesis of
this work is that structural analogs of lobelane in which the 2,6-phenethyl moieties
lobelane are changed to 1,4-phenethyl moieties will lead to a further increase in affinity
for VMAT2, and also increase potency to functionally inhibit VMAT2 to better modify
the effect of METH on VMAT2. A third hypothesis of this work was that introduction of
heteroatoms into the piperidine ring of the lobelane scaffold will result in compounds
with increased water solubility, while maintaining improved affinity for VMAT2 when
compared to lobelane.
1.2 Overall Aims
Psychostimulant abuse has become a severe worldwide problem that has shown
no sign of lessening the hold that it has on much of mainstream society. There exists an
ongoing need for new therapies and medications that can provide efficacy in the
treatment of psychostimulant abuse. METH especially is identified as an addictive and
increasingly popular psychostimulant drug, and there are no effective Food and Drug
Administration (FDA) approved pharmacological treatments available for the addicts
1

who wish to quit. This project has been designed to address those people who currently
abuse psychostimulants such as METH and need an effective therapy that will help them
to break away from their addiction. Within the following dissertation, the design and
synthesis of a library of analogs similar to lobelane is described, with alterations designed
into the molecules in an attempt to make them more potent at the target protein: VMAT2,
and to ultimately provide one or multiple candidates that could ultimately become a
treatment for psychostimulant abuse for the part of the population that currently abuses
psychostimulants but wishes to quit.
1.3 Methodology to be utilized in this study
•

To utilize the established drug discovery process to afford likely candidates for
treatment of METH abuse

•

To design molecules that can be synthesized that have characteristics that would
increase the likelihood of their affinity and functional inhibition of VMAT2

•

To use organic chemistry methods to synthesize and purify the previously
designed molecules in sufficient quantities as to afford their testing via high
throughput affinity assays as well as functional assays

•

Once pharmacological assay data has been obtained, to use modern methods of
ligand based pharmacophore modeling of the VMAT2 binding/uptake sites that
may allow further generations of molecules to be developed that show even
further enhanced potency and selectivity at VMAT2

2

1.4 Overview of Drug Discovery
Drug discovery consists of the combined processes in which new drugs are
invented, evaluated for their pharmacological activity and thereby selected for lead
molecule identification and subsequent optimization. A flow chart describing the drug
design process is shown in figure 1.1. Rational drug design is the inventive process by
which new medications are found based on a discovered target of biological origin.
Drugs are commonly small organic molecules that either activate or inhibit the normal
function of a protein or biomolecule target, and that interaction leads to a therapeutic
benefit or advantage in the patient to which the designed drug is given (Drews, J., 2000).
Prior scientific investigation reveals the key biological workings and mechanisms of both
the normal physiological function of the protein or biomolecule target and also the altered
state of function that is caused by a disease or other outside influence, such as drug abuse.
The identified mechanisms by which the proteins in question work provide drug
discovery scientists areas to manipulate, probe, and take overall advantage of in hopes of
developing novel pharmacotherapeutics that can provide a controlled curative medical
intervention. As these discovered physiological mechanisms are elucidated, their
processes and inner workings are seen as prime potential novel drug targets to the drug
discovery scientist. When considered in the most basic way, drug design involves the
design and synthesis of small molecules that are complementary to and correspond with
the shape and local net charge of the biomolecular target with which they are designed to
target and which therefore bind to the biomolecular target being queried. As far as the
overall scale of the biomolecular targets, they can truly be as small as molecular in scale,
for example peptides, receptors on a protein (for example a binding site on VMAT2), or
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they can be comprised of entire cellular and systemic scale processes (Drews, J., 2000).
Once the target has been recognized, it is the overriding goal of the drug design/discovery
scientists to produce a drug that can be used for further experimental purposes that can
lead to therapeutic medical intervention. It is also extremely important that the drug
designed for the specific target should be designed in such a way that the lead drug
molecule should not affect any other important biomolecules that are deemed off target,
as the drug molecule may stray from the designed course of action and produce
undesirable side effects in the patient.
There are at least four primary steps involved in the drug discovery process.
These are listed here in order of occurrence, but are equally important, and include 1.)
overall drug design, 2.) synthesis of the designed drug molecule, 3.) pharmacological
assay evaluation of the targeted and desired physiological/biological effect, and 4.)
structure-activity relationship (SAR) analysis of the data collected in order to generate the
subsequent generation of drug compounds that perform even better than the prior
generation. The results of SAR analysis are then mined for a better understanding of the
overall biological workings and mechanisms in place. It is key that the next generation of
drug candidates be improved in as many ways as possible, if not all aspects, when
compared to the first phase of drug synthesis.
There are also numerous important facets that must be taken into consideration
when entering the drug design phase. The overall structure of the biomolecular target,
the target’s location within the body, the distinct environmental surroundings in the area
of the target, the overall number of the biomolecular targets in the area of the body to be
effected by the drug, the stability of the drug molecule itself, and the potential for binding
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to other “off-target” sites that may result in side-effects. These are just a few of the
factors that must be considered when designing small molecule candidates that are to be
used to produce the desired effect on the targeted biomolecule and therefore on the
target’s subsequent function. These complications are a part of what makes drug design a
stimulating yet challenging process. Many of these challenges can be overcome or
avoided outright by utilization of the knowledge gathered about the nature of the
prospective drug target.
In the past, most drugs have been discovered by one of two ways. Either natural
products were isolated from plant sources that were known to have medicinal properties
(Sneader, 1985) or through unexpected and or unplanned discoveries in the laboratory
that reveal that a compound may have the desired effect (Drews, 2000). Drug design and
discovery scientists cannot depend on luck to provide the desired drug candidates,
therefore the most fruitful traditional method for providing promising drug candidates has
been through isolation and purification of compounds from both newly discovered
species and traditional medicinal sources such as plants. Currently there is a marked
emphasis on more modern strategies for the discovery of new drug entities. The more
modern methods consist of rational drug design and high-throughput synthesis and
subsequent high-throughput pharmacological assays of small organic molecules (Drews,
2000).
Rational drug design is, at its core, based on a thorough understanding of the
biomolecular target and the overall mechanism of the disease or abuse process and uses
this knowledge to build molecules that will be likely target specific, with known
mechanisms of action and prior knowledge of the likely molecular interactions. In an
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ideal world, rational drug design would allow for immediate improved drug activity
profiles, with higher potency and selectivity, while still introducing minimal toxicity into
the system. This is due to some prior knowledge of the target and the drug molecule
libraries that are constructed and customized to interact with the previously known
structural target. With all previously acquired knowledge of the location, nature of the
target, and the target’s function, relatively complicated organic synthetic chemistry
methodology can be used to generate families of compounds within the library that are
specifically constructed to interact and bind to the known molecular topographic features
of the target. Therefore, ideally, rational drug design can, in just one step, improve the
overall hit rate of the constructed compound library, while improving the lead
compound’s potency, selectivity, and toxicity profiles.
With the utilization of high throughput synthesis coupled to high throughput
screening methods, the synthesis of a vast number of compounds that can be made in a
relatively simple manner, with a low number of synthetic steps, with overall yield
balancing between cost of synthesis and the amount necessary for initial and subsequent
testing is the focus of synthetic drug discovery chemist. High throughput synthesis
coupled to high throughput screening attempts to discover active compounds by applying
the muscle of large scale library building medicinal chemistry such as parallel organic
chemistry (used in this work), or microwave based chemistry, to generate a large number
of compounds that will be screened to afford a small number of candidates. High
throughput synthesis must be coupled to high throughput screening methods due to the
volume of time that it characteristically takes to manage and test large libraries of
compounds (Drews, 2000). One major limitation of high throughput synthesis derives
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from the focus on the large number of compounds generated without initial concern for
the initial hit rate, drugability factors, or toxicity profile of the compounds generated.
The utter volume of compounds generated by the high throughput synthesis can offset the
issues of low initial hit rates and drugability factors. The number or initial hits and
preliminary drug candidates can allow for the drugability and toxicity profiles to come
into play after the preliminary screening. The ultimate and overriding goal of high
throughput synthesis and screening is to massively reduce the initial cost of
distinguishing high quality lead compounds for the desired pharmacological target of
interest. Another desirable aspect of high throughput synthesis coupled to high
throughput screening derives from the creativity possible when generating the compound
libraries. Often novel compounds that may have otherwise not been investigated are
generated when the medicinal chemist is compiling a compound library that lead to
unforeseen advancements and allow expedited optimization of novel lead drug
candidates.
Pharmacological evaluation processes are required to be developed into a much
more streamlined procedure when they are part of a large drug discovery process. Much
of the time, in the early testing process, the evaluation of compounds is limited to a single
screening effort where compounds are evaluated for one biological effect. Compounds
that show promise in the initial screen are then selected and considered as hits. These hit
compounds are then subjected to further biological testing (Drews, 2000). This is done to
reduce the number of compounds that require further biological consideration in an effort
to minimize the testing response time and therefore reducing cost, both in valuable
scientist hours and in monetary expense. It is in this manner that compounds deemed
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ineffectual can be discarded in favor of compounds that obtain a set level of drug
potential. This prevents the time-consuming and expensive in-depth pharmacological
tests from being carried out on compounds that hold little promise of becoming lead
drugs for the target of interest.
An important aspect of high throughput screening is that the data generated, both
of the positive and negative variety of results, from a large library of compounds is
invaluable in later compound modification and refinement. This characterization and
evaluation of the data generated is known as structure activity relationship (SAR)
analysis, and can reveal significant features about both the biomolecular target as well as
the interactions that the lead drug compounds has with the target. SAR analysis is a key
tool of the drug design/discovery scientist and is best defined as the science of
quantifying and evaluating interactions at the molecular level between the drug molecule
and the target it is interacting with. Modern SAR efforts require the use of computational
resources and programs that use mathematical models of the drug molecule and target.
This part of the drug discovery pathway has become more and more complex as it
evolves. Entire research groups are dedicated to the “virtual synthesis” and “virtual
screening” of molecules and drug targets. These virtual efforts go hand in hand with
traditional drug discovery procedures, and are mainly used to support the continuing
synthetic efforts to make more and more efficient drug candidates. By taking advantage
of the information gleaned from prior synthetic efforts and biological experimentation,
computational SAR can uncover the required molecular features of the lead compounds
from past generations of synthesis and provide direction and novel ideas for structural
chemical modification.
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The computational methods for computational SAR differ depending on the
circumstances and information at hand. The different methods are described as: 1.)
development of ligand-receptor models also known as docking models, and these are
used specifically for situations where the receptor or biomolecular target structure has
been previously identified through methods such as x-ray crystallography, or 2.)
development of a pharmacophore based model, also known as a ligand based model,
which consists of SAR modeling based on certain molecular features of the ligand
molecules from the constructed compound library, and these are used in situations where
less information is known about the drug target or when the critical molecular structural
features of the target are not well defined, as in this case with VMAT2. Once the nature
of the molecular interactions between the ligand and the target site has been elucidated,
SAR based computational models can be further used as a tool to predict new compounds
and structural motifs that should be improved in their drug candidate qualities. It is in
this manner that SAR leads to advancement in the next generation of compounds
synthesized, and in theory should lead to improvements in all aspects of the next lead
molecule, including potency and selectivity, and thereby enhance the toxicity and side
effect profile as well. It is through these combined efforts that improved
pharmacotherapies can be discovered to intervene in the disease/abuse process.
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Figure 1.1 Flow chart overview of the drug discovery process. Rational design and
synthesis and high throughput synthesis generate the libraries of compounds that are then
assayed for activity at the biomolecular target of interest. Each cycle of the flow chart
represents a single generation of compounds. SAR analysis can accelerate the cycle time,
with each generation yielding a new lead compound that is a more suitable drug
candidate.
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1.5 Methamphetamine abuse prevalence and limitations of viable therapies and
treatments
Psychostimulant abuse has become a severe worldwide problem that has shown
no sign of lessening the hold it has on much of mainstream society. METH is an
addictive and increasingly popular psychostimulant drug that affects the central nervous
system. METH is also known to users of the drug as chalk, ice and crystal. Currently
and most significantly there are no effective and accepted pharmacological treatments
available for addicts who wish to quit. METH exists in its pure form as a white
crystalline powder that is odorless, bitter tasting and readily soluble in water or alcohol,
and can be self-administered by several delivery routes. Users of METH have various
methods of delivery that include: nasal inhalation, smoking and inhalation into the lungs,
or via injection. The oral route of administration has not gained prevalence due to the
delayed onset of reward, and the relatively low bioavailability when compared to the
injection route. While the preferred method of abusing the drug varies by region,
smoking METH is the most common way of introducing the drug into the body.
Whatever the route of administration, the users quickly develop a strong desire to
continue using it due to the false sense of happiness and well-being associated with
METH’s use. Users report a rush or feeling of strength and invulnerability as well as a
surge of confidence, hyperactivity, and a drastic increase in energy level. As with many
stimulants, METH is often abused in a “binge and crash” manner. The “rush” felt by
users of the drug is maintained for a very short amount of time, sometimes only minutes,
and the users attempt to maintain the high by taking more and more of the drug. It has
been documented in many cases that abusers take part in a form of binging known on the
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street as a “run”, in which the user forgoes food and sleep for several days while
continuing to self-administer the drug (National Institute on Drug Abuse, 2013). In 2012,
approximately 1.2 million people (about 0.4% of the United States population) reported
using METH when asked. While this number is slightly down from previous estimates,
METH continues to exhibit regional variability, and abuse is strongest on the West coast
and in parts of the Midwest.
METH was developed in the laboratory from the parent drug, amphetamine, and
is considered the first purely synthetic drug of abuse. It was developed early in the
twentieth century and was used for a time as a nasal decongestant and to relieve bronchial
health issues in the form of an inhalable powder. METH was first synthesized from
ephedrine in 1893 by Japanese chemist Nagai Nagayoshi and in 1919 the hydrochloride
salt was synthesized by the pharmacologist Akira Ogata via a simple reduction of
ephedrine utilizing red phosphorus (commonly found in certain types of matches) and
iodine (Vermont, 2013). During World War II, METH was used extensively by the Axis
forces for its stimulant effects (Defalque, 2011). METH was synthesized in Germany in
1937 and subsequently was commercially released in 1938. It quickly became a popular
stimulant for workers in the “German War Machine” and also gained popularity as a
recreational drug for young people until the middle of 1941 when it became a controlled
substance inside Germany as well. METH continued to be abused by the German armed
forces during World War II when it was commonly distributed by commanding officers
(occasionally over the objections of the units' physicians) to prevent or treat the fatigue of
overworked troops and thus allow them to continue fighting (Defalque, 2011).
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METH does differ greatly from amphetamine in that, when used at the same
dosage level, it is a much more potent stimulant as it crosses the blood-brain barrier at a
greater rate. Due to the presence of the α−methyl group, it has a longer-lasting effect and
therefore has greater harmful effects on the central nervous system. METH has been
classified as a Schedule II stimulant by the United States Drug Enforcement
Administration, and while it can be legally prescribed in a non-refillable prescription, it is
rarely prescribed due mainly to the large abuse liability. In the medical field, it can still
be prescribed for the treatment of attention deficit hyperactivity disorder, and narcolepsy,
and can be utilized as a short-term component of weight loss treatments, albeit at doses
much lower than those that are readily abused (National Institute on Drug Abuse, 2013).
It is widely accepted that the vast majority of the METH abused in the United
States is illegally manufactured here in the United States or is made in Mexico and
trafficked into the United States. One of the major hurdles in combatting the illegal
manufacture of METH is due to the ease with which it can be prepared. Multiple
synthetic methods exist, and are easily found via search engines on the internet. METH
is easily made in small, readily mobile, covert “laboratories” (examples include
automobile trunks, rental storage units, hotel rooms and more recently, recreational
vehicles). Requiring inexpensive ingredients such as pseudoephedrine and relatively
easily to obtain ammonia (a common fertilizer used on farms across the United States),
combatting METH at its source is problematic, if not impossible.
Many users of METH liken its effects to that of cocaine, and the two drugs have
similar behavioral and physiological effects. There are however, several important
differences found in the mechanisms by which they produce the reward or “rush” felt by
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their users. One important aspect in which METH and cocaine differ is the duration of
time they remain in the body. The half-life (time it takes for the body to remove half of
the dose absorbed) of cocaine is roughly one hour; however, the half-life of METH is
much longer, approximately 12 hours (NIDA, 2013, Barr et al., 2006). Cocaine is
relatively quickly removed from the body and much of the dose is completely
metabolized within in the body in a short time; whereas METH has a much longer
duration of action, and is more slowly metabolized so that a larger percent of the dose
absorbed into the body remains unchanged. METH is metabolized into two primary
metabolites, amphetamine and 4-hydroxymethamphetamine (Keueger et al., 2005,
Yamada et al., 1984, Cashman et al., 1999) with amphetamine belonging to the same
class of stimulant compounds as METH and likely contributes to the pharmacological
activity felt by the users, while 4-hydroxymethamphetamine (also known as Pholedrine
as used in a clinical setting) does stimulate the sympathetic nervous system, it is not
thought to produce the same pharmacological affect as the parent drug, METH (Dasgupta
et al., 2012). It is administered in the clinical setting as a topical eye drop form for the
purpose of dilating the pupil and can be used to diagnose Horner's syndrome (Bates et al.,
1995). Thus, METH remains in the brain longer, and affords prolonged stimulant and
rewarding effects. Both cocaine and METH produce their reward through increased
levels of dopamine (DA) within the synapse of dopaminergic nerve terminals, but is has
been shown in studies in animal model that following administration of METH, the levels
of DA are much higher than when animals are administered cocaine (Barr et al., 2006,
NIDA, 2013, Wilson et al., 1996). The structural differences between METH and
cocaine are shown in Figure 1.2.
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Figure 1.2 Chemical Structures of Cocaine and Methamphetamine

METH has many effects on the human body, and these effects differ greatly
depending on the length of time a METH user has been abusing the drug. Short term
effects from the use of METH, even at what are considered small doses, include
increased activity, increased attention, increased respiration and rapid and or irregular
heartbeat, hyperthermia, decreased fatigue, decreased appetite, as well as the main effect
that METH users desire: quick onset of the rush and euphoria that leads to abuse.
Hyperthermia (increased core body temperature) and convulsions can occur after using
METH and are mainly associated with METH overdose, and if not treated by trained
medical professionals immediately can result in death (NIDA, 2013). It is widely
accepted that the main pleasurable effects the users feel when using METH stem from the
release of large concentrations of DA in the brain. DA is a neurotransmitter that involved
in motor function (as seen in Parkinson’s disease), motivation, and the experience of
pleasure. It is also believed that the high levels of DA released by METH causes some of
METH’s harmful effects on dopaminergic neurons in the brain (Barr, et al., 2006, NIDA,
2013). The structure of DA is shown in Figure 1.3.

15

Figure 1.3 Structure of the neurotransmitter dopamine (DA)

The long term effects of METH abuse has many more significant detrimental
consequences, not the least of which is a strong addiction to the drug. Addiction is
defined as the continued repetition of a behavior even though the behavior has strong
adverse consequences. Addiction, in the case of METH, is considered a chronic,
relapsing disease, that is characterized by an overwhelming compulsion to seek out more
of the drug and is also associated with molecular and functional changes within the
addict’s brain (NIDA, 2013, Wimalasena, 2011). Another long term effect of METH, as
is found with many drugs, is that tolerance develops quickly to METH’s desired
pleasurable effects when METH is taken repeatedly. Chronic users of the drug find
themselves needing to take higher and higher doses of the drug, in more frequent
administrations, or change the method of administration to achieve the same desired rush
and euphoria effect. It is also common for chronic users of METH to be unable to find
anything in life that provides them pleasure except for the drug, which in turn reinforces
the need for the METH. When users are unable to find or afford the drug, or have looked
for treatment in a clinical atmosphere, users experience extreme withdrawal symptoms
that include severe depression, fatigue, anxiety, dysphoric mood, increased appetite,
increased movement or decreased movement, lack of motivation, sleeplessness or
sleepiness, vivid or lucid dreams, violent behavior, memory loss and of course, an
intense, overwhelming craving for the drug (Shoptaw, 2009). Chronic abusers of METH
16

can also display numerous symptoms of psychosis that include paranoia, hallucinations
and delusions, an example of which is known by a common name “Meth Bugs” in which
the abuser has an intense sensation of insects crawling beneath their skin. Skin sores are
apparent in the users of METH experiencing this specific type of delusion, and are the
result of the addict scratching and picking at their skin in an attempt to relieve themselves
from the insects they imagine to be crawling underneath. These signs of psychosis can
last for years after a user has been drug free, and even small amounts of stress can bring
about recurrence of METH psychosis events (Barr et al., 2006, Iyo et al., 1997).
These types of symptoms allude to the substantial changes in the brain of abusers
of METH. In adults who used METH, magnetic resonance imaging (MRI) has shown
enlarged striatal volumes (Chang et al., 2005, Chang et al., 2007). In comparison,
children that have been exposed to prenatal METH show smaller striatal structures
(Chang, et al., 2007). Positron emission tomography (PET) studies have revealed that
several other functional aspects within the striatum have been altered. These include:
reduced dopamine transporter (DAT) density and reduced dopamine D(2) receptors in the
striatum of METH users (Volkow et al., 2001, McCann, et al., 1998, Sekine et al., 2001,
Iyo et al., 2004). PET studies also found lower levels of serotonergic transporter density
and vesicular monoamine transporter (VMAT2) density in the striatum, as well as altered
brain glucose metabolism (Chang et al., 2007), which were linked with the overall
severity of psychiatric symptoms in the limbic and orbitofrontal regions of the brain
(Chang et al., 2007).
Some of the changes in the brain of chronic METH abusers do appear to be at
least partially reversible. These neuronal recoveries take over a year of abstinence from
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METH, and were linked with improvements in both motor skills and verbal memory
examinations. Substantial damage to some brain regions of addicts does not show
marked signs of recovery even after the one year abstinence time frame, which indicates
that some of the METH-induced damage is very long lasting, if not permanent. Further
damage to the brain can occur due to an increased risk in METH abusers to experience a
stroke, which can cause death or in many cases irreversible and severe damage to the
brain (McIntosh, 2006). It has also been shown that as a consequence of METH’s effect
on the levels of DA in the brain, there is a greater occurrence of Parkinson’s disease in a
population of abusers of METH (Callaghan, 2011).
The detrimental effects that derive from METH abuse are numerous and severe.
The fact that there are currently no effective and accepted pharmacological treatments
available for the addicts that wish to quit makes it much more difficult to break the cycle
of addiction. Medications have been shown effective for treating other substance abuse
disorders, for example three drugs exist to treat alcoholism: disulfiram, naltrexone, and
acamprosate. No medications exist that counteract the effect of METH at the
biomolecular level or prolong abstinence from or reduce the abuse of METH by an
individual that has become addicted to the drug (NIDA, 2013). Currently the most
effective treatments for METH addiction are behavioral therapies that include cognitivebehavioral therapy and contingency-management interventions (NIDA, 2013). Results
from these behavioral therapies have proven somewhat effective, but treatment depends
much on the individual addict’s dedication to become drug free. It is clear that a
therapeutic treatment for METH abuse is needed, and must be a priority for the future
treatment of METH addicts.
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1.6 Methamphetamine Mechanism of Action, and the Role of VMAT2
The abuse liability of METH is thought mainly to be a product of an interaction
and subsequent alteration of the brain’s dopaminergic system. Inside the presynaptic
dopaminergic neuron METH interacts with the dopamine transporter (DAT), the
vesicular monoamine transporter-2 (VMAT2), and with monoamine oxidase (MAO)
(Dwoskin and Crooks, 2002). Signal transduction within monoaminergic neurons is
dependent on monoamine neurotransmission in the synaptic region of the neuron. (Henry
et al., 1998; Schuldiner et al., 1996; Rudnick, 1998). Monoamine neurotransmission can
be apportioned between several principle steps: (1) the initial biosynthesis of
monoaminergic neurotransmitters from their biochemical precursors within the
cytoplasm, followed by their active sequestration and accumulation into synaptic storage
vesicles utilizing an uptake mechanism driven by a proton gradient, (2) the constant
biosynthetic conversions within the synaptic vesicles, (3) the release of the
monoaminergic neurotransmitter via exocytosis or diffusion, chiefly the former in
response to a physiological stimulus, into the synaptic cleft, (4) interaction of the
neurotransmitter with the target receptor on the postsynaptic membrane (the distinct act
of signal transduction), and (5) the dissociation of the neurotransmitter molecule from the
target receptor and the subsequent reuptake into the cytosol of the presynaptic terminal
by plasma membrane monoamine transporters, of which the dopamine transporter (DAT)
is an example. DAT is a membrane spanning protein that functions to pump DA out of
the synapse back into cytosol, from which VMAT2 sequester DA into vesicles for later
storage and release. DA reuptake via DAT provides the primary mechanism through
which DA is removed from synapses, which effectively terminates the neurotransmitter
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signal across the neuron’s synaptic cleft, and provides a method for DA to be recycled
within the neuron rather than repeatedly biosynthesized when needed. DAT is also
referred to as a symporter, or a transporter that is involved in the movement of two or
more species of molecules or ions across a membrane. Ions that are transported are
generally moving down the concentration gradient, and that in turn allows the molecule
being co-transported to be moved against the concentration gradient. In this case, DAT
moves DA across the cell membrane by linking the movement of DA to the energeticallyfavorable movement of sodium ions moving from high to low concentration into the cell.
To be specific, the function of DAT requires the sequential binding and co-transport of
two positively charged sodium ions and one negatively charged chloride ion in order to
transport one molecule of DA. The movement of the sodium and chloride ions is
considered facilitated diffusion, while DA is being actively transported into the
presynaptic terminal from the synaptic cleft. The overall driving force for DAT-mediated
DA reuptake is the ion concentration gradient generated by the plasma membrane
sodium/potassium adenosine triphosphatase (Torres, 2003).
Those monoaminergic neurotransmitters not taken back up into the presynaptic
terminal are subject to monoamine metabolizing enzymes in the extracellular space, and
consequent inactivation, making it necessary for the biosynthesis of the neurotransmitter
to be repeated. Metabolizing enzymes are not allocated only within the extracellular
space, and the neurotransmitter can be metabolized within the cytosol itself by specific
enzymes, of which monoamine oxidase (MAO) is an example. Accordingly, the efficient
reuptake of the neurotransmitter from the synaptic cleft via plasma membrane
monoamine transporters, and their subsequent sequestration and reaccumulation into
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synaptic vesicles via vesicular monoamine transporters (VMATs), is vital to the process
of monoamine neurotransmission within monoaminergic synaptic neurons.
Vesicular monoamine transporters are in control of and responsible for the
process and mechanism of uptake of cytosolic monoamines into synaptic vesicles found
within monoaminergic neurons (Wimalasena, 2011). The VMAT exists as two distinct
isoforms: VMAT1 and VMAT2 (Erickson and Eiden, 1993; Erickson et al., 1992; Peter
et al., 1994; Zheng et al., 2006). Remarkably, the distribution of the two isoforms of
VMAT appears to vary from species to species. In the human, VMAT1 is primarily
expressed in neuroindocrine cells which include chromaffin cells of the adrenal medulla,
as well as enterochromaffin cells of the intestine (Peter et al., 1995; Weihe et al., 1994;
Stern-Bach et al., 1992; Howell et al., 1994). While recent studies have shown that the
VMAT1 isoform is also expressed in the brain (Lohoff et al., 2006), the VMAT2 isoform
is expressed in sympathetic postganglionic neurons in addition to adult human and
monoaminergic neurons of the central nervous system (Erickson et al., 1996; Peter et al.,
1995; Weihe et al., 1994; Stern-Bach et al., 1992; Howell et al., 1994) and is considered
the main transporter protein involved in the sequestration of cytoplasmic
neurotransmitters into vesicles for storage, as well as their subsequent release. The
accumulation and storage of the monoamines dopamine (DA), serotonin, norepinephrine,
and histamine are essential to the regulatory processes governing the concentrations of
these endogenous neurotransmitters available in the cytosol of monoaminergic neurons
(Erikson et al., 1996). The active transport of cytosolic monoamines into vesicles for
storage, against a high concentration gradient (synaptic vesicles can contain
concentrations of monoamines up to 0.5 M), is propelled by the pH gradient across the
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plasma membrane in vesicles as well as the electrochemical gradient originating from the
H+-ATPase in the chromaffin granule membrane (Wimalasena, 2011; Eiden et al., 2004;
Schuldiner, 1994; Gasnier, 2000; Henry et al., 1994).
VMAT1 and VMAT2 are glycoproteins with a molecular weight of 40 kDa (Liu
et al. 1992; Erickson and Eiden, 1993; Erickson et al., 1992). The origin of VMAT1 and
VMAT2 has been determined to be from two distinct genes; however they show high
sequence homology (Parsons, 2000; Bravo and Parsons, 2002). The crystallographic
structures have not yet been resolved for VMAT1 or VMAT2, the sequences have been
analyzed and related proteins suggest that their structure is consistent with
transmembrane proteins consisting of 12 transmembrane spanning domains similar in
structure to plasma membrane monoamine transporters such as the dopamine transporter
(DAT). It is believed that both the C-terminus as well as the N-terminus of the VMAT
series of transporters are located within the cytoplasmic side of the vesicle, and this is
supported by studies that show a lack of a cleavable sequence in VMAT2 (Erickson et
al.,1992).
Without a crystal structure determination of the crystallized protein, probes into the
tertiary structure of the protein are inconclusive at this time. Several studies have
investigated structure-function relationships of VMAT at the molecular level. Such
studies utilize mutations of specific amino acids and determine what effect such a
mutation has on the binding affinity of the protein for a specific substrate or molecule. In
what have been called the original studies in this field, (Shirvan et al., 1994) has shown
that when His419 (found to be His414 in human VMAT2, and located in the cytoplasmic
side of the membrane between TMDs X and XI) is mutated to either Arg or to Cys, the
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accumulation of serotonin (5-HT) and DA drop to zero, and a mutation at the same site
strongly inhibits the pH-dependent binding of Reserpine (RES) (Wimalasena, 2011).
These observations have led to the logical conclusion that His419 (His414 in human
VMAT2) plays a primary role in monoamine transport, likely through aiding the initial
proton-dependent conformational change of the transporter (Shirvan et al., 1994). It has
also been proposed that RES likely binds to this new conformation, and in the mutated
form of the transporter, the interaction has been impeded.
Another single-point mutation at the Asp431 (Asp426 in human VMAT2 found in
TMD XI) with either Glu or Ser again inhibits 5-HT transport without changing the rate
of RES binding to the preferred RES binding site (Steiner-Mordoch et al., 1996). Similar
to conclusions have been drawn from His419 mutations, and it has been postulated that
Asp431 (Asp426 in human VMAT2) is necessary for the completion of the substrate
transport cycle, and the concomitant proposed second conformational change of the
protein releasing the amine into the cytosol, in the same proposed model of VMAT
function. In contrast, a mutation replacing Asp404 (Asp399 in human VMAT2) in TMD
X with Cys or Ser does inhibit 5HT transport and also affects RES binding in rat
VMAT1, but when Asp404 (Asp399 in human VMAT2) is replaced with Glu, neither
5HT transport nor the binding of RES and tetrabenazine (TBZ) is altered in a significant
manner. The rationale behind this discovery is thought to be the presence of the carboxyl
moiety shared in Asp and Glu, but lacking in Ser and Cys. The presence of the carboxyl
group appears to play a vital function at site 404 (399 in human VMAT2) if VMAT is to
operate normally (Steiner-Mordoch et al., 1996).
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Other research has focused on the primary structure of the protein: the VMAT
sequence homology itself. Without lengthy mutation studies, it is possible to analyze
portions of the amino acid sequence, and, when overlaid, to find the portions of the
sequence that have been conserved between VMATs. This simple analysis has shown
that four Asp residues in TMD I, VI, X, and XI as well as a Lys residue found in TMD II
are conserved among all members of the VMAT protein family. Since they have been
dutifully conserved by evolution, it is likely that they have a critical role in both the
structure and function of this family of VMAT proteins.

1.7 Methamphetamine Mechanism of Action
Delving deeper into METH’s mechanism of action at the dopaminergic neuron,
specifically at DAT, VMAT2 and MAO, Figure 1.4 illustrates the numerous effects that
METH has at the biomolecular level.
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Figure 1.4 Illustration of METH’s effects on the dopaminergic neuron
(Adapted from G. Zheng, with permission)

METH effectively reverses the normal function of both DAT and VMAT2,
greatly increasing the free DA present in the cytosol and in the extracellular
space/synaptic cleft. METH also blocks the normal function of MAO, preventing the
metabolism of the DA into 3,4-dihydroxyphenylacetic acid (DOPAC), such that DA may
be released from the vesicles into the cytosol and then the extracellular space (Dwoskin
& Crooks, 2002).
VMAT2 is a relevant biomolecular target in the search for a viable treatment for
METH abuse (Sulzer et al., 2005). METH inhibits DA uptake at VMAT2 and promotes
25

DA release from vesicles to increase cytosolic DA. Therefore, pharmacological
compounds that modulate VMAT2 function or effectively redistribute DA from
presynaptic vesicles, in effect limiting vesicular and cytosolic DA available for METHinduced reverse transport, should be suitable candidates for the treatment of METH
addiction. Studies utilizing VMAT2 knockout mice demonstrate reduced drug-seeking
behavior compared to wild-type rats in locomotor response studies that included an array
of drugs, including amphetamine and cocaine (Takahashi et al., 1997; Wang et al., 1997).

1.8 Lobeline Background and Mechanism of Action as a Treatment for METH
abuse
(-)-Lobeline (LOB) is the major alkaloidal constituent of Lobelia inflata, which is
more commonly known as Indian tobacco. The common name “Indian tobacco” most
likely originated when Europeans new to the North American continent found that Native
Americans smoked the dried leaves of the plants (Millspaugh, 1974). In 1938, Proctor
prepared a liquid alkaloid extract from the plant and named it lobeline (Millspaugh,
1974). Since that time, the alkaloidal extract of Lobelia inflata has been used medically
as an expectorant, emetic, antiasthmatic, antispasmodic, respiratory stimulant, general
muscular relaxant, diaphoretic, diuretic, stimulant, and it has even been used to treat
narcotic overdose (Crooks et al., 2011). In the Lobelia inflata plant, LOB is by far the
most abundant alkaloid, as well as the most pharmacologically active constituent of more
than twenty related piperidine alkaloids (Felpin et al., 2004). The other alkaloids include,
but are not limited to, lobelanine, nor-lobelanine, lobelanidine, and nor-lobelanidine.
The structures of these alkaloids are shown in Figure 1.5.
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Figure 1.5 The chemical structures of lobeline (LOB) and structurally related
alkaloids present in Lobelia inflata.

The LOB molecule was purified and isolated from the plant extract and
characterized by Wiedland (Wieland, 1921; Wieland, et al., 1925; Wieland, et al., 1929).
Wieland followed the purification and isolation of LOB with the subsequent total
synthesis of the molecule to confirm the structure proposed in 1921 (Wieland, et al.,
1929). Following Wieland’s total synthesis, multiple synthetic methods for the
preparation of LOB have been reported either via racemic methodology (Scheuing, et al.,
1929; Schoepf, et al., 1935) or via the asymmetric synthesis approach (Schoepf, et al.,
1965; Compere, et al., 1999; Felpin, et al., 2002; Klinger, et al., 2006; Birman et al.,
2007).
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The free base form of LOB, as well as the sulfate and hydrochloride salt forms of
LOB, are stable to degradation in the solid, crystalline form. Conversely, when in
solution, LOB quickly undergoes a pH-dependent epimerization at carbon-2 (C2) of the
piperidine ring that yields a mixture of cis-LOB and trans-LOB (Compere, et al., 1999;
Felpin, et al., 2002; Zheng, et al., 2004). This epimerization is thought to ensue via the
transitory retro-aza Michael addition product. This process is shown in Figure 1.6.

Figure 1.6 Likely process of Lobeline epimerization (adapted from Crooks, et al, 2011)

Compounds possessing a β-aminoketone moiety do have a tendency to exhibit
stability issues, such as the epimerization process shown in Figure 1.6, as well as an
elimination process, thought to be due to the molecule’s predisposition to undergo retroaza Michael addition processes. Many of the cases where retro-aza Michael addition
pathways have been shown to occur happen under acidic conditions (Vazquez, et al.,
2001; Davis, et al., 2005), but the epimerization process does not occur in aqueous
solutions at a pH of 3.0 (Crooks, et al., 2011). This is quite useful information, and was
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used in a “quench” technique (after a set time at a higher pH, an aqueous solution of LOB
is decreased to a pH below 3.0, effectively terminating the epimerization process at that
point) (Crooks, et al., 2011). The quench technique was used to determine the kinetics of
epimerization and high performance liquid chromatography (HPLC) techniques were
used to determine the ratio of the two resulting epimers.
When in aqueous solution at room temperature, LOB epimerization proceeds to
afford an approximate 65:35 ratio of cis:trans, and the equilibrium stops at that point.
Interestingly, when in solution in chloroform, the ratio of cis:trans is 46:54 in favor of
the trans-isomer. More surprisingly, the cis:trans ratio within human plasma after
sublingual administration of LOB sulfate reaches 1:19 in favor of the trans-isomer. This
is reversed in rat plasma, after the same sublingual administration of LOB sulfate, i.e. the
ratio is 16:1 in favor of the cis isomer (Crooks et al., 2011).
Several reviews on the pharmacology of LOB exist in the literature (Zheng et al.,
2006; Dwoskin et al., 2002; Felpin et al., 2004; McCurdy et al., 2000). LOB is known to
display high affinity for nicotinic acetylcholine receptors (nAChRs) (Court et al., 1994;
Damaj et al., 1997; Flammia et al., 1999; Miller et al., 2004), and has been shown to have
many effects similar to nicotine, such as tachycardia (increased heart rate) and
hypertension (increased blood pressure) (Korczyn et al., 1969), analgesia (Damaj et al.,
1997), nausea (Bevan et al., 1966), improvement in learning and memory tests (Decker et
al., 1993), anxiolytic activity (Brioni et al., 1993), and hyperalgesic actions (Hamann et
al., 1994). In consequence, LOB has been characterized as a nicotinic receptor agonist,
despite the lack of structural similarities between LOB and nicotine (NIC) and further
SAR studies do not support LOB and NIC possessing the same pharmacophore profile
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(Barlow et al., 1989). It is not thought that LOB and NIC act via the same mechanism,
and this is supported by studies that show LOB and NIC have different effects in both
behavioral as well as neurochemical studies (Dwoskin & Crooks, 2002). In contrast to
NIC, LOB very marginally supports self-administration in mice (Rasmussen et al., 1998),
and does not show support for self-administration of any type in rats (Harrod et al.,
2003). As further evidence that LOB and NIC do not act via the same mechanism,
chronic administration of LOB does not increase locomotor activity in rats (Fudala et al.,
1986; Stolerman et al., 1995). In contrast, LOB diminishes hyperactivity induced by
repeated nicotine administration in rats (Miller et al., 2003). More specifically, LOB has
been shown to inhibit NIC-evoked [3H]DA overflow from striatal slices from rat brain
with an IC50 of approximately 1 µM, which suggests that LOB and NIC not only do not
act via the same mechanism, but demonstrate that LOB acts as an antagonist at nAChRs
that mediate NIC-evoked DA release (Miller et al., 2000). LOB has also been shown to
bind to α4β2 nAChRs with high affinity (Ki = 4 nM), while inhibiting NIC-evoked 86Rb+
(radiolabeled Rubidium) efflux from rat synaptosomes (IC50 = 0.7 µM), which further
supports contention that LOB is an antagonist at α4β2 nAChRs (Miller et al., 2000). In
addition, LOB has been shown to be an antagonist (IC50 = 8.5 µM) at human α7 nAChR
subtypes expressed in Xenopus oocytes (Briggs et al., 1998). The combined results from
the above studies suggest that LOB is not correctly categorized as a nicotinic receptor
agonist, but that it also acts as a potent, albeit nonselective, nAChR antagonist.
Along with the interaction of LOB with nAChRs, LOB also interacts with DAT
and VMAT2. LOB inhibits [3H]dihydrotetrabenazine (DTBZ) binding to VMAT2 (IC50
= 0.9 µM) and also inhibits [3H]DA uptake into vesicle preparations from rat striatum
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(IC50 = 0.88 µM) (Teng et al., 1997; Teng et al., 1998). Although LOB does inhibit
[3H]DA uptake into synaptosomal preparations from rat striatum (IC50 = 80 µM) via
DAT, it is noteworthy that the inhibition of DAT is of nearly 100-fold weaker in
comparison to LOB’s inhibition of VMAT2 (Teng et al., 1997). When VMAT2 and
DAT are both present on a co-expressed cell line, LOB was shown to induce [3H]DA
release through its interaction with VMAT2, rather than through an interaction with DAT
(Wilhelm et al., 2004). This finding was also supported with later data showing that LOB
caused a decrease in METH-evoked [3H]DA release (Wilhelm et al., 2008).
Research has shown that LOB inhibits the behavioral consequences of
amphetamine as well as the neurochemical effects of the drug in both rats and mice.
LOB decreases amphetamine-induced and METH-induced hyperactivity in rats and mice,
and has been shown to inhibit amphetamine-evoked DA release from superfused (the
process by which the maintenance of the normal metabolic or physiological activity of
the tissue by submitting it to a continuous flow of a sustaining medium over the outside)
slices from rat brain striatum (Miller et al., 2001). Most importantly, it was found that
LOB decreased METH self-administration in rats without acting as a substitute reinforcer
(Harrod et al., 2001; Harrod et al., 2003), and this is in accord with LOB not supporting
self-administration in rats (Harrod et al., 2000) suggesting a lack of abuse liability for
LOB.
Further behavioral studies in rats have demonstrated that LOB has significant
potential as a therapeutic agent for treatment of psychostimulant abuse. When
administered as a pretreatment, LOB reduces the intensity of METH-induced stereotypy
(a repetitive or ritualistic movement, posture, or utterance) in adolescent mice (Tatsuta, et
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al., 2006). While, LOB has also been shown to attenuate cocaine self-administration in
rats (Neugebauer, et al., 2007), the effects that LOB has on cocaine-induced hyperactivity
in rats are multifaceted and intricate. When administered acutely, LOB did not decrease
the effect that cocaine had on hyperactivity in rats. Conversely, when LOB was given via
repeated administration, it attenuated cocaine-induced hyperactivity in rats. LOB was
also found to prevent rats from becoming sensitized to cocaine (Crooks et al, 2011).
Phase 1b clinical evaluation of LOB is completed, and found that LOB is safe in human
METH addicted subjects (Clinical Trial ID #NCT00439504), and awaits investigation in
Phase II trials as a pharmacological treatment for METH abuse (Crooks et al., 2011).
The current understanding of the mechanism by which LOB reduces the
rewarding effects desired by abusers of psychostimulants such as amphetamine and
METH involves LOB’s alteration of DA concentrations within dopaminergic synapses
through an interaction with both VMAT2 and DAT (Dwoskin & Crooks, 2002; Crooks et
al., 2011). It is more plausible that the interaction between LOB and VMAT2 is more
essential to LOB’s inhibition of the behavioral effects of psychostimulant abuse, due to
LOB having an approximate 100-fold greater affinity for VMAT2 than for DAT (Teng, et
al, 1997; Dwoskin & Crooks, 2002; Crooks et al., 2011). A distinct and important
difference between LOB and METH is with respect to their actions on MAO. LOB does
not interfere with MAO, allowing the increased levels of DA within the cytosol to be
oxidized into dihydroxyphenylacetic acid (DOPAC), which does not interact with DA
receptors on the postsynaptic terminal (Alachar, et al., 2012). With these data
considered, the mechanism of action for LOB in the inhibition of METH induced
behavioral effects is due to the interaction of LOB with the DTBZ allosteric binding site
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on VMAT2, effectively inhibiting DA uptake into synaptic vesicles while promoting DA
release from the same storage vesicles within the presynaptic terminals of the
dopaminergic neuron (Dwoskin & Crooks, 2002; Crooks et al., 2011). Through this
mechanism, LOB diminishes the total DA pool available for reverse transport through
DAT to be released into the synaptic cleft. In that manner, less DA is available for
METH to be released from the presynaptic terminal, even if the addict fails to remain
drug free during treatment. Figures 1.7 and 1.8 illustrate the mechanism by which LOB
attenuates METH’s effect at the dopaminergic neuron.

Figure 1.7 Lobeline’s Mechanism of Action at the Dopaminergic Neuron
(Adapted from G. Zheng, With Permission)
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Figure 1.8 Lobeline’s inhibition of Methamphetamine
(Adapted from G. Zheng, With Permission)

1.9 Review of Structural Modifications of Lobeline and Lobelane to afford VMAT2
Inhibitors
The discovery of LOB as a VMAT2 ligand presents a novel scaffold and lead
molecule with which to explore inhibition of VMAT2, and this section is designed to
provide background information regarding previous studies that have been conducted in
this area prior to this author’s entrance into the area of study. Albeit, LOB is a molecule
that has been shown to interact with and bind to a number of biomolecular targets,
including nAChRs (Teng et al., 1997; Dwoskin & Crooks, 2002; Miller et al., 2000;
34

Hillmer et al., 2013; Kaniakova et al., 2011; Hojamat et al., 2010; Horton, et al., 2011),
opiate receptors (Hart, et al., 2010; Miller et al., 2007; Miller et al., 2011), VMAT2
(Meyer et al., 2013; Dimatelis, et al., 2012; Horton et al., 2011; Dwoskin & Crooks,
2002; Crooks et al., 2011; Horton et al., 2011; Nickell et al., 2010; Nickell et al., 2011;
Hojamat et al., 2010; Varkat et al., 2009; Wilhelm et al., 2004; Wilhelm et al., 2008;
Zheng et al., 2005; Zheng et al., 2006; Miller et al., 2004; Teng et al, 1998), and DAT
(Smith, et al., 2012; Horton et al, 2011; Nickell et al., 2010; Wilhelm et al, 2008; Li et al.,
2007;). Significant quantities of time and effort have been allocated to structurally
modifying the LOB molecule to improve potency and selectivity at VMAT2 while
limiting the effects at other neurotransmitter transporters and nAChRs (Crooks, et al.;
2011). A review of the studies conducted follows, with a linear timeline of strategies
attempted. Some of the first structural modifications attempted on the LOB scaffold
where oxidation and dehydration reactions under acidic conditions (these reactions are
shown in Scheme 1.1). When LOB is subjected to oxidizing conditions, the alcohol
functionality converts to a ketone (Jones oxidation with chromium (VI) oxide) affording
lobelanine. Acid-catalyzed (phosphoric acid) degradation of LOB yields the ketoalkene
(2-((2R, 6S)-1-methyl-6-styrylpiperidine-2-yl)-1-phenylethanone), and when LOB is
subjected to mild reduction conditions (sodium borohydride) the keto functionality is
reduced to afford the stereospecific product, lobelanidine.
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Scheme 1.1. Synthetic routes to lobelanine, lobelanidine, and the ketoalkene [2-((2R,
6S)-1-methyl-6-styrylpiperidine-2-yl]-1-phenylethanone

When compared to LOB (data shown in Table 1.1), lobelanine, ketoalkene, and
lobelanidine all showed decreased binding to α4β2* nAChRs by greater than 100-fold to
almost 10000-fold differences. At the α7* nAChRs, affinity was only slightly modified,
however, a 4-fold increase in affinity for VMAT2 was observed with the ketoalkene
analog. The radiolabeled ligands are: [3H]nicotine ([3H]NIC), for the nicotine binding
site on α4β2* nAChRs, [3H]methyllycaconitine ( [3H]MLA), for the MLA binding site on
α7* nAChRs, and [3H]methoxytetrabenazine ([3H]MTBZ), for the tetrabenazine (TBZ)
binding site on VMAT2. From these data, it can be determined that the presence of a
second keto moiety in the LOB scaffold causes a decrease in affinity for α4β2* and
α7*nAChRs, but only slightly improved potency at VMAT2. Removal of the alcohol
moiety in LOB results in a ketoalkene analog that exhibits moderately decreased affinity
for α4β2* and α7* nAChRs, but exhibits 4-fold increase in affinity for the TBZ binding
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site on VMAT2. Reduction of the keto moiety in LOB yields lobelanidine, which has
two alcohol moieties; when compared to LOB, lobelanidine shows less affinity for α4β2*
nAChRs, slightly greater affinity than LOB at α7* nAChRs, and 5-fold less affinity for
VMAT2 (Crooks, et al., 2011).
Values are Ki, µM
Compound

[3H]NIC Binding
α4β2* nAChR

[3H]MLA Binding
α7* nAChR

[3H]MTBZ
Binding VMAT2

LOB

0.004

11.6

5.46

lobelanine

37.1

22.7

2.41

ketoalkene (2)

3.10

3.29

25.9

lobelanidine

0.44

34.2

1.35

Table 1.1. Binding affinity of LOB, lobelanine, ketoalkene, and lobelanidine at α4β2*
and α7* nAChRs, and at VMAT2.

With this data in hand, both carboxylate and sulfonate esters of LOB were
synthesized. When assayed (data not shown; Hojamat et al., 2010), it was apparent that
the above modifications of the alcohol moiety of LOB affected the way in which the
compound bound to both α4β2* and α7* nAChRs, but did not effectively increase affinity
at VMAT2.
In order to systematically determine the SAR for the LOB scaffold, the next
logical step was to reduce/remove the keto functionality completely from the molecule.
To this end, the reactions outlined in Scheme 1.2 were conducted, and the products
isolated and characterized (Zheng et al., 2006).
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Scheme 1.2. The synthetic route to des-keto analogs of lobeline (Adapted from Crooks,
et al., 2011)

The aim of the synthetic work described in Scheme 1.2 was to produce a series of
LOB analogs with the keto group removed. To afford compound 1, a Clemmenson
reduction of LOB was used to remove the carboxyl moiety entirely, and this was
followed by oxidation of the alcohol to a ketone, which was then reduced to afford both
stereoisomers (R & S) of the corresponding alcohol (3a & 3b), as the synthesis of both
stereoisomers was desired. The oxidation step followed by reduction with sodium
borohydride was done to make it possible to obtain compounds 3a and 3b as a separable
mixture that each be isolated and purified by silica column chromatography. A portion of
the total synthesized amount of compounds 3a and 3b were then subjected to
hydrogenation conditions (hydrogen gas under pressure with palladium-on-charcoal) to
reduce the alkene moiety and afford compounds 5a and 5b, which were also separable via
silica column chromatography (Zheng, et al., 2006; Crooks et al., 2011). The process that
38

affords the keto alkene (2) is illustrated in Scheme 1.1. Products 4a and 4b, and 6a and 6b
can then be synthesized via the same route as used in the preparation of 3a and 3b and 5a
and 5b (i.e reduction of the ketone to an alcohol, separation and purification, then
hydrogenation followed by silica column separation and purification). The pure
compounds were assayed for biological activity as described in Table 1.1, with one
exception; rather than using [3H]methoxytetrabenazine ([3H]MTBZ, as the radioligand
[3H]dihydroxytetrabenazine ([3H]DTBZ) was used as the radioligand for the
tetrabenazine (TBZ) binding site on VMAT2, and the two radioligands have been used
interchangeably as ligands for the TBZ site on VMAT2. DTBZ is less susceptible to
metabolism in the periphrery when compared to TBZ and MTBZ, so in in vivo studies, it
is preferred (Welch et al., 2012). The biological data for the eight des-keto compounds
are shown in Table 1.2 (Zheng et al., 2006).
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LOB is included as well for comparison.

Values are Ki ± SEM, µM
Compound

[3H]NIC Binding
α4β2* nAChR

[3H]MLA Binding
α7* nAChR

[3H]DTBZ Binding
VMAT2

LOB

0.004 ± 0.000

6.26 ± 1.30

2.76 ± 0.64

3a

9.75 ± 0.91

>100

6.44 ± 0.54

3b

>100

>100

0.59 ± 0.15

4a

4.19 ± 0.80

1.70 ± 0.32

5.16 ± 0.30

4b

>100

>100

6.06 ± 0.45

5a

1.77 ± 0.61

39.3 ± 12.9

3.09 ± 0.41

5b

>100

>100

6.60 ± 2.96

6a

2.36 ± 0.18

1.21 ± 0.09

1.98 ± 0.31

6b

33.6 ± 8.54

>100

3.01 ± 0.44

Table 1.2. Binding affinity of des-keto LOB analogs at α4β2* and α7* nAChRs, and at
VMAT2

The data shown in Table 1.2 clearly show that when the keto functionality is
removed from the LOB scaffold, the affinity for α4β2* and α7* nAChRs dropped
considerably (in the order of 25000-fold). Interestingly, when the keto group was
removed from the LOB molecule, the resultant analogs had affinities for VMAT2
comparable to that of LOB. To summarize: the keto functionality in LOB appears to be
important for maintaining high affinity for nAChRs, but the same cannot be stated with
respect to VMAT2. In continuation of the systematic approach for studying the SAR of
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the LOB scaffold, the next step was to generate analogs in which of all oxygen
functionalities in the LOB molecule are removed.

Scheme 1.3. Synthetic routes to LOB analogs in which all oxygen functionalities have
been removed (defunctionalized LOB analogs)) (adapted from Crooks et al., 2011).

The synthesis of defunctionalized LOB analogs is described in Scheme 1.3. It is
through this synthetic modification of the LOB molecule that a compound of significant
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interest was discovered, i.e. lobelane (Zheng, et al., 2005). All synthetic compounds
generated in Scheme 1.3 began with LOB as the starting material. The synthesis of
compounds 7a and 7b began with epimerization of the LOB starting material by
subjecting LOB to a basic solution via addition of potassium carbonate in methanol. This
was followed by reduction with sodium borohydride to yield a mixture of lobelanidine
isomers (structure of this compound illustrated previously in Scheme 1.1). The mixture
of dihydroxyl isomers was treated with phosphoric acid to promote removal of both
hydroxyl moieties via dehydration to form C-C double bonds. The resulting mixture of
7a (meso-transdiene) and 7b ((-)-trans-transdiene) were separable via silica column
chromatography to afford pure samples of 7a and 7b. Compounds 7a and 7b were each
subjected to hydrogenation conditions (hydrogen gas, palladium-on-carbon) to reduce the
double bonds in the phenethylene linkers, yielding 9a (cis-lobelane) and 9b ((2S,6S)-1methyl-2,6-diphenethylpiperidine).
The synthesis of compounds 10a and 10b also began with LOB as the starting
material. The same ketoalkene analog synthesized in Scheme 1.1 was again generated,
and then subjected to epimerization via potassium carbonate in methanol, yielding a
mixture of cis-ketoalkene and trans-ketoalkene isomers. This mixture was subjected to
catalytic hydrogenation conditions, to yield a mixture of four isomers, which was then
was subjected to acid catalyzed dehydration with phosphoric acid, to yield a separable
mixture of the two products, 10a ((2S,6R)-1-methyl-2-phenethyl-6-styrylpiperidine) and
10b ((2S,6S)-1-methyl-2-phenethyl-6-styrylpiperidine).
Starting with LOB, compounds 11a and 11b were prepared via a five step process,
with Clemmenson reduction followed by Jones oxidation, compound 1 was generated via
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the same methodology as in Scheme 1.2, and then subjected to epimerization with
potassium carbonate in methanol. This mixture of epimers then underwent catalytic
hydrogenation to yield a mixture of four isomers, which was then subjected to acid
catalyzed dehydration to yield a mixture of 11a ((2R,6S)-1-methyl-2-phenethyl-6styrylpiperidine and 11b ((2R,6R)-1-methyl-2-phenethyl-6-styrylpiperidine) which were
separable via silica column chromatography to yield the pure samples of each compound.
The synthesis of compounds 8 and 12 in Scheme 1.3 also began with LOB, and
followed the same synthetic route, beginning with epimerization of the LOB starting
material by subjecting LOB to a basic solution via addition of potassium carbonate in
methanol. This was followed by reduction with sodium borohydride to yield a mixture of
lobelanidine isomers (structure of this compound illustrated previously in Scheme 1.1), at
which point the mixture of epimers was then subjected to reduction via sodium
borohydride, then to acid catalyzed dehydration of the alcohol with phosphoric acid to
yield a mixture of compounds 7a and 8. The isomeric mixture of compounds 7a and 8
was then purified via silica column chromatography to yield two pure compounds: the
previously synthesized 7a and 8 ((2R,6R)-1-methyl-2,6-distyrylpiperidine). When analog
8 was subjected to catalytic hydrogenation, compound 12 ((2R,6R)-1-methyl-2,6diphenethylpiperidine) was obtained.
The results for the ten des-oxygen compounds are shown in Table 1.3 (Zheng et
al., 2005). LOB is included as well for easy comparison. Compound 7a (mesotransdiene; MTD), is an unsaturated, fully deoxygenated analog of LOB, and was found
to have little to no affinity at either α4β2* (11.6 µM) or α7* (>100 µM) nAChRs, but had
comparable affinity for VMAT2 as LOB (i.e. less than 4-fold difference).
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Values are Ki ± SEM, µM
Compound

[3H]NIC Binding
α4β2* nAChR

[3H]MLA Binding
α7* nAChR

[3H]DTBZ Binding
VMAT2

LOB

0.004 ± 0.000

6.26 ± 1.30

2.76 ± 0.64

7a

11.6 ± 2.01

>100

9.88 ± 2.22

7b

>100

>100

19.4 ±1.25

8

>100

>100

7.09 ± 2.42

9a (lobelane)

14.9 ± 1.67

26.0 ± 6.57

0.97 ± 0.19

9b

>100

25.3 ± 4.27

5.32 ± 0.45

10a

>100

>100

2.50 ±0.23

10b

>100

55.1 ± 13.3

5.27 ± 1.32

11a

>100

>100

2.67 ± 0.56

11b

>100

25.2 ± 3.00

>100

12

>100

40.0 ± 14.1

6.46 ± 1.70

Table 1.3. Binding affinity of “des-oxygen” LOB analogs at α4β2* & α7* nAChRs, and
at VMAT2

Compounds 7b [(-)-trans-transdiene] and 8, are the two trans-enantiomers of
MTD, and both showed no affinity for either α4β2* (>100 µM) or α7* (>100 µM)
nAChRs, so they were more selective than LOB for VMAT2, but were less potent than
LOB at VMAT2 with affinities of 19.4 and 7.09 µM respectively. When MTD and the
two enantiomers of the trans-transdiene were subjected to hydrogenation, two
compounds were generated, viz.: 9a (cis-lobelane) and 9b (trans-lobelane). The cis-
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isomer of lobelane (9a) (hereafter referred to as simply lobelane) showed selectivity for
VMAT2, with approximately 4000-fold less affinity for α4β2* (14.9 µM) or α7* (26.0
µM) nAChRs, and had the greatest affinity of any of the compounds in Table 3 for
VMAT2 (0.97 µM). The trans-isomer of lobelane, 9b, showed similar selectivity for
VMAT2, but was not quite as potent (5.32 µM).
Nearly all the other defunctionalized analogs of LOB followed suit, with one
exception: compounds 10a, 10b, 11a and 11b possess little to no affinity at α4β2* or α7*
nAChRs, and 10a, 10b, and 11a have similar affinities for VMAT2 as does LOB,
however, 11b, the (2R,6R)-1-methyl-2-phenethyl-6-styrylpiperidine compound lacked
affinity for VMAT2 (>100 µM). The TBZ binding site on VMAT2 was unable to
distinguish between the (2S,6R) stereochemistry of compound 10a, the (2S,6S)
stereochemistry of compound 10b, and the (2R,6S) stereochemistry of compound 11a,
but was not as efficient at recognizing the (2R,6R) stereochemistry of compound 11b,
and it is noteworthy that VMAT2 could differentiate between these subtle changes in
stereochemistry (Zheng et al., 2005; Crooks et al., 2011).
Most importantly, for studies focused on targeting VMAT2, a new lead
compound was identified, lobelane (9a), that was specific for VMAT2 over α4β2* or α7*
nAChRs, and had greater affinity for the TBZ binding site of VMAT2 than LOB. At this
point, emphasis shifted from structural modification of LOB to structural modification of
the defunctionalized analog, lobelane. The second iteration of the SAR flowchart cycle
had begun with lobelane, the second generation lead compound.
The systematic approach to the alteration of the lobelane scaffold progressed in a
similar manner to the approach taken with LOB modification; however, a study of greater
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depth was undertaken for each remaining functionality of the lobelane scaffold. First,
synthesis was undertaken that effectively fragmented the lobelane scaffold to better
determine which portion(s) of the molecule were most important in binding to the TBZ
site on VMAT2. Second, the phenyl rings in the lobelane scaffold were modified, either
by addition of aromatic substituents, or by replacing the phenyl moieties with other
aromatic ring systems. Third, the lobelane scaffold was isomerized with respect to the
location and stereochemistry of the 2,6-substituents on the central piperidine ring.
Fourth, the length of the ethylene linkers between the central piperidine ring and the
phenyl groups were varied. Fifth, the N-methyl substituent of the lobelane molecule was
modified, either by increasing the length of the methyl group, or by introducing a variety
of other substituents with greater organic functionality and polarity. Sixth, the central
piperidine ring in lobelane was altered by replacement with other heterocycles, e.g. a
piperazino ring or a five membered pyrrolidine ring, as well as with conformationally
restricted ring systems, such as the tropane ring. Each of these structural modifications
provided important information and the vast amount of work completed has been
reviewed (Crooks et al., 2011).
Structural fragmentation of the lobelane scaffold was undertaken to determine if
the complete lobelane scaffold was necessary to maintain potent binding to the TBZ site
on VMAT2. The synthetic methodology used in generating fragmented lobelane analogs
is shown in Scheme 1.4.
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Scheme 1.4. Synthetic methods used in generating fragmented
lobelane analogs (Zheng et al., 2005; Crooks et al., 2011).

The methodology used to generate analogs 13 and 14 in Scheme 4 involved seven
steps. Beginning with 2-bromopyridine, Sonogashira coupling chemistry was used to
couple phenylacetylene to 2-bromopyridine to generate 2-(phenylethynyl)pyridine, which
was further modified under acidic conditions (sulfuric acid/reflux) to the ketone to yield
1-phenyl-2-(pyridin-2-yl)ethanone. The keto compound was hydrogenated with Adam’s
catalyst (platinum (IV) oxide) to reduce the pyridine ring to a piperidine ring, and set the
stereochemistry of the phenethyl linker, yielding the nor-(R)-1-phenyl-2-(piperidin-2yl)ethanone. N-methylation via formaldehyde addition afforded the N-methyl analog,
(R)-2-(1-methylpiperidin-2-yl)-1-phenylethanone. The keto functionality was then
reduced with sodium borohydride and dehydrated under acidic conditions with
phosphoric acid to produce compound 13, (R,E)-1-methyl-2-styrylpiperidine. A portion
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of this product was again subjected, in the final step, to hydrogenation conditions
(hydrogen gas, palladium-on-carbon) to yield the lobelane fragment analog compound
14, (R)-1-methyl-2-phenethylpiperidine (Zheng, et al., 2005).
Four acyclic compounds in which the piperidine ring was removed in favor of
acyclic analogs were also prepared as lobelane fragment analogs. Two compounds, 15
((S)-N-methyl-1,9-diphenylnonan-3-amine) and 16 ((R)-N-methyl-1,9-diphenylnonan-3amine) were fortuitously formed as side products and separated via silica column
chromatography from the hydrogenation of the previously discussed compounds 7b ((-)trans-transdiene) and compound 8 respectively, formed via ring opening during the
hydrogenation process. Two compounds, 17 ((E)-N-cinnamyl-N-methyl-3-phenylprop2-en-1-amine) (Blickle et al., 1939) and 18 (N-methyl-3-phenyl-N-(3phenylpropyl)propan-1-amine) (Stuhmer et al., 1954) were synthesized via established
methods. These four acyclic analogs of lobelane are shown in Figure 1.9.

Figure 1.9. Structures of acyclic fragmented lobelane analogs
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The biological results for the six fragmented lobelane analogs are shown in Table
1.4 (Zheng et al., 2005). Compound 13, the fragmented MTD analog, (R,E)-1-methyl-2styrylpiperidine, had no affinity for any of the receptors tested (IC50>100 µM).
Compound 14, the lobelane fragment analog, (R)-1-methyl-2-phenethylpiperidine,
showed only slight affinity for the α4β2* nAChR, but had no affinity for the α7* nAChR,
and surprisingly had no affinity at VMAT2 (IC50>100 µM). These data indicate that both
side chain linkers are required for the lobelane scaffold to bind to VMAT2. The acyclic
fragments of lobelane, compounds 15, 16, 17, and 18 had no affinity for either α4β2* or
α7* nAChRs, but had similar binding affinity as LOB at VMAT2, but slightly decreased
affinity for VMAT2 when compared to lobelane. The combined data from Table 1.4
indicate that the amine moiety and the two phenethyl moieties are required for binding to
the TBZ site on VMAT2, and in the case of the acyclic analogs, the data suggests that an
intact piperidine ring may be needed to maintain affinity for the TBZ site on VMAT2.
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Values are Ki ± SEM, µM
Compound

[3H]NIC Binding
α4β2* nAChR

[3H]MLA Binding
α7* nAChR

[3H]DTBZ
Binding VMAT2

LOB

0.004 ± 0.000

6.26 ± 1.30

2.76 ± 0.64

lobelane

14.9 ± 1.67

26.0 ± 6.57

0.97 ± 0.19

13

>100

>100

>100

14

4.52 ± 0.58

>100

>100

15

>100

>100

5.21 ± 1.23

16

>100

>100

3.96 ± 0.80

17

>100

>100

2.37 ± 0.55

18

>100

>100

3.07 ± 1.72

Table 1.4 Binding affinity of acyclic fragmented lobelane analogs
at α4β2* & α7* nAChRs, and at VMAT2

The next phase of modification of the lobelane scaffold involved alteration of the
phenyl rings, either by addition of aromatic substituents, or by replacing the phenyl rings
with other aromatic ring systems into those positions of the scaffold. Scheme 1.5 outlines
the chemistry necessary for the synthesis of symmetrically substituted phenyl ring
modification of the lobelane scaffold.
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Scheme 1.5. Synthetic methods for generation of symmetrically substituted phenyl ring
analogs of lobelane (Zheng et al., 2005).

Synthesis of symmetrical substituted phenyl ring analogs of lobelane utilizes 2,6methylpyridine as a starting material, which undergoes a condensation type reaction with
substituted aryl aldehydes when refluxed in acetic anhydride to yield the corresponding
2,6-distyrylpyridine with a variety of substituted phenyl rings. The phenyl substituted
2,6-distyrylpyridine compounds are then subjected to hydrogenation conditions with
Adam’s catalyst (platinum(IV)oxide) to reduce the central pyridine ring to a piperidine
ring (affording 2,6-cis-stereochemistry) and the two alkene moieties to alkanes. At this
stage of the synthesis, phenyl substituted (2S,6R)-2,6-diphenethylpiperidine is generated.
If all positions on the phenyl rings are hydrogen rather than other functionalities, the
compound generated is nor-lobelane, (des-methyl lobelane). To introduce the N-methyl
group present in Lobeline and lobelane, the phenyl substituted (2S,6R)-2,6diphenethylpiperidine intermediates were exposed to reductive amination conditions with
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paraformaldehyde and sodium cyanoborohydride in methanol to yield the corresponding
phenyl substituted (2S,6R)-1-methyl-2,6-diphenethylpiperidine scaffold. Symmetrical
phenyl substituted analogs of both lobelane and nor-lobelane were generated via this
methodology, and their structures and binding affinities for α4β2* & α7* nAChRs, and for
VMAT2 are included in Table 1.5.

Values are Ki ± SEM, µM
Compound

Compound Structure

Identifier

LOB

O

OH
N
CH3

N
CH3

lobelane

[3H]NIC
Binding
α4β2*
nAChR

[3H]MLA
Binding
α7* nAChR

[3H]DTBZ
Binding
VMAT2

VMAT2
[3H]DA
Uptake

0.004 ±
0.000

6.26 ± 1.30

2.76 ± 0.64

0.47 ± 0.045

14.9 ± 1.67

26.0 ± 6.57

0.97 ± 0.19

0.045± 0.002

>100

>100

2.31 ± 0.21

0.043 ±0.008

>100

>100

1.60 ± 0.10

0.042±0.011

>100

>100

1.07 ± 0.07

0.057± 0.010

Nor-lobelane
N
H

F

F
N
H

19a

F

19b

F
N
CH3

Table 1.5 (continued)
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F

F

N
H

20a

F

49.2 ± 21.3

1.60 ± 0.08

0.036 ±0.006

>100

16.6 ± 3.47

0.57 ± 0.07

0.093±0.018

F

>100

>100

1.25 ± 0.08

0.021± 0.004

F

>100

>100

0.98 ± 0.31

0.030± 0.008

>100

>100

1.87 ± 0.19

0.026 ± 0.004

>100

29.7 ± 7.73

0.58 ± 0.04

0.026 ± 0.004

>100

>100

1.67 ± 0.07

0.040± 0.006

>100

25.1 ± 2.23

0.43 ± 0.03

0.030± 0.005

>100

>100

3.32 ± 0.82

0.013±0.003

>100

>100

1.73 ± 0.20

0.015 ± 0.002

>100

>100

2.34 ± 0.16

0.191± 0.146

F

N
CH3

20b

>100

N
H

21a

F

21b

F

N
CH3

H3C

H3C

O

O

N
H

22a

H3C

H3C

O

O

N
CH3

22b

H3C

O

N
H

O

CH3

23a

H3C

O

N
CH3

O

CH3

23b

H3C

24a

H3C

24b

O

25a

O

N
H
O

O

N
CH3

N
H

O

CH3

O

CH3

O
O
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O

25b

O

26a

H3C

26b

H3C

O

N
CH3

O

>100

18.2 ± 6.87

0.52 ± 0.25

0.043± 0.011

CH3

>100

>100

3.23 ± 0.10

0.59 ± 0.010

CH3

>100

>100

4.36 ± 0.18

0.154± 0.008

>100

>100

9.90 ± 2.01

0.836± 0.361

>100

>100

1.51 ± 0.07

0.19± 0.015

Cl

>100

>100

1.32 ± 0.18

0.182± 0.005

Cl

>100

>100

1.04 ± 0.06

0.016± 0.005

Ph

>100

>100

>100

0.127 ± 0.034

Ph

>100

>100

10.7 ± 6.60

0.034± 0.008

>100

>100

5.96 ± 1.76

0.247± 0.042

N
H

N
CH3

F3C

CF3

N
H

27a

F3C

27b

Cl

Cl

28a

CF3

N
CH3

N
H
Cl

Cl

Cl
N
CH3

28b

Cl

29a

Ph

29b

Ph

N
H

N
CH3

N
H

30

O
O

O
O
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N
H

31

32a

32b

OH

HO

N
H

N
CH3

>100

>100

5.26 ± 0.47

0.047± 0.017

>100

>100

4.68 ± 0.70

*

>100

>100

0.63 ± 0.16

*

>100

>100

>100

*

>100

>100

2.03 ± 0.45

*

N
H

33a

33b

N
CH3

Table 1.5 Structures of substituted phenyl analogs of lobelane and assay data from
[3H]NIC Binding α4β2* nAChR, [3H]MLA Binding α7* nAChR, [3H]DTBZ Binding
VMAT2, and VMAT2 [3H]DA Uptake

Twenty eight lobelane analogs with a variety of substitutions in the phenyl rings
were synthesized in this series. All of the compounds within this series had either lower
or comparable affinities at α4β2* & α7* nAChRs when compared to lobelane, with the
exception of compounds 29a ((2S,6R)-2,6-bis(2-(biphenyl-4-yl)ethyl)piperidine) and 33a
((2S,6R)-2,6-bis(2-(naphthalen-2-yl)ethyl)piperidine), which were both nor-analogs with
bulky biphenyl (compound 29a) and 2-naphthyl (compound 33a) analogs, all compounds
had comparable affinity to lobelane at VMAT2. Analogs 20b ((2S,6R)-2,6-bis(3fluorophenethyl)-1-methylpiperidine), 22b ((2S,6R)-2,6-bis(2-methoxyphenethyl)-1-
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methylpiperidine), and 23b ((2S,6R)-2,6-bis(3-methoxyphenethyl)-1-methylpiperidine)
had the highest affinity for VMAT2 with Ki values of 0.57, 0.58, and 0.43 µM,
respectively. Also the N-methyl analogs consistently exhibited higher affinity at VMAT2
when compared to their corresponding nor-counterparts. All in all, modification of the
phenyl rings in the lobelane scaffold via addition of a variety of aromatic substituents that
were either electron withdrawing, electron donating, or replacement of the phenyl rings
with more bulky aromatic moieties was successful in further reducing the affinity of these
analogs at α4β2* & α7* nAChRs, while maintaining and perhaps slightly improving
affinity for the TBZ binding site on VMAT2. The compounds that had the greatest
affinity for the TBZ binding site on VMAT2 and their corresponding aromatic
substituents were 19b (2-fluoro substituted phenyl), 20b (3-fluoro substituted phenyl),
21b (4-fluoro substituted phenyl), 22b (2-methoxy substituted phenyl), 23b (3-methoxy
substituted phenyl), 24b (4-methoxy substituted phenyl), 25b (3,4-methylenedioxy
substituted phenyl), and 28b (2,4-dichloro substituted phenyl), each of which possessed
affinity for the TBZ site on VMAT2 of approximately 1 µM and each possessed a Nmethyl moiety. This subgroup of eight compounds also had correspondingly potent
values in the VMAT2 [3H]DA Uptake assay with values ranging from 15-93 nM. It
cannot be overstated that the importance of the VMAT2 [3H]DA Uptake assay is much
greater than that of the TBZ site binding assay. The TBZ binding assay does determine
the affinity of the ligand in question for the TBZ binding site on VMAT2, but the
VMAT2 [3H]DA Uptake assay accurately determines the effect of the ligand on the
functioning vesicles’ ability to sequester DA into the vesicle for storage and later
use/release. More information on these two assays will be addressed in Chapter 5.
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Two further synthetic schemes were designed to modify the phenyl moieties
present in the lobelane scaffold. Scheme 1.6 outlines the synthesis of lobelane analogs
possessing heteroaromatic rings in place of the phenyl rings, and Scheme 1.7 outlines the
synthesis of asymmetric lobelane analogs that possess two different aromatic moieties in
place of the two phenyl rings of the lobelane scaffold.

Scheme 1.6 Synthetic methods for generation of symmetrically substituted
heteroaromatic ring analogs of lobelane (Varkat et al., 2010).

The synthetic procedure illustrated in Scheme 1.6 began with N-methylated 2,6dimethylpyridinium iodide as the staring material. The starting material underwent a
condensation reaction with the required heteroaromatic aldehyde to form the conjugated
backbone of the scaffold. When subjected to hydrogenation conditions (Adam’s catalyst
and hydrogen gas), five final products with heteroaromatic moieties in place of the
phenyl rings found in the lobelane scaffold were generated. Their structures and binding
affinities at VMAT2 are included in Table 1.6.
Asymmetric lobelane analogs which integrate two non-identical aromatic
functionalities into the lobelane scaffold were also being prepared. The synthesis of these
asymmetric lobelane analogs is outlined in Scheme 1.7.
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Scheme 1.7 Synthetic methods for the generation of asymmetrical
lobelane analogs (Crooks, et al., 2011)

Two asymmetric analogs were prepared via the chemistry outlined in Scheme 1.7.
Beginning with 2-bromo-6-pyridinecarboxaldehyde as the starting material, a Wittig
reaction with a benzyl ylid afforded a cis-trans mixture of 2-bromo-6-styrylpyridine.
This cis-trans mixture was taken without isolation and subjected to Sonogashira coupling
chemistry with either 1-ethynylnaphthalene or 3-ethynylanisole to afford the conjugated
intermediates, 2-(naphthalen-1-ylethynyl)-6-styrylpyridine and 2-((3methoxyphenyl)ethynyl)-6-styrylpyridine respectively.
The two conjugated intermediates (2-(naphthalen-1-ylethynyl)-6-styrylpyridine
and 2-((3-methoxyphenyl)ethynyl)-6-styrylpyridine) were first subjected to
hydrogenation conditions with Adam’s catalyst and hydrogen gas, and then N-methylated
via reductive amination. The two final products, compound 39, (2S,6R)-1-methyl-2-(2(naphthalen-1-yl)ethyl)-6-phenethylpiperidine, and compound 40 (2S,6R)-2-(3-
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methoxyphenethyl)-1-methyl-6-phenethylpiperidine and their binding affinities for
VMAT2 are included in Table 1.6.

Compound

Values are Ki ±
SEM, µM

Compound Structure

[3H]DTBZ Binding
VMAT2

Identifier
O

OH

LOB

N
CH3

2.76 ± 0.64

lobelane

N
CH3

0.97 ± 0.19

N

34

35

N
CH3

N

N

N
CH3

37

N
CH3
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5.87 ± 1.72

N

N
CH3

36

N

N

33.3 ± 16.3

N

0.96 ± 0.37

2.64 ± 1.41
N

38
N
CH3

39

40

N
CH3

9.21 ± 1.65
N
H3C

N
CH3

1.02 ± 0.30

N
CH3

0.83 ± 0.23

CH3
O

Table 1.6 Structures and Binding affinity of heteroaromatic substituted and asymmetrical
lobelane analogs for VMAT2

Of the five analogs that were designed and synthesized to contain two heteroaromatic ring substituents instead of rather than the two phenyl rings found in lobelane,
three (i.e. compounds 34, 35, and 38) will be positively charged due to protonation at
physiological pH, i.e. nitrogen moieties with pKa’s greater than 7.2-7.4 at three distinct
sites on the molecule. The majority of the compounds containing nitrogen atoms
susceptible to protonation at physiological pH exhibited lower affinities for the TBZ
binding site on VMAT2 (compounds 34, 35, 37 and 38). The lone exception was
compound 36, where the phenyl rings that are found in lobelane have been replaced by
two 2-quinolinyl moieties; this analog showed similar affinity to lobelane at VMAT2
(Varkat, et al., 2010). This is important information, since it shows that the TBZ binding
site on VMAT2 prefers neutral aryl substituents in order to bind effectively.
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The two asymmetric analogs of lobelane (compounds 39 and 40) exhibited similar
affinities as lobelane at the TBZ binding site on VMAT2. Compound 39, containing one
naphthyl ring and one phenyl ring did have slightly less affinity than the symmetrical
naphthyl analog (1.02 µM vs 0.63 µM, respectively). Compound 40, containing one
anisole ring and one phenyl ring also had slightly less affinity for VMAT2 than the
symmetrical 3-anisolyl analog (0.83 µM vs 0.43 µM).
The next two phases of modification of the lobelane scaffold involved altering
both the location of attachment of the phenethyl linkers on the central piperidine ring as
well as varying the length of the methylene linkers that connect the aryl rings to the
central piperidine ring, in order to determine the importance of the intramolecular
distance between the piperidine ring amine moiety and the phenyl rings (Crooks et al.,
2011). Schemes 1.8, and 1.9 outline the chemistry used in these modifications of the
lobelane scaffold.
Scheme 1.8 illustrates the synthesis of isomerized lobelane analogs in which the
phenethyl linkers have been moved from the 2,6 positions of the piperidine ring to the
1,2-, 1,3-, and 1,4-positions. Several analogs were also generated that contained a threecarbon linker between the piperidine ring and the phenyl rings. The synthesis utilizes an
appropriate 2-methylpyridine, 3-methylpyridine, or 4-methylpyridine, depending on the
desired attachment point of the linker on the piperidine ring. The stating material is
condensed with benzaldehyde in refluxing acetic anhydride to yield the conjugated 2, 3,
or 4 substituted (E)-styrylpyridine. These conjugated products are then subjected to
hydrogenation conditions with Adam’s catalyst (platinum(IV) oxide) and hydrogen gas to
yield the appropriate 2, 3, or 4 substituted phenethylpiperidine.
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Scheme 1.8 Synthetic methods for generation of isomerized lobelane
analogs (Zheng et al., 2005; Crooks et al., 2011)

The substituted phenethylpiperidines were reacted via one of two methods to
yield either N1 linked phenethyl analogs or N1 linked phenpropyl analogs. In the case of
the N1 substituted phenethyl compounds, the substituted phenethylpiperidines were
reacted with phenylacetaldehyde and sodium cyanoborohydride to yield the desired series
of products. In the case of the N1 substituted phenpropyl compounds, the substituted
phenethylpiperidines were reacted with trans-cinnamyl bromide with potassium
carbonate serving as a base, to yield the desired series of products. The exact structures
of the analogs generated in Scheme 1.8 and the resultant binding affinities at α4β2* & α7*
nAChRs, and at VMAT2 are shown in Table 1.7.
Scheme 1.9 outlines the chemistry used in generating a series of four compounds
where the phenethyl linkers have been moved to the 2,4 and 3,5 positions of the central
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piperidine ring of the lobelane scaffold. In order to more clearly indicate where the
amine moiety is in the ring, it has been given a marker labeled as such in the scheme.

Scheme 1.9 Synthetic methods for generation of isomerized lobelane analogs with
phenethyl linkers in the 2,4 and 3,5 position of the piperidine ring (Zheng et al., 2005;
Crooks et al., 2011)

The synthesis of the four analogs generated in Scheme 1.9 necessitated two
different reaction conditions for the appropriate starting materials. When the starting
material was 2,4-lutidine, also known as 2,4-dimethylpyridine, the hydrogen atoms on the
methyl groups were sufficiently acidic to allow condensation reaction to be utilized. 2,4Lutidine was subjected to condensation reaction conditions with benzaldehyde in
refluxing acetic anhydride to yield the desired conjugated intermediate, 2,4distyrylpyridine. However, the presence of the methyl groups in the 3 and 5 positions of
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the pyridine ring in 3,5-lutidine (also known as 3,5-dimethylpyridine) made the hydrogen
atoms on the methyl groups less acidic, and a different chemistry was required to
generate the conjugated intermediate, 3,5-distyrylpyridine. Starting with 3,5-lutidine, the
condensation reaction proceeded only with an activated form of benzaldehyde, i.e. Nbenzylidene-4-chloroaniline, using potassium t-butoxide as a base in dimethylformamide.
The two appropriately substituted conjugated intermediates, 2,4-distyrylpyridine and 3,5distyrylpyridine, were then subjected to hydrogenation conditions with Adam’s catalyst
and hydrogen gas to yield nor-(2S,4S)-2,4-diphenethylpiperidine and nor-(3R,5S)-3,5diphenethylpiperidine, respectively. In order to introduce the N-methyl moiety, the norcompounds were exposed to reductive amination conditions with paraformaldehyde and
sodium cyanoborohydride in methanol to generate analogs (2S,4S)-1-methyl-2,4diphenethylpiperidine and (3R,5S)-1-methyl-3,5-diphenethylpiperidine. The binding
affinities of the four analogs generated in Scheme 1.9 at α4β2* & α7* nAChRs, and at
VMAT2 are shown in Table 1.7.
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Values are Ki ± SEM, µM
Compound

Compound Structure

Identifier

LOB

O

OH

[3H]NIC
Binding
α4β2* nAChR

[3H]MLA
Binding α7*
nAChR

[3H]DTBZ
Binding
VMAT2

0.004 ± 0.000

6.26 ± 1.30

2.76 ± 0.64

14.9 ± 1.67

26.0 ± 6.57

0.97 ± 0.19

>100

66.9 ± 27.4

3.32 ± 0.74

>100

>100

3.95 ± 0.61

7.62 ± 1.47

>100

1.87 ± 0.25

N
CH3

N
CH3

lobelane

41
N

42

43

N

N
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44

>100

9.02 ± 1.54

3.35 ± 0.80

>100

>100

4.04 ± 1.76

46

>100

>100

2.47 ± 0.70

47

>100

>100

1.36 ± 0.11

>100

>100

6.11 ± 0.92

N

N

45

N

N
H

48
HN

Table 1.7 (continued)
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49

>100

>100

2.62 ± 0.51

>100

>100

11.7 ± 0.65

N
CH3

50
H3C

N

Table 1.7 Compound structures and α4β2* & α7* nAChRs, and VMAT2 binding
affinity of isomerized lobelane analogs with phenethyl linkers in the N1, C2; N1,
C3; N1, C4; C2, C4 and C3, C5 positions.

The above isomerized analogs of lobelane had the low affinities at α4β2* & α7*
nAChRs, and interestingly maintained similar affinities to lobelane at the TBZ binding
site on VMAT2 (within one order of magnitude). Compounds 43, 46, and 49 were
especially interesting, since they exhibited binding affinity better than most other analogs
in the table; the linkers in these analogs were in the C2, C4 and N1, C4 positions. The
extra carbon in the N1 linker of compound 46 only moderately decreased the analog’s
affinity for VMAT2. These data indicate that isomerization of the lobelane scaffold to
afford compounds with linkers in varying positions of attachment around central
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piperidine ring does not greatly hinder binding to VMAT2, and allows for interesting
opportunities involving scaffold optimization and chemical space.
The fourth stage of the systematic approach to the alteration of the lobelane
scaffold comprised of designing analogs with variable methylene linker lengths between
the central piperidine ring of the scaffold and the phenyl rings, therefore increasing and
decreasing intramolecular distances between the amine moiety and the phenyl rings. The
number of carbon atoms between the piperidine ring and the phenyl rings was varied
from zero to three in the C2 and C6 positions, affording 17 compounds in this series
(Zheng et al., 2008; Crooks et al., 2011). Schemes 1.10, 1.11, and 1.12 outline the
chemistry designed to produce the three symmetrical scaffolds.

Scheme 1.10 Synthesis of a symmetrical lobelane analog with zero methylene groups
between the piperidine ring and the phenyl rings (Zheng et al., 2008; Crooks et al., 2011)

Synthesis of the symmetrical lobelane analog with no carbon atoms between the
piperidine ring and the two phenyl rings (i.e. a molecule which is devoid of methylene
units between the central piperidine ring and two phenyl rings) was synthesized by initial
N-methylation of the starting material, 2,6-biphenylpyridine, via reaction with methyl ptosylate, generating the quaternary ammonium salt as an intermediate. Subsequent two
step reduction of the quaternary ammonium salt with NaBH4, followed by catalytic

68

hydrogenation with palladium- on-carbon and hydrogen gas afforded the desired
compound, (2S,6R)-1-methyl-2,6-diphenylpiperidine.
The synthesis of the symmetrical lobelane analog with one methylene group
between the piperidine ring and the two phenyl rings is shown in Scheme 1.11.

Scheme 1.11 Synthesis of the symmetrical lobelane analog with one methylene group
between the piperidine ring and the phenyl rings (Zheng et al., 2008; Crooks et al., 2011)

The synthesis of the symmetrical analog with one methylene group between the
piperidine ring and the two phenyl rings utilized 2,6-dibromopyridine as the starting
material.
Application of Kumada coupling chemistry, which consists of a cross coupling reaction,
which is widely used in organic synthesis for generating carbon–carbon bonds by the reaction of
a Grignard reagent, in this case (3-phenylpropyl)magnesium bromide and an organic halide,

i.e. 2,6-dibromopyridine . The Kumada coupling procedure uses transition metal
catalysts, in this case dichloro[1,3-bis(diphenylphosphino)propane]nickel, to couple the
2,6-dibromopyridine starting material with (3-phenylpropyl)magnesium bromide to
afford the desired 2,6-dibenzylpyridine intermediate. Reduction of this intermediate via
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hydrogenation conditions utilizing Adam’s catalyst and hydrogen gas yielded nor(2S,6R)-2,6-dibenzylpiperidine. In order to introduce the N-methyl moiety the norcompound was exposed to reductive amination conditions with paraformaldehyde and
sodium cyanoborohydride in methanol to generate lobelane analog (2S,6R)-2,6-dibenzyl1-methylpiperidine.
A similar synthetic strategy for the symmetrical lobelane analog with three
methylene groups between the piperidine ring and the two phenyl rings is shown in
Scheme 1.12.

Scheme 1.12 Synthesis of the symmetrical lobelane analog with three methylene groups
between the piperidine ring and the phenyl rings (Zheng et al., 2008; Crooks et al., 2011)

The synthesis of the symmetrical analog with three methylene groups linking the
piperidine ring and the two phenyl rings also utilized 2,6-dibromopyridine as the starting
material. Again, via the application of Kumada coupling chemistry to couple the 2,6dibromopyridine starting material with (3-phenylpropyl)magnesium bromide afford the
desired 2,6-bis(3-phenylpropyl)pyridine intermediate. Reduction of the intermediate via
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hydrogenation conditions with Adam’s catalyst and hydrogen gas yielded the nor(2R,6S)-2,6-bis(3-phenylpropyl)piperidine compound. In order to introduce the N-methyl
moiety found in the lobelane scaffold, the nor-compounds were exposed to reductive
amination conditions with paraformaldehyde and sodium cyanoborohydride in methanol
to generate lobelane analog (2R,6S)-1-methyl-2,6-bis(3-phenylpropyl)piperidine.
The asymmetric compounds in this series required more involved chemistry and
multiple synthetic steps. The synthesis of the analog containing zero carbons between the
piperidine ring and the phenyl ring on one side of the molecule and one carbon between
the piperidine ring and the phenyl ring on the opposite side of the molecule is outlined in
Scheme 1.13.

Scheme 1.13 Synthesis of an asymmetrical lobelane analog with zero carbons and one
carbon in the linkers between the piperidine ring and the phenyl rings (Zheng et al., 2008;
Crooks et al., 2011).

The starting material for the synthesis outlined in Scheme 1.13 was 2-bromo-6methoxypyridine. Application of Kumada coupling chemistry with benzylmagnesium
chloride afforded the 2-benzyl-6-methoxypyridine intermediate, which was then
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subjected to reaction with phosphoryl chloride to transform the methoxy group to a
chlorine functionality, which yielded the 2-benzyl-6-chloropyridine intermediate. This in
turn, was subjected to Suzuki coupling with phenylboronic acid catalyzed with [1,3bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)-palladium(II) dichloride
(PEPPSI-IPr) and KOtBu as base in isopropanol, to yield the 2-benzyl-6-phenylpyridine
intermediate. Reduction of this intermediate via hydrogenation with Adam’s catalyst and
hydrogen gas yielded the nor- (2R,6S)-2-benzyl-6-phenylpiperidine. In order to
introduce the N-methyl moiety, the nor-compound was exposed to reductive amination
conditions with paraformaldehyde and sodium cyanoborohydride in methanol to generate
the lobelane analog (2R,6S)-2-benzyl-1-methyl-6-phenylpiperidine.
The synthesis of the analogs containing zero methylene units between the
piperidine ring and the phenyl ring on one side of the molecule and either two methylene
units or three methylene units between the piperidine ring and the phenyl ring on the
opposite side of the molecule is outlined in Scheme 1.14.
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Scheme 1.14 Synthesis of asymmetrical lobelane analog with zero methylene units and
either two or three methylene units in the linkers between the piperidine ring and the
phenyl rings (Zheng et al., 2008; Crooks et al., 2011).

The synthesis of both asymmetrical compounds began with 2-bromo-6methylpyridine as the starting material, which was reacted with phenylboronic acid under
Suzuki coupling conditions to yield the common intermediate, 2-methyl-6phenylpyridine. From this point the syntheses diverged. To make the asymmetrical
compound with zero and two methylene units in the linkers, the common intermediate
was subjected to a condensation reaction with benzaldehyde in refluxing acetic
anhydride. This afforded the conjugated product (E)-2-phenyl-6-styrylpyridine, which
was then reduced under hydrogenation conditions to nor-(2R,6S)-2-phenethyl-6phenylpiperidine. The N-methyl group was introduced utilizing reductive amination
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conditions with paraformaldehyde and sodium cyanoborohydride in methanol to generate
the desired product, (2R,6S)-1-methyl-2-phenethyl-6-phenylpiperidine. To prepare the
asymmetrical compound with zero and three carbons in the linker units, the common
intermediate 2-methyl-6-phenylpyridine was subjected to deprotonation of the 2-methyl
group followed by an SN2 reaction with 2-iodoethylbenzene to afford 2-phenyl-6-(3phenylpropyl)pyridine, which was then reduced under hydrogenation conditions to nor(2S,6S)-2-phenyl-6-(3-phenylpropyl)piperidine followed by N-methylation to afford the
desired product, (2S,6S)-1-methyl-2-phenyl-6-(3-phenylpropyl)piperidine.
The synthesis of the analog containing one methylene unit between the piperidine
ring and the phenyl ring on one side of the molecule and two methylene units between the
piperidine ring and the phenyl ring on the opposite side of the molecule is outlined in
Scheme 1.15. Starting with 2-benzyl-6-chloropyridine, Negishi coupling of the starting
material with 2-phenyl-1-ethylzinc iodide (generated in situ) using PEPPSI-IPr as a
catalyst afforded 2-benzyl-6-phenethylpyridine, which was then subjected to catalytic
hydrogenation to yield nor- (2S,6R)-2-benzyl-6-phenethylpiperidine and N-methylated
with paraformaldehyde and sodium cyanoborohydride in methanol to generate the desired
product, (2S,6R)-2-benzyl-1-methyl-6-phenethylpiperidine.
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Scheme 1.15 Synthesis of the asymmetrical lobelane analog with one methylene units
and two methylene units in the linkers between the piperidine ring and the phenyl rings
(Zheng et al., 2008; Crooks et al., 2011).

The synthesis of the analog containing one methylene unit between the piperidine
ring and the phenyl ring on one side of the molecule and three methylene units between
the piperidine ring and the phenyl ring on the opposite side of the molecule is outlined in
Scheme 1.16. Starting with 2-benzyl-6-chloropyridine, Negishi coupling of the starting
material with 3-phenyl-1-propylzinc iodide (generated in situ) using PEPPSI-IPr as a
catalyst afforded 2-benzyl-6-(3-phenylpropyl)pyridine, which was then subjected to
catalytic hydrogenation to yield nor- (2S,6S)-2-benzyl-6-(3-phenylpropyl)piperidine. Nmethyl under reductive amination conditions with paraformaldehyde and sodium
cyanoborohydride in methanol afforded the desired product, (2S,6S)-2-benzyl-1-methyl6-(3-phenylpropyl)piperidine.
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Scheme 1.16 Synthesis of an asymmetrical lobelane analog with one methylene
unit and two methylene units in the linkers between the piperidine ring and the phenyl
rings (Zheng et al., 2008; Crooks et al., 2011).

The synthesis of the analog containing two methylene units between the
piperidine ring and the phenyl ring on one side of the molecule and three methylene units
between the piperidine ring and the phenyl ring on the opposite side of the molecule is
outlined in Scheme 1.17. The starting material, 2,6-lutidine, was subjected to monocondensation with benzaldehyde (both mono and disubstituted products were produced,
and the mono product was separated via column chromatography), to afford the
conjugated product, (E)-2-methyl-6-styrylpyridine. The conjugated product was then
subjected to deprotonation of the 2-methyl group followed by SN2 reaction with (2iodoethyl)benzene to yield (E)-2-(3-phenylpropyl)-6-styrylpyridine, which was subjected
to catalytic hydrogenation to yield nor-(2S,6S)-2-phenethyl-6-(3-phenylpropyl)piperidine
and N-methylated to afford the desired product, (2S,6S)-1-methyl-2-phenethyl-6-(3phenylpropyl)piperidine.
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Scheme 1.17 Synthesis of an asymmetrical lobelane analog with two methylene units and
three methylene units in the linkers between the piperidine ring and the phenyl rings
(Zheng et al., 2008; Crooks et al., 2011).

The 17 lobelane analogs generated in this fourth stage of the systematic approach
to the alteration of the lobelane scaffold comprised of designing analogs with modified
lengths between the central piperidine ring of the scaffold, therefore varying the
intramolecular distance between the amine moiety and the phenyl rings; their binding
affinities at the TBZ binding site on VMAT2 are shown in Table 1.8.
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Compound

Compound Structure

Values are Ki ± SEM,
µM
[3H]DTBZ Binding
VMAT2

Identifier
OH

O

LOB

N
CH3

2.76 ± 0.64

lobelane

N
CH3

0.97 ± 0.19

51

N
CH3

>100

52a

N
H

7.68 ± 1.44

52b

N
CH3

10.5 ± 3.36

53a

N
H

4.50 ± 1.02

53b

N
CH3

1.00 ± 0.23

54a

N
H
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24.1 ± 6.10

N
CH3

54b

13.6 ± 8.14

55a

N
H

28.4 ± 7.30

55b

N
CH3

16.1 ± 4.07

56a

N
H

28.6 ± 2.44

56b

N
CH3

62.5 ± 16.6

57a

N
H

12.2 ± 0.19

57b

N
CH3

2.77 ± 1.77

58a

N
H

1.13 ± 0.28

58b

N
CH3

1.62 ± 0.39
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59a

N
H

4.60 ± 0.56

59b

N
CH3

0.88 ± 0.30

Table 1.8 Compound structures and VMAT2 binding affinity of modified lobelane
analogs with differing intramolecular distances between the piperidine ring and the
phenyl rings in the molecule (Zheng et al., 2008; Crooks et al., 2011).

From the data in Table 1.8, it has been shown that altering the intramolecular
distance between the piperidine ring and the phenyl rings on the lobelane scaffold has
dramatic effects on the ability of the analogs to bind to the TBZ binding site on VMAT2.
The removal of the ethylene linker on both sides of the piperidine ring of lobelane to
afford compound 51 resulted in a complete loss of affinity for the TBZ binding site on
VMAT2. When the linkers are one methylene unit in length some of the affinity for
VMAT2 returns, but then only moderately, as compound 52b still exhibited a 10-fold
decrease in affinity compared to lobelane. In order to bind to the TBZ site on VMAT2, it
appears that it is necessary to extend the length of the methylene linkers between the
piperidine ring and the phenyl rings to at least two carbons (the distance found in
lobelane) or longer. Compound 53b, which is a symmetrical analog of lobelane (three
carbons in each linker), exhibits the same affinity for VMAT2 as does lobelane (Ki = 1.00
µM). The asymmetric analog 59b also had an affinity similar to lobelane (Ki = 0.88 µM),
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and the linkers between the piperidine ring and the phenyl rings were two and three
methylene units in length.
In the fifth stage of the systematic approach to alteration of the lobelane scaffold ,
the N-methyl group of lobelane was modified, either by increasing the length of the alkylmoiety, or by replacing the methyl group with a variety of other N-substituents with
greater organic functionality and polarity. The seven compounds generated in this series
of structural modifications and their affinities for the TBZ binding site on VMAT2 are
shown in Table 1.9.

Compound

Compound Structure

Values are Ki ± SEM,
µM
[3H]DTBZ Binding
VMAT2

Identifier
OH

O

LOB

N
CH3

2.76 ± 0.64

lobelane

N
CH3

0.97 ± 0.19

N

3.41 ± 0.67

N

1.87 ± 0.25

60
H3C

61

CH3
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62
H3C

63

N
N

>100
CH3

N

22.6 ± 0.23

N

5.59 ± 0.94

N

64

NH2

N

65

H3C

N

CH3

N

66

9.59 ± 1.47

0.56 ± 0.08

HO
HO

Table 1.9 Compound structures and VMAT2 binding affinity of modified lobelane
analogs (Crooks et al., 2011)

In compounds 60 and 61 the length of the N-methyl substituent has been
increased from methyl to ethyl and propyl. The N-ethyl and N-propyl analogs exhibited
slightly lower affinity at VMAT2 compared to lobelane. By replacing the N-methyl
group with a dimethylhydrazine moiety, as in compound 62, led to a complete loss of
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affinity for the TBZ site on VMAT2. When the N-methyl group was replaced with a
cyanomethyl moiety (compound 63), aminoethyl (compound 64), or a
dimethylaminoethyl moiety (compound 65), the affinity for VMAT2 was also reduced by
about one order of magnitude (5-20 fold) when compared to lobelane (Crooks et al.,
2011). One very interesting compound was discovered in this series (compound 66), in
which the N-methyl group was replaced with a 1,2(R)-dihydroxypropyl moiety.
Compound 66, (R)-3-((2S,6R)-2,6-diphenethylpiperidin-1-yl)propane-1,2-diol, exhibited
slightly better affinity than lobelane for the TBZ binding site on VMAT2, and was much
more water soluble than lobelane, which is a highly desirable characteristic in compounds
selected for further study in animals and humans.
In the sixth phase of the systematic approach to structural changes in the lobelane
scaffold, the central piperidine ring was subjected to structural modification. The
piperidine ring was altered by incorporating an additional heteroatom, to afford a
piperazine ring system. The piperidine ring was also replaced with a smaller fivemembered pyrrolidine ring, as well as with a larger conformationally restricted tropane
ring system. The synthesis of the piperazine ring analogs is outlined in Scheme 1.18.
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Scheme 1.18 Synthetic outline for generation of piperazine analogs of lobelane

Two compounds were constructed in the piperazine series of analogs, viz:,
(2R,6S)-2,6-diphenethylpiperazine and (2R,6S)-1,4-dimethyl-2,6-diphenethylpiperazine.
The chemistry involved in making these two compounds differs only in the starting
material when compared to the synthesis of the piperidine analogs in Scheme 1.5, since
2,6-dimethylpyrazine is used in place of 2,6-dimethylpyridine. The two piperazine
compounds generated in this series and their affinities for the TBZ binding site on
VMAT2 are shown in Table 1.9.
The piperidine ring was also replaced with a five-membered pyrrolidine ring, and
the structures and affinities of such compounds at the TBZ binding site on VMAT2 are
also shown in Table 1.9.
Finally, the piperidine ring was replaced with a more conformationally restricted
tropane ring. The outline of the chemistry used to synthesize the seven compounds in
this series is shown in Schemes 1.19 and 1.20.
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Scheme 1.19 Synthesis of tropane analogs of lobelane (Zheng et al., 2005)

Scheme 1.20 Synthesis of tropane analogs of lobelane with extended linkers
(Zheng et al., 2005)

Briefly, the synthesis of the seven analogs in the tropane series began with
tropinone as the starting material, which was subjected to an Aldol condensation reaction
with either aryl aldehydes or trans-cinnamaldehyde. Clemmenson reduction of the
conjugated Aldol products followed by catalytic hydrogenation with palladium-on-carbon
and hydrogen gas afforded the substituted (2R,4S)-2,4-dibenzyl-8-methyl-8-
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azabicyclo[3.2.1]octane and (2R,4S)-8-methyl-2,4-bis(3-phenylpropyl)-8azabicyclo[3.2.1]octane analogs of lobelane.

Compound

Compound Structure

Values are Ki ± SEM,
µM
[3H]DTBZ Binding
VMAT2

Identifier
O

OH

LOB

N
CH3

2.76 ± 0.64

lobelane

N
CH3

0.97 ± 0.19

H
N

67

N
H

37.6 ± 20.3

CH3
N

68

6.09 ± 0.19
N
CH3

69

N
H

1.50 ± 0.22

70

N
CH3

14.5 ± 2.13

71

N
H

3.02 ± 0.17
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N
CH3

72

73

74

H3C

H3C

8.80 ± 2.30

N

1.30 ± 0.21

N

>100

F

75

H3C

N

1.38 ± 0.20

F
F

76

H3C

N

>100

F
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H3C
O

77

H3C

N

4.80 ± 1.70

H3C O
H3C
O

78

H3C

N

3.88 ± 0.90

H3C O

H3C

N

79

3.95 ± 0.54

Table 1.10 Structures and VMAT2 binding affinities of modified lobelane analogs
(Zheng et al., 2005; Crooks et al., 2011)

In the piperazine series of compounds, only compound 68 ((2R,6S)-1,4-dimethyl2,6-diphenethylpiperazine) had similar affinity to lobelane at VMAT2. In the pyrrolidine
series of analogs, affinities for VMAT2 were lower in all compounds, but interestingly
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the nor-compounds had higher affinities than their N-methyl counterparts, which
contrasts greatly compared to the previous piperidine series of lobelane analogs. In the
tropane series of analogs,, compounds 73 and 75 had affinities similar to lobelane, while
their saturated counterparts had no affinity for VMAT2 (IC50>100 µM). The double
bond present in the tropane ring of compounds 73 and 75 appear to be important in
providing the correct configuration of the tropane ring, as well as the orientations of the
two phenethyl side chains.

1.10 Portions of the lobelane scaffold that are critical in binding to VMAT2
From the library of compounds designed, synthesized, and evaluated for their
affinity for VMAT2, it is possible to infer which portions of the lobelane scaffold is
essential for the molecule to bind to VMAT2. A graphical representation of each section
of the molecule that must be conserved in order to maintain affinity for VMAT2 is shown
in Figure 1.9.

Figure 1.10 Graphical representation of the lobelane scaffold depicting the parts of the
molecule that are essential for binding to VMAT2

Three distinct sections of the lobelane scaffold have been shown to be important
with respect to binding to VMAT2. First, a cationic nitrogen moiety must be present
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(depicted in Figure 1.9 in blue), and preferably the nitrogen atom is located inside a
cyclic system such as the piperidine ring. Second, two hydrophobic moieties must be
present (depicted in Figure 1.9 in green), preferably both phenyl rings. Substitution of
the phenyl rings with fluoro or methoxy moieties can improve affinity for the VMAT2
binding site. Third, the cationic site and the two hydrophobic sites must be linked
together via methylene linkers (depicted in Figure 1.9 in red) of at least two methylene
units in length. The methylene linkers can be attached at the 2,6 or 1,4 positions on the
central nitrogen containing ring without a decrease in binding affinity for the VMAT2
binding site.

1.11 Modification and optimization of the lobelane scaffold

With the data from all six stages of lobelane scaffold modifications in hand, three
structural groups within the library of compounds appear to be prime candidates for
optimization and further exploration. These three areas are 1.) further studies on the
design and synthesis of structural analogs of lobelane that maintain the 2,6-substituted
piperidine scaffold but introduced preferred moieties, i.e. chloro, fluoro, or methoxy
moieties, into the phenyl rings present in lobelane, 2.) further studies into structural
analogs of lobelane that move the phenethyl linkers present in the 2,6-substituted position
on the piperidine ring in lobelane to the 1,4-substituted position could be designed and
synthesized that also include the preferred moieties, i.e. chloro, fluoro, or methoxy
moieties to enhance their affinity and function at VMAT2 , and 3.) further studies into
lobelane analogs that introduce an additional nitrogen atom into the piperidine ring of the
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lobelane scaffold that would increase water- solubility while maintaining similar affinity
for VMAT2. These three areas are explored in Chapters 2, 3, and 4, and have become the
main focus of this work.

Copyright © John P. Culver 2015
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Chapter 2.
Synthesis of 2,6-disubstituted piperidine analogs structuraly related to lobelane
2.1 Prior studies with this scaffold
As discussed in Chapter 1 of this dissertation, (section 1.8), a series of 28
symmetrical 2,6-substituted lobelane analogs have previously been synthesized and their
affinities at α4β2* & α7* nAChRs and at the TBZ binding site on VMAT2 have been
evaluated. All of the compounds within this series had either lower or comparable
affinities at α4β2* & α7* nAChRs when compared to lobelane, with the exception of
compounds 29a ((2S,6R)-2,6-bis(2-(biphenyl-4-yl)ethyl)piperidine) and 33a ((2S,6R)-2,6bis(2-(naphthalen-2-yl)ethyl)piperidine), which were both nor-analogs with bulky
biphenyl (compound 29a) and 2-naphthyl (compound 33a) aromatic rings incorporated
into the molecule in place of the phenyl moieties. These compounds had comparable
affinity to lobelane at VMAT2. Analogs 20b ((2S,6R)-2,6-bis(3-fluorophenethyl)-1methylpiperidine), 22b ((2S,6R)-2,6-bis(2-methoxyphenethyl)-1-methylpiperidine), and
23b ((2S,6R)-2,6-bis(3-methoxyphenethyl)-1-methylpiperidine) had the highest affinity
for VMAT2 with Ki values of 0.57, 0.58, and 0.43 µM respectively. Also the N-methyl
analogs consistently exhibited higher affinity at VMAT2 when compared to the
corresponding nor-counterparts.

2.2 Design and synthesis of the 2,6-disubstituted piperidine scaffold
Further optimization and study was needed to ascertain if addition of different
substituents into the phenyl ring would enhance binding affinity at VMAT2. Addition of
two substituents into the phenyl ring was also explored in order to determine if multiple
substituents could also improve affinity. The synthesis of eighteen compounds in this
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series was accomplished. The general synthetic scheme that was utilized is shown in
Scheme 2.1, and the structures and analytical data follow in Figures 2.1 through 2.18.

Scheme 2.1 Synthesis of the 2,6-substituted piperidine analog scaffold of lobelane

The general synthetic scheme begins with 2,6-dimethylpyridine as the starting
material, which is subjected to condensation reaction conditions with the appropriate
mono-substituted or di-substituted aryl aldehyde. This affords the appropriate crude 2,6distyrylpyridine compound (purified by crystallization or via silica column
chromatography), which was then exposed to acidic hydrogenation conditions with
Adam’s catalyst (platinum(IV)oxide) and hydrogen gas in acetic acid. After 18-72 hours,
depending on the aromatic substitution pattern of the distyrylpyridine, the reaction yields
the appropriate nor-(2S,6R)-2,6-diphenethylpiperidine (purified via silica column
chromatography), as the meso-isomer (cis stereochemistry at the C2 and C6 positions on
the piperidine ring. N-methylation was accomplished by exposing the nor-compounds to
reductive amination conditions with paraformaldehyde and sodium cyanoborohydride in
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methanol to generate lobelane analogs containing the N-methyl moiety (purified by silica
column chromatography). The structures of the compounds synthesized in this series and
the structural analytical data for each compound are shown in Figures 2.1 through 2.20.
NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on one of three
Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are reported in ppm
relative to either TMS as internal standard or as relative to the solvent peak present in
13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC incorporating an
Agilent 7683 autosampler and an Agilent 5973 MSD. All compounds were converted to
their hydrochloric acid salts prior to submission for pharmacological evaluation. A
detailed example of the procedure used in the synthesis of the 2,6-substituted piperidine
series of lobelane analogs follows (example procedure is for the synthesis of JPC-001 and
JPC-011.

Condensation reaction procedure: To a clean, dry 250 ml round bottom flask equipped
with a magnetic stirbar and a water jacketed condenser was added 3.772 grams (0.0352
moles) of 2,6-lutidine, 10.0 grams (0.071 moles) of 3,5-difluorobenzaldehyde, and 10 ml
of acetic anhydride. The reaction mass was heated to reflux and maintained at reflux for
72 hours. The reaction was then cooled to room temperature and the excess solvent was
removed under vacuum. The gummy residue was purified via silica column
chromatography (300 grams of 400 mesh silica) utilizing a 10:1 mixture of hexane:ethyl
acetate. The excess solvent was removed from the product fraction via vacuum, and a
solid white product was isolated. The product (2,6-bis(3,5-difluorostyryl)pyridine) was
isolated in 52% yield (6.5 grams (0.0183 moles)).
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Hydrogenation reaction procedure: 2.0 grams (5.63 mmol) of the product of the
condensation reaction (2,6-bis(3,5-difluorostyryl)pyridine) was placed in a clean, dry 250
ml Parr hydrogenation flask and brought into solution with 50 ml of concentrated acetic
acid. To this was added 0.5 mole % (6.3 mg (0.0282 mmol)) of Adam’s catalyst
(platinum (IV) oxide). This heterogeneous catalyst reaction mass was placed on a Parr
hydrogenator and purged three times with hydrogen gas with shaking. The reaction was
then pressurized to 50 psi (3.45 atm) with hydrogen gas under room temperature. The
Parr hydrogenator’s shaking function was used and the reaction allowed to proceed for 18
hours. The pressure was then released and the reaction was filtered through a pad of
celite to remove the platinum catalyst. The remaining filtrate was subjected to reduced
pressure under vacuum to remove excess acetic acid. The reaction mass was then
basified with a saturated solution of sodium bicarbonate in water, and extracted three
times with dichloromethane. The organic layer was dried with sodium sulfate, filtered,
and the dichloromethane removed under reduced pressure. The remaining gummy
residue was purified via column chromatography (60 grams of silica (400 mesh))
utilizing a solvent mixture of 50:1:0.2 chloroform: methanol: ammonium hydroxide. The
product fractions were combined, and the solvent removed via vacuum to yield 1.52
grams (4.16 mmol (73.9% isolated yield) of (2S,6R)-2,6-bis(3,5difluorophenethyl)piperidine (JPC-001) as a gummy material. The purified product was
converted to the hydrochloride salt by dissolving the gum residue in a minimum amount
of dichloromethane and adding 1.0 M hydrochloric acid in dry diethyl ether dropwise
until a precipitate formed. This reaction mass was stirred for four hours at room
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temperature and the excess solvent removed via reduced pressure. The residue was
triturated in dry diethyl ether until a white powder of the hydrochloride salt of the product
formed. The powder was filtered off and dried under vacuum overnight to yield 1.35
grams (3.36 mmol) of (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidinium chloride in
80.75% isolated yield.
Reductive amination procedure: 1.0 grams (2.49 mmol) of (2S,6R)-2,6-bis(3,5difluorophenethyl)piperidinium chloride product was added to a clean, dry 50 ml round
bottom flask and brought into solution with 10 ml of methanol. 210 mg (2.49 mmol) of
dry sodium bicarbonate was added to the solution and stirred for thirty minutes to convert
the hydrochloride salt to the freebase form. To the reaction mass was added five
equivalents of sodium cyanoborohydride (783 mg (12.45 mmol)) and ten equivalents
(748 mg (24.9 mmol)) of paraformaldehyde, and this reaction was stirred under room
temperature for 18 hours. The excess solvent was then removed via reduced pressure and
the reaction mass was subjected to extraction with saturated sodium chloride in water and
dichloromethane three times. The organic layer was then collected, combined, and dried
with sodium sulfate and filtered. The excess dichloromethane was removed under
reduced pressure to yield a gummy residue which was purified via silica column
chromatography (30 grams of silica (400 mesh)) via a solvent mixture of 50:1:0.2
chloroform:methanol: ammonium hydroxide. The product fractions were combined, and
the solvent removed via reduced pressure to yield the pure product (2S,6R)-2,6-bis(3,5difluorophenethyl)-1-methylpiperidine (JPC-011) as a gummy material. The yield of the
product was (746 mg (1.97 mmol) or 79% yield. The freebase product was a gummy,
oily residue and was therefore brought up in a minimum volume of dichloromethane to
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which 1.0 M hydrochloric acid is dry diethyl ether was added until a precipitate began to
form. This mixture was stirred under room temperature for four hours at which time the
solvent was removed via reduced pressure. The residue was triturated with dry diethyl
ether until a white powder of the hydrochloride salt formed. The powder was filtered off
and dried under vacuum to yield 594 mg (1.43 mmol) of (2S,6R)-2,6-bis(3,5difluorophenethyl)-1-methylpiperidinium chloride resulting in a 72.5% isolated yield for
the hydrochloride salt formation.
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Figure 2.1 Structure of (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidine (JPC-001)
Chemical Formula: C21H23F4N Molecular Weight: 365.41

This molecule was designed to evaluate the effect of 3,5-difluoro substituents on
VMAT2 binding. Since the fluoro-moieties are very electronegative they cause inductive
withdrawal, or withdrawal of electrons from the phenyl rings, but since the fluoromoieties have non-bonding electrons they can donate electron density through pi bonding
or resonance donation. The synthesis utilized 2,6-dimethylpyridine as the starting
material, which was subjected to Aldol condensation with 3,5-difluorobenazldehyde to
yield 2,6-bis(3,5-difluorostyryl)pyridine. Catalytic hydrogenation of the styryl
intermediate afforded (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidine (JPC-001).
H NMR (500 MHz, CDCl3): δ 1.28-1.81 (m, 10H), 2.11 (s, 1H), 2.33-2.41 (m, 2H),
2.70 (t, 4H), 6.53-6.62 (m, 2H), 6.68-6.73 (m, 4H) ppm.

1

C NMR (125 MHz, CDCl3): δ 25.3, 31.9, 32.3, 35.6, 63.1, 101.8, 113.6, 147.1, 164.2
ppm.
13

MS (EI) m/z 365 (M+).

98

Figure 2.2 Structure of (2S,6R)-2,6-bis(3,5-difluorophenethyl)-1-methylpiperidine
(JPC-011) Chemical Formula: C22H25F4N Molecular Weight: 379.43

This molecule was designed to evaluate the effect of 3,5-difluoro substitution of
lobelane on VMAT2 binding similar to JPC-001, but to also preserve the N-methyl
substituent on the amine. (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidine (JPC-001)
was N-methylated by exposed to reductive amination conditions with paraformaldehyde
and sodium cyanoborohydride in methanol to provide N-methylated (2S,6R)-2,6-bis(3,5difluorophenethyl)-1-methylpiperidine (JPC-011).
1

H NMR (500 MHz, CDCl3): δ 1.31-1.84 (m, 10H), 2.14 (s, 3H), 2.36-2.40 (m, 2H),

2.66 (t, 4H), 6.59-6.64 (m, 2H), 6.71-6.74 (m, 4H) ppm.
C NMR (125 MHz, CDCl3): δ 25.5, 31.8, 32.3, 35.9, 40.5, 62.4, 101.5, 111.6, 147.4,

13

164.5 ppm.
MS (EI) m/z 379 (M+).
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Figure 2.3 Structure of (2S,6R)-2,6-bis(3-chlorophenethyl)piperidine (JPC-002)
Chemical Formula: C21H25Cl2N Molecular Weight: 362.34

This molecule was designed to evaluate the effect of the 3-chloro substitution of
lobelane on VMAT2 binding. The chlorine atom is an electron-withdrawing aromatic
substituent and can cause similar inductive and resonance based electron effects on the
phenyl rings as the fluoro substituent, however the chlorine atom is larger in radius, and
slightly more polarizable than the fluoro moiety. The synthesis began with 2,6dimethylpyridine as the starting material, which was subjected to Aldol condensation
with 3-chlorobenzaldehyde to yield 2,6-bis(3-chlorostyryl)pyridine. Subsequent catalytic
hydrogenation afforded (2S,6R)-2,6-bis(3-chlorophenethyl)piperidine (JPC-002).
However, during hydrogenation, reductive dechlorination occurred, leading to a difficult
separation and very little JPC-002 was isolated, even when scaled up to larger reaction
amounts. For this reason alone, the N-methyl analog was not prepared.
1

H NMR (300 MHz, CDCl3): δ 1.37-1.78 (m, 10H), 2.11 (s, 1H), 2.33-2.41 (m, 2H), 2.60

(t, 4H), 7.13-7.21 (m, 2H), 7.34-7.46 (m, 4H), 7.51, (s, 2H) ppm.
C NMR (75 MHz, CDCl3): δ 22.3, 30.5, 32.8, 35.8, 58.1, 121.6, 121.9, 128.5, 129.1,

13

136.3, 142.2 ppm.
MS (EI) m/z 361 (M+).
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Figure 2.4 Structure of 3,3'-(2,2'-((2S,6R)-piperidine-2,6-diyl)bis(ethane-2,1diyl))dianiline (JPC-008) Chemical Formula: C21H29N3 Molecular Weight: 323.48

This molecule was designed to evaluate the effect of introducing a 3-amino
substituent into the lobelane scaffold on VMAT2 binding. The amino moiety is an
electron donating group that donates some of its electron density into the conjugated π
system of the phenyl ring. The 2,6-dimethylpyridine starting material was subjected to
Aldol condensation reaction conditions with 3-nitrobenazldehyde to yield 2,6-bis(3nitrostyryl)pyridine. Subsequent catalytic hydrogenation afforded the desired compound,
3,3'-(2,2'-((2S,6R)-piperidine-2,6-diyl)bis(ethane-2,1-diyl))dianiline (JPC-008).
1

H NMR (300 MHz, CDCl3): δ 1.35-1.83 (m, 10H), 2.08 (s, 1H), 2.56 (t, 4H), 2.71 (m,

2H), 5.24 (s, 4H), 6.43-6.48 (m, 2H), 6.59-6.67 (m, 4H), 7.10, (m, 2H)ppm.
C NMR (75 MHz, CDCl3): δ 21.5, 29.7, 32.3, 35.9, 54.8, 111.6, 114.7, 117.3, 127.1,

13

138.2, 147.5 ppm.
MS (EI) m/z 323 (M+).
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Figure 2.5 Structure of (2S,6R)-2,6-bis(2-cyclohexylethyl)piperidine (JPC-003)
Chemical Formula: C21H39N Molecular Weight: 305.54

This molecule was designed to evaluate the effect of complete saturation of the
phenyl rings in nor-lobelane to cyclohexyl moieties on VMAT2 binding (Note, this
compound and the N-methyl derivative has been prepared previously) (Zheng et al.,
2005). 2,6-Dimethylpyridine was the starting material, which was subjected to Aldol
condensation reaction conditions with benzaldehyde to yield the intermediate 2,6bis(styryl)pyridine. Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen
gas afforded of the desired compound, (2S,6R)-2,6-bis(2-cyclohexylethyl)piperidine
(JPC-003).
1

H NMR (300 MHz, CDCl3): δ 1.37-2.38 (m, 36H), 2.05 (s, 1H), 2.67 (m, 2H) ppm.
C NMR (75 MHz, CDCl3): δ 20.7, 24.7, 25.3, 28.6, 29.8, 32.7, 33.0, 33.1, 49.8 ppm.

13

MS (EI) m/z 305 (M+).
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Figure 2.6 Structure of (2S,6R)-2,6-bis(2-cyclohexylethyl)-1-methylpiperidine (JPC-007)
Chemical Formula: C22H41N Molecular Weight: 319.57

This molecule was designed to evaluate the effect of complete saturation of the
phenyl rings in Lobeline to cyclohexyl moieties, while preserving the N-methyl
substituent, on VMAT2 binding. (2S,6R)-2,6-bis(2-cyclohexylethyl)piperidine (JPC-003)
was exposed to reductive amination conditions with paraformaldehyde and sodium
cyanoborohydride in methanol to afford N-methylated (2S,6R)-2,6-bis(2cyclohexylethyl)-1-methylpiperidine (JPC-007).
1

H NMR (300 MHz, CDCl3): δ 1.45-2.34 (m, 36H), 2.08 (m, 2H). 2.17 (s, 3H) ppm.
C NMR (75 MHz, CDCl3): δ 21.1, 24.9, 25.6, 28.7, 29.6, 32.9, 33.4, 33.9, 38.8, 54.6

13

ppm.
MS (EI) m/z 319 (M+).
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Figure 2.7 Structure of (2S,6R)-2,6-bis(2,4-difluorophenethyl)piperidine (JPC-130a)
Chemical Formula: C21H23F4N Molecular Weight: 365.41

This molecule was designed to evaluate the effect of introducing 2,4-difluoro
aromatic substituents into the nor-lobelane structure on VMAT2 binding. Again, since
the fluoro-substituents are electronegative they cause inductive withdrawal of electrons
from the aromatic ring, but since the fluoro-moieties have non-bonding electrons they can
also donate electron density through pi bonding or resonance donation. Synthesis began
with 2,6-dimethylpyridine as the starting material, which was subjected to Aldol
condensation reaction conditions with 2,4-difluorobenzaldehyde to yield 2,6-bis(2,4difluorostyryl)pyridine. Catalytic hydrogenation with Adam’s catalyst (PtO2) and
hydrogen gas afforded the desired product, (2S,6R)-2,6-bis(2,4difluorophenethyl)piperidine (JPC-130a).
H NMR (500 MHz, CDCl3): δ 1.28-1.73 (m, 10H), 2.17 (s, 1H), 2.30-2.41 (m, 2H),
2.73 (t, 4H), 6.60-6.67 (m, 2H), 6.87-6.95 (m, 2H), 7.17-7.23 (m, 2H) ppm.

1

C NMR (125 MHz, CDCl3): δ 24.3, 25.6, 31.7, 32.3, 60.3, 101.8, 109.4, 120.9, 128.9,
161.1, 164.2 ppm.
13

MS (EI) m/z 365 (M+).
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Figure 2.8 Structure of (2S,6R)-2,6-bis(2,4-difluorophenethyl)-1-methylpiperidine
(JPC-130b) Chemical Formula: C22H25F4N Molecular Weight: 379.43

This molecule was designed to evaluate the effect of introducing 2,4difluoro aromatic substituents into lobelane on VMAT2 binding, while retaining the Nmethyl substituent on the piperidine ring. (2S,6R)-2,6-bis(2,4difluorophenethyl)piperidine (JPC-130a) was exposed to reductive amination conditions
with paraformaldehyde and sodium cyanoborohydride in methanol to provide the desired
compound, N-methylated (2S,6R)-2,6-bis(2,4-difluorophenethyl)-1-methylpiperidine
(JPC-130b).
1

H NMR (500 MHz, CDCl3): δ 1.35-1.76 (m, 10H), 2.15 (s, 3H), 2.35 (m, 2H), 2.65 (t,

4H), 6.73-6.78 (m, 4H), 7.13-7.15 (m, 2H) ppm.
C NMR (125 MHz, CDCl3): δ 25.1, 25.2, 26.8, 29.9, 34.9, 62.6, 103.7, 111.0, 122.7,

13

131.3, 160.6, 162.5 ppm.
MS (EI) m/z 379 (M+).
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Figure 2.9 Structure of (2S,6R)-2,6-bis(3,5-dimethoxyphenethyl)piperidine (JPC-004)
Chemical Formula: C25H35NO4 Molecular Weight: 413.55

This molecule was designed to evaluate the effect of introducing 3,5-dimethoxy
aromatic substituents into the nor-lobelane molecule on VMAT2 binding. Since the
methoxy substituents are electronegative they cause inductive withdrawal, or withdrawal
of electrons from the carbon atom of benzene, but since they also have non-bonding
electrons they can donate electron density through pi bonding or resonance donation.
The methoxy group is substantially larger than fluoro group in the previous compounds,
and will provide some steric effects at the binding site of VMAT2, if space on the site is
limited around the phenyl ring binding regions. The starting material, 2,6dimethylpyridine was reacted with 3,5-dimethoxybenazldehyde under Aldol
condensation reaction conditions to yield 2,6-bis(3,5-dimethoxystyryl)pyridine. Catalytic
hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas eafforded (2S,6R)-2,6bis(3,5-dimethoxyphenethyl)piperidine (JPC-004).
1

H NMR (300 MHz, CDCl3): δ 1.33-1.82 (m, 10H), 2.20 (s, 1H), 2.41 (m, 2H), 2.65 (t,

4H), 3.78 (s, 12H), 6.52-6.64 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 21.6, 29.6, 32.6, 39.9, 55.6, 58.3, 97.2, 106.3, 143.9, 160.1

13

ppm.
MS (EI) m/z 413 (M+).
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Figure 2.10 Structure of (2S,6R)-2,6-bis(3,5-dimethoxyphenethyl)-1-methylpiperidine
(JPC-010) Chemical Formula: C26H37NO4 Molecular Weight: 427.58

This molecule was designed to evaluate the effect of introducing 3,5-dimethoxy
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the
N-methyl substituent on the piperidine ring. (2S,6R)-2,6-bis(3,5dimethoxyphenethyl)piperidine (JPC-004) was exposed to reductive amination conditions
with paraformaldehyde and sodium cyanoborohydride in methanol to afford (2S,6R)-2,6bis(3,5-dimethoxyphenethyl)-1-methylpiperidine (JPC-010).
1

H NMR (300 MHz, CDCl3): δ 1.26-1.87 (m, 10H), 2.22 (s, 3H), 2.35 (m, 2H), 2.63 (t,

4H), 3.78 (s, 12H), 6.31-6.36 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 21.6, 29.6, 30.9, 32.6, 33.1, 39.9, 55.2, 97.9, 106.2, 144.8,

13

160.6 ppm.
MS (EI) m/z 427 (M+).
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Figure 2.11 Structure of (2S,6R)-2,6-bis(3,4-dimethoxyphenethyl)piperidine (JPC-033)
Chemical Formula: C25H35NO4 Molecular Weight: 413.55

This molecule was designed to evaluate the effect of introducing 3,4-dimethoxy
aromatic substituents into the nor-lobelane scaffold on VMAT2 binding. Synthesis
began with 2,6-dimethylpyridine as the starting material, which was subjected to Aldol
condensation with 3,4-dimethoxybenazldehyde to yield 2,6-bis(3,4dimethoxystyryl)pyridine. Catalytic hydrogenation afforded (2S,6R)-2,6-bis(3,4dimethoxyphenethyl)piperidine (JPC-033).
1

H NMR (300 MHz, CDCl3): δ 1.30-1.75 (m, 10H), 2.17 (s, 1H), 2.49 (m, 2H), 2.57 (t,

4H), 3.79 (s, 12H), 6.72-6.87 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 23.6, 29.3, 31.2, 35.9, 55.3, 62.4, 107.9, 111.5, 119.9,

13

134.5, 146.2, 148.1 ppm
MS (EI) m/z 413 (M+).
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Figure 2.12 Structure of (2S,6R)-2,6-bis(3,4-dimethoxyphenethyl)-1-methylpiperidine
(JPC-034) Chemical Formula: C26H37NO4 Molecular Weight: 427.58

This molecule was designed to evaluate the effect of introducing 3,4-dimethoxy
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the
N-methyl moiety on the piperidine ring. The synthesis utilized (2S,6R)-2,6-bis(3,4dimethoxyphenethyl)piperidine (JPC-033) which was exposed to reductive amination
conditions with paraformaldehyde and sodium cyanoborohydride in methanol to afford
(2S,6R)-2,6-bis(3,4-dimethoxyphenethyl)-1-methylpiperidine (JPC-034).
1

H NMR (300 MHz, CDCl3): δ 1.30-1.95 (m, 10H), 2.20 (s, 3H), 2.45 (m, 2H), 2.61 (t,

4H), 3.86 (s, 12H), 6.76 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 24.8, 26.3, 30.2, 31.9, 36.3, 55.7, 62.4, 110.9, 111.5,

13

119.9, 135.0, 146.7, 148.4 ppm.
MS (EI) m/z 427 (M+).
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Figure 2.13 Structure of (2S,6R)-2,6-bis(2,3-dimethoxyphenethyl)piperidine (JPC-035)
Chemical Formula: C25H35NO4 Molecular Weight: 413.55

This molecule was designed to evaluate the effect of introducing 2,3-dimethoxy
aromatic substituents into the nor-lobelane scaffold on VMAT2 binding. The starting
material, 2,6-dimethylpyridine, was subjected to Aldol condensation with 2,3dimethoxybenzaldehyde to yield 2,6-bis(2,3-dimethoxystyryl)pyridine. Catalytic
hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded (2S,6R)-2,6bis(2,3-dimethoxyphenethyl)piperidine (JPC-035).
1

H NMR (300 MHz, CDCl3): δ 1.30-1.85 (m, 10H), 2.13 (s, 1H), 2.41 (m, 2H), 2.62 (t,

4H), 3.81 (s, 12H), 6.77-6.94 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 23.4, 25.7, 27.8, 33.1, 55.9, 60.7, 62.2, 111.2, 121.1,

13

123.0, 130.1, 146.1, 152.0 ppm.
MS (EI) m/z 413 (M+).
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Figure 2.14 Structure of (2S,6R)-2,6-bis(2,3-dimethoxyphenethyl)-1-methylpiperidine
(JPC-036) Chemical Formula: C26H37NO4 Molecular Weight: 427.58

This molecule was designed to evaluate the effect of introducing 2,3-dimethoxy
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the
N-methyl moiety on the piperidine ring. (2S,6R)-2,6-bis(2,3dimethoxyphenethyl)piperidine (JPC-035) was exposed to reductive amination conditions
with paraformaldehyde and sodium cyanoborohydride in methanol to afford (2S,6R)-2,6bis(2,3-dimethoxyphenethyl)-1-methylpiperidine (JPC-036).
1

H NMR (300 MHz, CDCl3): δ 1.30-1.95 (m, 10H), 2.27 (s, 3H), 2.45 (m, 2H), 2.68 (t,

4H), 3.83 (s, 12H), 6.77-6.98 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 24.6, 26.4, 27.0, 31.0, 35.2, 55.5, 60.5, 63.2, 109.8, 121.7,

13

123.6, 136.1, 146.7, 152.4 ppm
MS (EI) m/z 427 (M+).
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Figure 2.15 Structure of (2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)piperidine (JPC-041)
Chemical Formula: C25H35NO4 Molecular Weight: 413.55

This molecule was designed to evaluate the effect of introducing 2,5-dimethoxy
aromatic substituents into nor-lobelane on VMAT2 binding. 2,6-Dimethylpyridine was
subjected to Aldol condensation with 2,5-dimethoxybenzaldehyde to yield 2,6-bis(2,5dimethoxystyryl)pyridine. Catalytic hydrogenation with Adam’s catalyst (PtO2) and
hydrogen gas afforded (2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)piperidine (JPC-041).
1

H NMR (300 MHz, CDCl3): δ 1.39-1.85 (m, 10H), 2.21 (s, 1H), 2.35 (m, 2H), 2.65 (t,

4H), 3.74 (s, 12H), 6.63-6.76 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 22.3, 26.2, 31.9, 34.9, 55.1, 55.7, 62.9, 110.4, 110.6,

13

110.8, 116.0, 132.3, 151.4, 153.1 ppm.
MS (EI) m/z 413 (M+).
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Figure 2.16 Structure of (2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)-1-methylpiperidine
(JPC-042) Chemical Formula: C26H37NO4 Molecular Weight: 427.58

This molecule was designed to evaluate the effect of introducing 2,5-dimethoxy
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the
N-methyl moiety on the piperidine ring. (2S,6R)-2,6-bis(2,5dimethoxyphenethyl)piperidine (JPC-041) which was exposed to reductive amination
conditions with paraformaldehyde and sodium cyanoborohydride in methanol to afford
(2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)-1-methylpiperidine (JPC-041).
1

H NMR (300 MHz, CDCl3): δ 1.25-1.90 (m, 10H), 2.20 (s, 3H), 2.35 (m, 2H), 2.63 (t,

4H), 3.72 (s, 12H), 6.63-6.76 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 25.0, 27.0, 27.2, 31.2, 34.7, 55.4, 55.7, 62.9, 110.4, 110.8,

13

116.0, 132.3, 151.4, 153.1 ppm.
MS (EI) m/z 427 (M+).
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Figure 2.17 Structure of (2S,6R)-2,6-bis(4-fluoro-3-methoxyphenethyl)piperidine
(JPC-161b)Chemical Formula: C23H29F2NO2 Molecular Weight: 389.48

This molecule was designed to evaluate the effect of introducing 4 fluoro,3methoxy aromatic substituents on VMAT2 binding. 2,6-Dimethylpyridine was subjected
to Aldol condensation with 4-fluoro-3-methoxybenzaldehyde to yield 2,6-bis(4-fluoro-3methoxystyryl)pyridine. Subsequent catalytic hydrogenation with Adam’s catalyst
(PtO2) and hydrogen gas afforded (2S,6R)-2,6-bis(4-fluoro-3-methoxyphenethyl)piperidine (JPC-161b).
1

H NMR (300 MHz, CDCl3): δ 1.30-1.75 (m, 10H), 2.09 (s, 1H), 2.53 (m, 2H), 2.62 (t,

4H), 3.81 (s, 6H), 6.72-7.10 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 22.6, 29.9, 32.3, 36.5, 55.3, 61.4, 109.7, 114.1, 123.9,

13

136.1, 148.4, 148.6 ppm.
MS (EI) m/z 389 (M+).
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Figure 2.18 Structure of (2S,6R)-2,6-bis(4-fluoro-3-methoxyphenethyl)-1methylpiperidine (JPC-161c)
Chemical Formula: C24H31F2NO2 Molecular Weight: 403.51

This molecule was designed to evaluate the effect of introducing 4 fluoro,3methoxy aromatic substituents into the lobelane scaffold on VMAT2 binding while
retaining the N-methyl moiety on the piperidine ring. (2S,6R)-2,6-bis(4-fluoro-3methoxy- phenethyl)piperidine (JPC-161b) was exposed to reductive amination with
paraformaldehyde and sodium cyanoborohydride in methanol to afford (2S,6R)-2,6-bis(4fluoro-3-methoxyphenethyl)-1-methylpiperidine (JPC-161c).
1

H NMR (300 MHz, CDCl3): δ 1.35-1.75 (m, 10H), 2.17 (s, 3H), 2.43 (m, 2H), 2.58 (t,

4H), 3.87 (s, 6H), 6.70-7.10 (m, 6H) ppm.
C NMR (75 MHz, CDCl3): δ 21.9, 30.2, 31.9, 34.5, 38.2, 55.8, 61.9, 111.3, 114.0,

13

123.7, 138.1, 148.2, 148.5 ppm.
MS (EI) m/z 403 (M+).
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2.3 Summary of the 2,6-disubstituted piperidine analog series

In summary, eighteen compounds were designed and synthesized in the 2,6disubstituted piperidine scaffold of lobelane, fourteen of which contained two
substituents in each of the phenyl rings. These substituents consisted of difluoro-,
dimethoxy-, and 4-fluoro-3-methoxyphenyl substituents. Seven of the compounds were
analogs of the nor-lobelane scaffold, and seven analogs were analogs of the lobelane
scaffold. Their affinities for the TBZ site of VMAT2, as well as their functional ability to
prevent DA uptake into the vesicles of the dopaminergic neuron are discussed in Chapter
5.

Copyright © John P. Culver 2015
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Chapter 3.
Design and Synthesis of 1,4-Disubstituted Piperidine Analogs of lobelane

3.1 Prior studies with the 1,4-disubstituted scaffold
As discussed in Chapter 1, (section 1.8), a series of isomerized lobelane analogs
have been designed and synthesized. These analogs have different positions of
attachment of the phenethyl moieties around the central piperidine ring. Of these
structural modifications, the analogs with phenethyl moieties in the N1 and C4 positions
of the piperidine ring showed more promise for optimization and further study, since their
binding affinities at VMAT2 were quite similar to lobelane, and they exhibited little to no
affinity for α4β2* & α7* nAChRs. The symmetry present in the 1,4-substituted scaffold
allows for the relatively fast synthesis of a library of compounds with a variety of
substituents in the phenyl rings, and also provides opportunities to explore the
introduction of non-aromatic functionalities in place of one of the phenyl rings in
lobelane, resulting in analogs with higher polarity improved water solubility
characteristics, which is a desirable property in the development of drugs with improved
bioavailability over lobelane.

3.2 Design and Synthesis of 1,4-substituted piperidine scaffold analogs
Further optimization and study was needed to ascertain if addition of different
substituents into the phenyl rings of the 1,4-substituted lobelane scaffold would enhance
binding affinity at VMAT2. Addition of multiple aromatic substituents into the phenyl
rings was also explored in order to determine if multiple substituents could also improve
affinity. The synthesis of 43 compounds in this series were designed and synthesized.
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The general synthetic scheme is shown in Scheme 3.1, and the structures and analytical
data follow in Figures 3.1 through 3.43.

Scheme 3.1 Synthetic route to the 1,4-disubstituted piperidine analogs of lobelane

The general synthetic route to the 1,4-disubstituted piperidine analogs of lobelane
began with 4-picoline (also known as 4-methylpyridine) as the starting material. Similar
chemistry to that used in the 2,6-disubstituted piperidine scaffold was utilized. The
starting material was subjected to Aldol condensation with the appropriately substituted
benzaldehyde in refluxing acetic anhydride to afford the corresponding (E)-4styrylpyridine intermediate. After purification via silica gel column chromatography, this
intermediate was subjected to catalytic hydrogenation with Adam’s catalyst and hydrogen
gas in acetic acid to afford the appropriately substituted 4-phenethylpiperidine
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intermediate, which was then subjected to a SN2 reaction with potassium carbonate and
the appropriately substituted bromoethylbenzene to yield the final 1,4-disubstituted
piperidine analogs of lobelane. A detailed example of the procedure used in the synthesis
of the 1,4-disubstituted piperidine analogs of lobelane is given below (example is for
JPC-077 (1,4-bis(2-methoxyphenethyl)piperidine ). The exact structures of the
compounds synthesized and the analytical data for each compound are shown in Figures
3.1 through 3.43. NMR spectra were recorded in either CDCl3 or DMSO-d6 (as
designated) on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as
indicated are reported in ppm relative to either TMS as internal standard or as relative to
the solvent peak present in 13C spectra. GC-mass spectra were recorded on an Agilent
6890 GC incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD. All
compounds were converted into their hydrochloride or fumarate salt forms prior to use in
pharmacological assay experiments.

Condensation reaction procedure: To a clean, dry 250 ml round bottom flask equipped
with a magnetic stirbar and a water jacketed condenser was added 2.30 grams (0.0247
moles) of 3-picoline, 5.044 grams (0.0371 moles) of 2-methoxybenzaldehyde, and 25 ml
of acetic anhydride. The reaction mass was heated to reflux and maintained at reflux for
72 hours. The reaction was then cooled to room temperature and the excess solvent was
removed under vacuum. The gummy residue was purified via silica column
chromatography (200 grams of 400 mesh silica) utilizing a 5:1 mixture of hexane:ethyl
acetate. The excess solvent was removed from the product fraction via vacuum, and a
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solid off-white product isolated. The product (E)-4-(2-methoxystyryl)pyridine was
isolated in 54% yield (2.81 grams (0.0133 moles)).

Hydrogenation reaction procedure: 2.0 grams (9.47 mmol) of the product of the
condensation reaction ((E)-4-(2-methoxystyryl)pyridine) was placed in a clean, dry 250
ml Parr hydrogenation flask and brought into solution with 50 ml of concentrated acetic
acid. To this was added 0.5 mole % (10.75 mg (0.0473 mmol)) of Adam’s catalyst
(platinum (IV) oxide). This heterogeneous catalyst reaction mass was placed on a Parr
hydrogenator and purged three times with hydrogen gas and shaking. The reaction was
then pressurized to 50 psi (3.45 atm) with hydrogen gas under room temperature. The
Parr hydrogenator’s shaking function was used and the reaction was allowed to proceed
for 72 hours. The pressure was then released and the reaction was filtered through a pad
of celite to remove the platinum catalyst. The remaining filtrate was subjected to reduced
pressure under vacuum to remove excess acetic acid. The reaction mass was then
basified with a saturated solution of sodium bicarbonate in water, and extracted three
times with dichloromethane. The organic layer was dried with sodium sulfate, filtered,
and the dichloromethane removed under reduced pressure. The remaining gummy
residue was purified via column chromatography (60 grams of silica (400 mesh))
utilizing a solvent mixture of 10:1:0.2 dichloromethane: methanol: ammonium
hydroxide. The product fractions were combined, and the solvent removed via vacuum
to yield 1.39 grams (6.35 mmol (67.0% isolated yield) of 4-(2methoxyphenethyl)piperidine as a gummy material. The purified product was converted
to the hydrochloride salt by dissolving the gum residue in a minimum amount of
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dichloromethane and adding 1.0 M hydrochloric acid in dry diethyl ether dropwise until a
precipitate formed. This reaction mass was stirred for four hours at room temperature
and the excess solvent was removed via reduced pressure. The residue was triturated in
dry diethyl ether until a white powder of the hydrochloride salt of the product formed.
The powder was filtered off and dried under vacuum overnight to yield 1.27 grams (4.97
mmol) of 4-(2-methoxyphenethyl)piperidinium chloride in 78.2% isolated yield.
N-alkylation reaction procedure (SN2 reaction): To a clean, dry 100 ml round bottomed
flask that has been purged with argon gas and equipped with a magnetic stirbar and a
water jacketed condenser was added 350 mg (1.37 mmol) of 4-(2methoxyphenethyl)piperidinium chloride (from the hydrogenation reaction above), 325
mg (1.51 mmol) of 2-methoxyphenethylbromide, and 10 ml of dimethylformamide
(DMF) as solvent. To this reaction mass was added 500 mg (3.43 mmol) of potassium
carbonate and 11.6 mg (0.07 mmol) of potassium iodide. Under an argon atmosphere the
reaction mass was heated in an oil bath (with stirring) to 60° C and maintained at that
temperature for 18 hours. The reaction flask was then subjected to reduced pressure
while maintaining the heat in the oil bath in order to remove excess DMF from the
reaction mixture. The residue from this procedure was subjected to extraction with
dichloromethane and saturated sodium chloride (brine solution) in water three times. The
organic layers are combined, dried with sodium sulfate, filtered, and the combined filtrate
was subjected to reduced pressure to remove the dichloromethane solvent. The residue
from this procedure was purified via silica column chromatography (20 g of silica (400
mesh)) utilizing a 20:1 mixture of dichloromethane: methanol. The fractions containing
the product were combined and the solvents removed under reduced pressure. The

121

residue of the pure compound JPC-077 (1,4-bis(2-methoxyphenethyl)piperidine) (356
mg, 1.01 mmol , 73.7% yield) was a thick oil at this stage, so the purified product was
converted to the hydrochloride salt by dissolving the gum residue in a minimum amount
of dichloromethane and adding 1.0 M hydrochloric acid in dry diethyl ether dropwise
until a precipitate formed. This reaction mass was stirred for four hours at room
temperature and the excess solvent was removed via reduced pressure. The residue was
triturated in dry diethyl ether until a white powder of the hydrochloride salt of the product
formed. The powder was filtered off and dried under vacuum overnight to yield 276 mg
(0.702 mmol) of (1,4-bis(2-methoxyphenethyl)piperidinium chloride in 70.2% yield.
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Figure 3.1 Structure of 1-(2-methoxyphenethyl)-4-phenethylpiperidine (JPC-57)
Chemical Formula: C22H29NO Molecular Weight: 323.47

This molecule was designed to evaluate the effect of introducing a 2-methoxy
substituent into the phenyl ring of the phenethyl moiety attached to N1 in the 1,4disubstituted piperidine scaffold on VMAT2 binding. 4-Methylpyridine was subjected to
Aldol condensation with benzaldehyde in refluxing acetic anhydride to yield (E)-4styrylpyridine (which was purified via silica column chromatography before use).
Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4phenethylpiperidine (purified via silica column chromatography before use), which was
then reacted via an SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-2methoxybenzene to yield the final product, 1-(2-methoxyphenethyl)-4phenethylpiperidine (JPC-57) (purified via column chromatography). .
1

H NMR (300 MHz, CDCl3): δ 1.38-1.80 (m, 7H), 2.52-3.01 (m, 10H). 3.78 (s, 3H),

6.83-7.31(m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 27.8, 32.7, 34.1, 35.4, 37.0, 54.2, 55.1, 61.1, 110.2,

13

120.9, 127.1, 127.9, 128.8, 128.9, 129.6, 131.4, 140.7, 157.2 ppm.
MS (EI) m/z 323 (M+).
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Figure 3.2 Structure of 1-(3,4-dimethoxyphenethyl)-4-phenethylpiperidine (JPC-058)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing 3,4-dimethoxy
substituents into the phenyl ring of the phenethyl moiety attached to N1 in the 1,4disubstituted piperidine scaffold on VMAT2 binding. Synthesis began with the common
intermediate 4-phenethylpiperidine prepared previously, which was reacted via an SN2
reaction with potassium carbonate and 1-(2-bromoethyl)-3,4-dimethoxybenzene to yield
the final product 1-(3,4-dimethoxyphenethyl)-4-phenethylpiperidine (JPC-058) after
purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.19-2.07 (m, 10H), 2.51-3.07 (m, 7H). 3.81 (s, 6H),

6.70-6.76(m, 5H), 7.11-7.21 (m, 3H) ppm.
C NMR (75 MHz, CDCl3): δ 29.7, 32.6, 34.1, 35.8, 37.6, 54.0, 55.1, 61.7, 110.4,

13

111.6, 114.7, 114.8, 120.7, 121.3, 129.1, 129.3, 140.4, 144.1, 157.3 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.3 Structure of 1-(3-methoxyphenethyl)-4-phenethylpiperidine (JPC-059)
Chemical Formula: C22H29NO Molecular Weight: 323.47

This molecule was designed to evaluate the effect of the introducing the 3methoxy substituent into the phenyl ring of the phenethyl linker attached to N1 in the 1,4disubstituted piperidine scaffold on VMAT2 binding. Synthesis began with the common
intermediate 4-phenethylpiperidine, which was reacted with potassium carbonate and 1(2-bromoethyl)-3-methoxybenzene to yield the final product 1-(3-methoxyphenethyl)-4phenethylpiperidine (JPC-059) after was purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.24-1.98 (m, 10H), 2.51-2.98 (m, 7H). 3.80 (s, 3H),

6.73-7.23 (m, 9H) ppm.
C NMR (100 MHz, CDCl3): δ 28.7, 29.3, 32.0, 32.6, 37.2, 38.9, 51.6, 55.0, 56.5, 112.2,

13

114.3, 120.8, 125.7, 128.2, 128.3, 129.6, 138.9, 141.9, 159.4 ppm.
MS (EI) m/z 323 (M+).

125

Figure 3.4 Structure of 1-(4-methoxyphenethyl)-4-phenethylpiperidine (JPC-060)
Chemical Formula: C22H29NO Molecular Weight: 323.47

This molecule was designed to evaluate the effect of introducing the 4-methoxy
substituent into the phenyl ring of the phenethyl moiety attached to N1 in the 1,4substituted piperidine scaffold on VMAT2 binding. Synthesis began with the common
intermediate 4-phenethylpiperidine, which was reacted via a SN2 reaction with potassium
carbonate and 1-(2-bromoethyl)-4-methoxybenzene to yield the final product 1-(4methoxyphenethyl)-4-phenethylpiperidine (JPC-060) after purification via silica gel
column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.18-1.94 (m, 10H), 2.38-2.95 (m, 7H). 3.82 (s, 3H),

6.78-7.21 (m, 9H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.4, 28.7, 32.0, 32.6, 37.2, 38.9, 51.6, 55.0, 56.9,

13

114.0, 125.7, 128.2, 128.3, 129.1, 129.6, 141.9, 158.0 ppm.
MS (EI) m/z 323 (M+).
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Figure 3.5 Structure of 1-(2-chlorophenethyl)-4-phenethylpiperidine (JPC-072)
Chemical Formula: C21H26ClN Molecular Weight: 327.89

This molecule was designed to evaluate the effect of introducing the 2-chloro
substituent into the phenyl ring of the phenethyl linker attached to N1 in the 1,4substituted piperidine scaffold on VMAT2 binding 4-Phenethylpiperidine was reacted
with potassium carbonate and 1-(2-bromoethyl)-2-chlorobenzene to afford the final
product 1-(2-chlorophenethyl)-4-phenethylpiperidine (JPC-072) after purification via
silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.39-1.77 (m, 7H), 2.10-3.09 (m, 10H), 7.08-7.28 (m, 9H)

ppm.
C NMR (75 MHz, CDCl3): δ 31.0, 31.9, 33.3, 35.2, 38.4, 53.9, 58.6, 125.8, 127.1,

13

127.9, 128.5, 129.6, 131.1, 134.0, 142.6 ppm.
MS (EI) m/z 327 (M+).
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Figure 3.6 Structure of 1-(4-fluorophenethyl)-4-phenethylpiperidine (JPC-073)
Chemical Formula: C21H26FN Molecular Weight: 311.44

This molecule was designed to evaluate the effect of the introducing a 4-chloro
substituent into the phenyl ring of the phenethyl linker attached to N1 in the 1,4disubstituted piperidine scaffold on VMAT2 binding. 4-Phenethylpiperidine was reacted
with potassium carbonate and 1-(2-bromoethyl)-4-fluorobenzene to yield the final
product, 1-(4-fluorophenethyl)-4-phenethylpiperidine (JPC-073) after purification via
silica column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.32-2.01 (m, 10H), 2.51-3.01 (m, 7H), 6.93-6.99 (m,

2H), 7.12-7.31 (m, 7H) ppm.
C NMR (75 MHz, CDCl3): δ 32.6, 33.3, 33.4, 35.6, 38.7, 54.2, 61.3, 115.1, 115.4,

13

125.8, 128.4, 130.1, 130.2, 136.2, 142.9 ppm.
MS (EI) m/z 311 (M+).
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Figure 3.7 Structure of 4-(2-methoxyphenethyl)-1-phenethylpiperidine (JPC-078)
Chemical Formula: C22H29NO Molecular Weight: 323.47

This molecule was designed to evaluate the effect of introducing a 2-methoxy
substituent into the phenyl ring of the phenethyl moiety attached to C4 in the piperidine
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Methylpyridine
was subjected to Aldol condensation with 2-methoxybenzaldehyde in refluxing acetic
anhydride to yield (E)-4-(2-methoxystyryl)pyridine (purified via silica column
chromatography). Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen
gas afforded 4-(2-methoxyphenethyl)piperidine (purified via silica column
chromatography), which was reacted with potassium carbonate and (2bromoethyl)benzene to yield the final product, 4-(2-methoxyphenethyl)-1phenethylpiperidine (JPC-078) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.32-1.98 (m, 7H), 2.54-2.98 (m, 10H). 3.81 (s, 3H),

6.83-7.31(m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 27.6, 32.7, 34.2, 35.9, 37.0, 54.3, 55.5, 61.4, 110.4,

13

120.5, 126.1, 126.9, 128.5, 128.8, 129.7, 131.4, 140.8, 157.5 ppm.
MS (EI) m/z 323 (M+).
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Figure 3.8 Structure of 1,4-bis(2-methoxyphenethyl)piperidine (JPC-077)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(2Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-methoxybenzene to yield the final product, 1,4-bis(2-methoxyphenethyl)piperidine (JPC-077) after was purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.32-2.02 (m, 7H), 2.52-3.06 (m, 10H). 3.83 (s, 6H),

6.84-7.27 (m, 8H) ppm.
C NMR (75 MHz, CDCl3): δ 27.6, 28.3, 32.7, 35.9, 37.0, 54.2, 55.5, 59.5, 110.4,

13

110.5, 120.5, 120.6, 126.9, 127.4, 129.7, 130.4, 131.4, 157.5, 157.6 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.9 Structure of 4-(2-methoxyphenethyl)-1-(3methoxyphenethyl)piperidine (JPC-094)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.
Synthesis began with 4-(2-methoxyphenethyl)piperidine which was reacted with
potassium carbonate and 1-(2-bromoethyl)-3-methoxybenzene to yield the final product,
4-(2-methoxyphenethyl)-1-(3-methoxyphenethyl)- piperidine (JPC-094) which was
purified via column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.27-1.98 (m, 7H), 2.48-3.04 (m, 10H). 3.82 (s, 6H),

6.89-7.22 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.5, 28.7, 29.3, 32.9, 35.8, 51.6, 55.0, 55.21, 55.22,

13

56.5, 109.5, 110.6, 112.2, 114.3, 120.3, 120.8, 124.4, 127.1, 129.6, 138.9, 157.0, 159.4
ppm.
MS (EI) m/z 353 (M+).

131

Figure 3.10 Structure of 4-(2-methoxyphenethyl)-1-(4methoxyphenethyl)piperidine (JPC-095)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.
Synthesis began with the common intermediate 4-(2-methoxyphenethyl)piperidine that
had been prepared previously, which was reacted with potassium carbonate and 1-(2bromoethyl)-4-methoxybenzene to yield the final product 4-(2-methoxyphenethyl)-1-(4methoxyphenethyl) piperidine (JPC-095) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.28-2.04 (m, 7H), 2.44-2.91 (m, 10H). 3.80 (s, 6H),

6.81-7.30 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 26.5, 28.4, 28.7, 32.9, 35.8, 43.3, 51.6, 55.0, 55.2,

13

56.9, 109.4, 110.6, 120.3, 127.1, 129.1, 129.5, 129.7, 157.0, 158.0 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.11 Structure of 4-(2-methoxyphenethyl)-1-(2chlorophenethyl)piperidine (JPC-096)
Chemical Formula: C22H28ClNO Molecular Weight: 357.92

This molecule was designed to evaluate the effect of introducing the combination
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1 and a
2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. The
combination of methoxy and chloro substituents had not previously been investigated in
any lobelane scaffold thus far. 4-(2-Methoxyphenethyl)piperidine was reacted with
potassium carbonate and 1-(2-bromoethyl)-2-chlorobenzene to yield the final product 4(2-methoxyphenethyl)-1-(2-chlorophenethyl)piperidine (JPC-096) after purification via
silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.30-1.97 (m, 10H), 2.48-2.94 (m, 7H). 3.81 (s, 3H),

6.80-7.28 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 26.5, 27.8, 28.7, 32.8, 35.8, 43.3, 51.6, 54.9, 55.2,

13

110.6, 120.2, 127.1, 127.6, 128.9, 129.4, 129.5, 129.7, 131.1, 133.0, 134.8, 157.0 ppm.
MS (EI) m/z 357 (M+).
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Figure 3.12 Structure of 4-(2-methoxyphenethyl)-1-(4-fluorophenethyl)piperidine
(JPC-097) Chemical Formula: C22H28FNO Molecular Weight: 341.46

This molecule was designed to evaluate the effect of introducing the combination
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1 and a
2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(2Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-fluorobenzene to yield the final product, 4-(2-methoxyphenethyl)-1-(4fluorophenethyl)piperidine (JPC-097) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.30-1.97 (m, 10H), 2.50-3.00 (m, 7H). 3.81 (s, 3H),

6.82-7.25(m, 8H) ppm.
C NMR (75 MHz, CDCl3): δ 27.6, 32.7, 33.3, 35.9, 37.0, 54.3, 55.5, 61.4, 110.3,

13

115.1, 115.3, 120.5, 127.0, 129.6, 130.1, 130.2, 131.3, 136.3, 136.4, 157.4, 163.0 ppm.
MS (EI) m/z 341 (M+).
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Figure 3.13 Structure of 4-(3-methoxyphenethyl)-1-phenethylpiperidine
(JPC-079) Chemical Formula: C22H29NO Molecular Weight: 323.47

This molecule was designed to evaluate the effect of introducing a 3-methoxy
substituent into the phenyl ring of the phenethyl linker attached to C4 in the piperidine
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Methylpyridine
was subjected to Aldol condensation with 3-methoxybenzaldehyde in refluxing acetic
anhydride to yield (E)-4-(3-methoxystyryl)pyridine (purified via silica column
chromatography). Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen
gas afforded 4-(3-methoxyphenethyl)piperidine (purified via silica column
chromatography), which was reacted with potassium carbonate and (2bromoethyl)benzene to yield the final product, 4-(3-methoxyphenethyl)-1phenethylpiperidine (JPC-079) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.25-2.03 (m, 7H), 2.55-3.03 (m, 10H). 3.80 (s, 3H),

6.71-7.31 (m, 9H) ppm.
C NMR (75 MHz, CDCl3) δ 25.6, 30.7, 34.1, 36.3, 37.0, 49.3, 55.6, 59.9, 110.9, 113.8,

13

120.5, 126.1, 128.5, 128.8, 129.7, 139.4, 140.8, 159.5 ppm.
MS (EI) m/z 323 (M+).
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Figure 3.14 Structure of 1-(2-methoxyphenethyl)-4-(3methoxyphenethyl)piperidine (JPC-080)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1 and
a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(3methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-methoxybenzene to yield the final product 1-(2-methoxyphenethyl)-4-(3methoxyphenethyl)- piperidine (JPC-080) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-2.04 (m, 10H), 2.42-3.07 (m, 7H), 3.77 (s, 6H),

6.65-6.89(m, 4H), 7.11-7.21 (m, 4H) ppm.
C NMR (75 MHz, CDCl3): δ 28.3, 32.7, 33.5, 35.7, 38.6, 53.7, 54.1, 55.4, 55.5, 59.5,

13

110.4, 111.0, 114.3, 120.5, 120.9, 127.3, 129.1, 129.4, 130.3, 144.6, 157.6, 159.7 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.15 Structure of 1,4-bis(3-methoxyphenethyl)piperidine (JPC-081)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(3Methoxyphenethyl) was reacted with potassium carbonate and 1-(2-bromoethyl)-3methoxybenzene to yield the final product 1,4-bis(3-methoxyphenethyl)- piperidine
(JPC-081) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.19-2.07 (m, 10H), 2.51-3.07 (m, 7H). 3.79 (s, 6H),

6.73-6.76(m, 5H), 7.15-7.21 (m, 3H) ppm.
C NMR (75 MHz, CDCl3): δ 32.7, 33.5, 34.2, 35.6, 38.6, 54.2, 55.4, 61.2, 111.0,

13

111.4, 114.3, 114.7, 120.9, 121.3, 129.4, 129.5, 142.4, 144.6, 159.7 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.16 Structure of 1-(4-methoxyphenethyl)-4-(3methoxyphenethyl)piperidine (JPC-082)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(3Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-methoxybenzene to yield the final product, 1-(4-methoxyphenethyl)-4-(3methoxyphenethyl)piperidine (JPC-082) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-1.96 (m, 7H), 2.41-2.97 (m, 10H). 3.82 (s, 6H),

6.81-7.23 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.2, 28.7, 32.0, 32.6, 37.1, 43.3, 51.6, 54.9, 55.0,

13

56.9, 109.5, 111.1, 113.9, 114.0, 120.5, 129.0, 129.3, 129.6, 143.6, 158.1, 159.3 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.17 Structure of 1-(2-chlorophenethyl)-4-(3methoxyphenethyl)piperidine (JPC-083)
Chemical Formula: C22H28ClNO Molecular Weight: 357.92

This molecule was designed to evaluate the effect of introducing the combination
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and a
3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(3Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-chlorobenzene to yield the final product 1-(2-chlorophenethyl)-4-(3methoxyphenethyl)piperidine (JPC-083) was after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.22-1.94 (m, 10H), 2.43-2.99 (m, 7H). 3.80 (s, 3H),

6.88-7.32 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 27.4, 28.3, 28.9, 32.1, 37.2, 43.4, 51.8, 55.0, 111.2,

13

114.1, 120.6, 127.7, 129.4, 131.2, 133.2, 134.1, 134.9, 143.7, 159.3, 166.4 ppm.
MS (EI) m/z 357 (M+).
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Figure 3.18 Structure of 1-(4-fluorophenethyl)-4-(3-methoxyphenethyl)piperidine
(JPC-084) Chemical Formula: C22H28FNO Molecular Weight: 341.46

This molecule was designed to evaluate the effect of introducing the combination
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and a
3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted scaffold on VMAT2 binding. 4-(3Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-fluorobenzene to yield the final product 1-(4-fluorophenethyl)-4-(2chlorophenethyl)piperidine (JPC-084) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.24-1.96 (m, 10H), 2.46-3.02 (m, 7H). 3.80 (s, 3H),

6.83-7.21(m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.4, 28.7, 32.0, 32.6, 37.1, 43.3, 51.6, 54.9, 56.6,

13

111.1, 113.9, 115.2, 115.4, 120.5, 129.3, 130.5, 130.6, 133.5, 143.6, 159.3, 162.3 ppm.
MS (EI) m/z 341 (M+).
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Figure 3.19 Structure of 4-(4-methoxyphenethyl)-1-phenethylpiperidine
(JPC-085) Chemical Formula: C22H29NO Molecular Weight: 323.47

This molecule was designed to evaluate the effect of introducing a 4-methoxy
substituent into the phenyl ring of the phenethyl linker attached to C4 in the piperidine
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Methylpyridine
was subjected to Aldol condensation with 4-methoxybenzaldehyde in refluxing acetic
anhydride to yield (E)-4-(4-methoxystyryl)pyridine (purified via silica gel column
chromatography). Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen
gas afforded 4-(4-methoxyphenethyl)piperidine (purified via silica gel column
chromatography), which was reacted with potassium carbonate and (2bromoethyl)benzene to yield the final product 4-(4-methoxyphenethyl)-1phenethylpiperidine (JPC-085) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-1.97 (m, 10H), 2.36-2.91 (m, 7H). 3.83 (s, 3H),

6.81-7.24 (m, 9H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.7, 29.3, 31.0, 32.5, 37.4, 43.3, 51.6, 54.9, 56.6,

13

109.5, 113.7, 126.7, 128.60, 128.61, 129.1, 133.72, 137.4, 157.3 ppm.
MS (EI) m/z 323 (M+).
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Figure 3.20 Structure of 1-(2-methoxyphenethyl)-4-(4methoxyphenethyl)piperidine (JPC-086)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(4Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-methoxybenzene to yield the final product 1-(2-methoxyphenethyl)-4-(4methoxyphenethyl)piperidine (JPC-086) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.27-2.06 (m, 7H), 2.48-3.05 (m, 10H). 3.84 (s, 6H),

6.87-7.30 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.3, 28.7, 31.0, 32.5, 37.4, 43.3, 51.5, 54.9, 55.3,

13

55.4, 110.9, 113.7, 120.5, 124.4, 125.0, 128.3, 129.1, 130.0, 133.7, 157.0, 157.3 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.21 Structure of 1-(3-methoxyphenethyl)-4-(4methoxyphenethyl)piperidine (JPC-087)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted scaffold on VMAT2 binding. 4-(4Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-3-methoxybenzene to yield the final product 1-(3-methoxyphenethyl)-4-(4methoxyphenethyl)piperidine (JPC-087), after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.23-1.98 (m, 7H), 2.38-2.94 (m, 10H). 3.81 (s, 6H),

6.87-7.28 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.7, 29.3, 31.0, 32.5, 37.4, 43.3, 51.6, 54.9, 55.0,

13

56.5, 112.2, 113.7, 114.3, 120.8, 129.1, 129.6, 133.7, 138.9, 157.3, 159.4 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.22 Structure of 1,4-bis(4-methoxyphenethyl)piperidine (JPC-088)
Chemical Formula: C23H31NO2 Molecular Weight: 353.50

This molecule was designed to evaluate the effect of introducing the combination
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(4Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-methoxybenzene to yield the final product 1-(4-methoxyphenethyl)-4-(4methoxyphenethyl)piperidine (JPC-088) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-2.05 (m, 7H), 2.38-2.91 (m, 10H). 3.82 (s, 6H),

6.76-7.23 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.4, 28.7, 31.1, 32.6, 37.5, 51.6, 54.95, 55.04, 56.9,

13

109.5, 113.7, 114.0, 124.4, 129.08, 129.12, 129.7, 133.8, 157.4, 158.1 ppm.
MS (EI) m/z 353 (M+).
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Figure 3.23 Structure of 1-(2-chlorophenethyl)-4-(4methoxyphenethyl)piperidine (JPC-089)
Chemical Formula: C22H28ClNO Molecular Weight: 357.92

This molecule was designed to evaluate the effect of introducing the combination
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and a
4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(4Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-chlorobenzene to yield the final product, 1-(2-chlorophenethyl)-4-(4methoxyphenethyl)piperidine (JPC-089) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.26-1.95 (m, 10H), 2.41-3.02 (m, 7H). 3.81 (s, 3H),

6.84-7.33 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 27.2, 28.7, 31.1, 32.5, 37.4, 43.3, 51.6, 55.0, 109.5,

13

113.7, 124.4, 127.6, 128.9, 129.3, 131.1, 133.1, 133.8, 134.8, 157.4, 165.9 ppm.
MS (EI) m/z 357 (M+).
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Figure 3.24 Structure of 1-(4-fluorophenethyl)-4-(4-methoxyphenethyl)piperidine
(JPC-090) Chemical Formula: C22H28FNO Molecular Weight: 341.46

This molecule was designed to evaluate the effect of introducing the combination
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and a
4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(4Methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-fluorobenzene to yield the final product 1-(4-fluorophenethyl)-4-(4methoxyphenethyl)piperidine (JPC-090) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-1.94 (m, 10H), 2.49-3.07 (m, 7H). 3.83 (s, 3H),

6.87-7.28(m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.4, 28.7, 31.0, 32.5, 37.4, 51.6, 54.9, 56.5, 113.7,

13

115.2, 115.4, 124.4, 129.1, 130.5, 130.6, 133.50, 133.53, 133.7, 159.9, 162.3 ppm.
MS (EI) m/z 341 (M+).
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Figure 3.25 Structure of 4-(2,4-difluorophenethyl)-1-phenethylpiperidine
(JPC-098) Chemical Formula: C21H25F2N Molecular Weight: 329.43

This molecule was designed to evaluate the effect of introducing 2,4-difluoro
substituents into the phenyl ring of the phenethyl linker attached to C4 in the piperidine
ring of the 1,4-disubstituted scaffold on VMAT2 binding. 4-Methylpyridine was
subjected to Aldol condensation with 2,4-difluorobenzaldehyde in refluxing acetic
anhydride to yield (E)-4-(2,4-difluorostyryl)pyridine (purified via silica gel column
chromatography). Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen
gas afforded 4-(2,4-difluorophenethyl)piperidine (purified via silica gel column
chromatography), which was reacted with potassium carbonate and (2bromoethyl)benzene to yield the final product 4-(2,4-difluorophenethyl)-1phenethylpiperidine (JPC-098) was after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.31-1.95 (m, 9H), 2.44-3.02 (m, 8H). 6.65-6.91(m, 6H),

7.13-7.30 (m, 2H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.7, 28.6, 29.3, 32.7, 35.9, 43.29, 43.30, 51.6, 56.6,

13

103.6, 109.5, 111.4, 124.4, 126.7, 128.6, 131.7, 137.3, 142.2 ppm.
MS (EI) m/z 329 (M+).
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Figure 3.26 Structure of 4-(2,4-difluorophenethyl)-1-(2methoxyphenethyl)piperidine (JPC-099)
Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4(2,4-Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-methoxybenzene to yield the final product, 4-(2,4-difluorophenethyl)-1(2-methoxyphenethyl)piperidine (JPC-099) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.28-2.02 (m, 9H), 2.51-3.00 (m, 8H). 3.81 (s, 3H), 6.65-

6.81(m, 5H), 7.11-7.26 (m, 2H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.3, 24.7, 28.6, 32.6, 35.8, 43.3, 51.5, 55.3, 55.4,

13

103.5, 109.5, 110.9, 111.2, 120.5, 124.4, 125.0, 128.3, 130.0, 157.1 ppm.
MS (EI) m/z 359 (M+).
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Figure 3.27 Structure of 4-(2,4-difluorophenethyl)-1-(3methoxyphenethyl)piperidine (JPC-100)
Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 2,4-difluoro substituents in the phenyl ring of the phenethyl linker attached to C4 of
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4(2,4-Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-3-methoxybenzene to yield the final product, 4-(2,4-difluorophenethyl)-1(3-methoxyphenethyl)piperidine (JPC-100) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.31-2.01 (m, 9H), 2.57-3.05 (m, 8H). 3.79 (s, 3H), 6.72-

6.81(m, 5H), 7.11-7.26 (m, 2H) ppm.
C NMR (75 MHz, CDCl3): δ 25.9, 32.3, 34.0, 35.5, 37.2, 54.1, 55.4, 61.0, 103.7,

13

111.1, 111.2, 111.4, 114.6, 121.2, 129.5, 130.8, 130.88, 130.91, 142.1, 159.7 ppm.
MS (EI) m/z 359 (M+).
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Figure 3.28 Structure of 4-(2,4-difluorophenethyl)-1-(4-methoxyphenethyl)piperidine
(JPC-101) Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4(2,4-Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-methoxybenzene to yield the final product 4-(2,4-difluorophenethyl)-1-(4methoxyphenethyl)piperidine (JPC-101) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.32-1.98 (m, 9H), 2.57-3.04 (m, 8H). 3.83 (s, 3H), 6.69-

6.84(m, 5H), 7.09-7.21 (m, 2H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.7, 28.4, 28.6, 32.7, 35.9, 43.3, 51.5, 55.0, 56.9,

13

103.5, 111.1, 111.3, 114.0, 124.4, 124.7, 124.8, 129.1, 129.6, 129.1, 131.6, 158.0 ppm.
MS (EI) m/z 359 (M+).
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Figure 3.29 Structure of 1-(2-chlorophenethyl)-4-(2,4-difluorophenethyl)piperidine
(JPC-102) Chemical Formula: C21H24ClF2N Molecular Weight: 363.87

This molecule was designed to evaluate the effect of introducing the combination
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1 and
2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(2,4Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-chlorobenzene to yield the final product, 1-(2-chlorophenethyl)-4-(2,4difluorophenethyl)piperidine (JPC-102) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.31-1.97 (m, 9H), 2.46-2.94 (m, 8H), 6.65-7.26 (m, 7H)

ppm.
C NMR (100 MHz, DMSO-d6): δ 24.7, 27.2, 28.6, 32.6, 35.8, 42.4, 43.3, 51.5, 54.9,

13

103.6, 109.5, 111.2, 124.6, 127.6, 128.9, 129.4, 131.1, 131.7, 133.0, 134.8, 159.5 ppm.
MS (EI) m/z 363 (M+).
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Figure 3.30 Structure of 4-(2,4-difluorophenethyl)-1-(4-fluorophenethyl)piperidine
(JPC-103) Chemical Formula: C21H24F3N Molecular Weight: 347.42

This molecule was designed to evaluate the effect of introducing the combination
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and
2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(2,4Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-fluorobenzene to yield the final product 4-(2,4-difluorophenethyl)-1-(4fluorophenethyl)piperidine (JPC-103) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.34-2.02 (m, 9H), 2.41-3.06 (m, 8H), 6.61-7.29 (m, 7H)

ppm.
C NMR (100 MHz, DMSO-d6): δ 24.7, 28.5, 32.7, 35.9, 37.6, 42.1, 43.3, 51.6, 56.5,

13

103.6, 109.5, 111.3, 115.2, 115.4, 124.4, 124.7, 130.6, 131.6, 133.5, 159.9, 162.0 ppm.
MS (EI) m/z 347 (M+).
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Figure 3.31 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-phenethylpiperidine
(JPC-104) Chemical Formula: C22H28FNO Molecular Weight: 341.46

This molecule was designed to evaluate the effect of introducing 2-fluoro-4methoxy substituents into the phenyl ring of the phenethyl linker attached to C4 in the
piperidine ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4Methylpyridine was subjected to Aldol condensation with 2-fluoro-4-methoxy
benzaldehyde in refluxing acetic anhydride to yield (E)-4-(2-fluoro-4-methoxy
styryl)pyridine (purified via silica gel column chromatography). Catalytic hydrogenation
with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2-fluoro-4methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and (2-bromoethyl)benzene to yield the final
product 4-(2-fluoro-4-methoxyphenethyl)-1-phenethylpiperidine (JPC-104) after
purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.27-1.89 (m, 9H), 2.38-2.94 (m, 8H), 3.82 (s, 3H), 6.74-

7.38 (m, 8H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.6, 28.7, 29.3, 32.6, 36.1, 43.3, 51.6, 55.5, 56.6,

13

101.5, 109.5, 110.1, 120.1, 126.7, 128.6, 130.9, 131.0, 137.3, 157.2, 158.8, 158.9 ppm.
MS (EI) m/z 341 (M+).
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Figure 3.32 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(2methoxyphenethyl)piperidine (JPC-105)
Chemical Formula: C23H30FNO2 Molecular Weight: 371.49

This molecule was designed to evaluate the effect of introducing the combination
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached
to C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2
binding. 4-(2-Fluoro-4-methoxyphenethyl)piperidine was reacted with potassium
carbonate and 1-(2-bromoethyl)-2-methoxybenzene to yield the final product, 4-(2fluoro-4-methoxyphenethyl)-1-(2-methoxyphenethyl)piperidine (JPC-105) after
purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-1.97 (m, 9H), 2.41-2.99 (m, 8H), 3.81 (s, 6H), 6.71-

7.35 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.1, 25.7, 26.2, 27.0, 36.2, 43.1, 55.2, 56.6, 58.1,

13

101.5, 111.2, 120.5, 126.7, 130.2, 130.5, 132.6, 158.1, 159.4, 161.2 ppm.
MS (EI) m/z 371 (M+).
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Figure 3.33 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(3methoxyphenethyl)piperidine (JPC-106)
Chemical Formula: C23H30FNO2 Molecular Weight: 371.49

This molecule was designed to evaluate the effect of introducing the combination
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached
to C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2
binding. 4-(2-Fluoro-4-methoxyphenethyl)piperidine was reacted with potassium
carbonate and 1-(2-bromoethyl)-3-methoxybenzene to yield the final product, 4-(2fluoro-4-methoxyphenethyl)-1-(3-methoxyphenethyl)piperidine (JPC-106) was after
purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.21-1.98 (m, 9H), 2.40-2.92 (m, 8H), 3.80 (s, 6H), 6.78-

7.31 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 24.2, 25.2, 26.3, 36.1, 38.0, 55.1, 57.6, 60.3, 101.5,

13

109.5, 112.0, 114.2, 128.1, 130.5, 142.7, 157.7, 159.9, 160.7 ppm.
MS (EI) m/z 371 (M+).
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Figure 3.34 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(4methoxyphenethyl)piperidine (JPC-107)
Chemical Formula: C23H30FNO2 Molecular Weight: 371.49

This molecule was designed to evaluate the effect of introducing the combination
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1 and
e2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached to
C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.
4-(2-Fluoro-4-methoxy phenethyl)piperidine was reacted with potassium carbonate and
1-(2-bromoethyl)-4-methoxybenzene to yield the final product, 4-(2-fluoro-4methoxyphenethyl)-1-(4-methoxyphenethyl)piperidine (JPC-107) after purification via
silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.27-1.97 (m, 9H), 2.32-3.04 (m, 8H), 3.82 (s, 6H), 6.71-

7.21 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 23.7, 24.9, 26.0, 34.1, 36.0, 55.1, 55.2, 60.7, 101.3,

13

109.2, 113.9, 130.0, 130.1, 130.3, 132.7, 157.5, 158.3, 159.2 ppm.
MS (EI) m/z 371 (M+).

156

Figure 3.35 Structure of 1-(2-chlorophenethyl)-4-(2-fluoro-4methoxyphenethyl)piperidine (JPC-108)
Chemical Formula: C22H27ClFNO Molecular Weight: 375.91

This molecule was designed to evaluate the effect of introducing the combination
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and
2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached to
C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.
4-(2-Fluoro-4-methoxyphenethyl)piperidine was reacted with potassium carbonate and
1-(2-bromoethyl)-2-chlorobenzene to yield the final product, 1-(2-chlorophenethyl)-4-(2fluoro-4-methoxyphenethyl)piperidine (JPC-108) was after purification via silica gel
column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.29-2.07 (m, 9H), 2.48-2.98 (m, 8H), 3.82 (s, 3H), 6.65-

7.39 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 27.0, 28.1, 30.9, 31.2, 36.1, 53.1, 55.6, 56.0, 102.1,

13

109.9, 127.7, 129.9, 130.1, 131.0, 131.7, 134.2, 158.2, 159.1 ppm.
MS (EI) m/z 375 (M+).
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Figure 3.36 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(4fluorophenethyl)piperidine (JPC-109)
Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and
2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached to
C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.
4-(2-Fluoro-4-methoxyphenethyl)piperidine was reacted with potassium carbonate and 1(2-bromoethyl)-4-fluorobenzene to yield the final product, 4-(2-fluoro-4methoxyphenethyl)-1-(4-fluorophenethyl)piperidine (JPC-109) after purification via
silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.28-2.09 (m, 9H), 2.45-3.01 (m, 8H), 3.79 (s, 3H), 6.69-

7.37 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 27.1, 28.0, 30.5, 32.7, 36.0, 52.7, 55.7, 57.1, 101.9,

13

110.3, 114.2, 114.3, 129.8, 129.9, 130.3, 158.5, 159.9, 160.2 ppm.
MS (EI) m/z 359 (M+).
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Figure 3.37 Structure of 4-(3,5-difluorophenethyl)-1-phenethylpiperidine
(JPC-110) Chemical Formula: C21H25F2N Molecular Weight: 329.43

This molecule was designed to evaluate the effect of introducing 3,5-difluoro
substituents into the phenyl ring of the phenethyl linker attached to C4 in the piperidine
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Methylpyridine
was subjected to Aldol condensation with 3,5-difluorobenzaldehyde in refluxing acetic
anhydride to yield (E)-4-(3,5-difluorostyryl)pyridine (purified via silica gel column
chromatography). Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen
gas afforded 4-(3,5-difluorophenethyl)piperidine (purified via silica gel column
chromatography), which was reacted with potassium carbonate and (2bromoethyl)benzene to yield the final product 4-(3,5-difluorophenethyl)-1phenethylpiperidine (JPC-110) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.31-1.95 (m, 9H), 2.44-3.02 (m, 8H). 6.71-7.34 (m, 8H)

ppm.
C NMR (100 MHz, DMSO-d6): δ 27.7, 30.7, 32.3, 33.0, 34.9, 52.9, 59.3, 107.7, 112.9,

13

126.5, 127.9, 128.7, 162.1 ppm.
MS (EI) m/z 329 (M+).
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Figure 3.38 Structure of 4-(3,5-difluorophenethyl)-1-(2methoxyphenethyl)piperidine (JPC-111)
Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4(3,5-Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-methoxybenzene to yield the final product, 4-(3,5-difluorophenethyl)-1(2-methoxyphenethyl)piperidine (JPC-111) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.28-1.97 (m, 9H), 2.47-3.08 (m, 8H). 3.80 (s, 3H), 6.63-

7.31 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 27.1, 29.2, 29.9, 30.6, 34.3, 51.7, 54.2, 57.0, 107.9,

13

110.5, 113.7, 120.1, 129.9, 130.3, 130.6, 158.0, 162.4 ppm.
MS (EI) m/z 359 (M+).
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Figure 3.39 Structure of 4-(3,5-difluorophenethyl)-1-(3methoxyphenethyl)piperidine (JPC-112)
Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4(3,5-Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-3-methoxybenzene to yield the final product, 4-(3,5-difluorophenethyl)-1(3-methoxyphenethyl)piperidine (JPC-112) after purified via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.29-2.03 (m, 9H), 2.56-3.03 (m, 8H). 3.79 (s, 3H), 6.68-

6.76(m, 5H), 7.13-7.29 (m, 2H) ppm.
C NMR (75 MHz, CDCl3): δ 32.6, 33.16, 34.13, 35.5, 38.0, 54.1, 55.4, 61.1, 100.9,

13

101.3, 101.6, 111.0, 111.32, 114.6, 121.2, 129.4, 142.3, 146.7, 154.6, 157.9, 161.3, 164.6
ppm.
MS (EI) m/z 359 (M+).
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Figure 3.40 Structure of 4-(3,5-difluorophenethyl)-1-(4methoxyphenethyl)piperidine (JPC-113)
Chemical Formula: C22H27F2NO Molecular Weight: 359.45

This molecule was designed to evaluate the effect of introducing the combination
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1,
and 3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4(3,5-Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-methoxybenzene to yield the final product 4-(3,5-difluorophenethyl)-1-(4methoxyphenethyl)piperidine (JPC-113) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.22-2.03 (m, 9H), 2.41-3.02 (m, 8H). 3.82 (s, 3H), 6.59-

7.32 (m, 7H) ppm.
C NMR (100 MHz, DMSO-d6): δ 28.9, 30.5, 31.8, 33.9, 36.1, 53.0, 55.1, 59.4, 108.4,

13

114.9, 116.0, 124.1, 159.9, 161.8 ppm.
MS (EI) m/z 359 (M+).
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Figure 3.41 Structure of 1-(2-chlorophenethyl)-4-(3,5difluorophenethyl)piperidine (JPC-114)
Chemical Formula: C21H24ClF2N Molecular Weight: 363.87

This molecule was designed to evaluate the effect of introducing the combination
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and
3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(3,5Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-2-chlorobenzene to yield the final product 1-(2-chlorophenethyl)-4-(3,5difluorophenethyl)piperidine (JPC-114) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.30-1.99 (m, 9H), 2.51-3.07 (m, 8H), 6.68-7.29 (m, 7H)

ppm.
C NMR (100 MHz, DMSO-d6): δ 27.9, 30.1, 31.0, 31.9, 34.7, 51.1, 54.8, 107.6, 114.2,

13

127.2, 127.4, 128.9, 129.7, 131.5, 161.7 ppm.
MS (EI) m/z 363 (M+).
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Figure 3.42 Structure of 4-(3,5-difluorophenethyl)-1-(4fluorophenethyl)piperidine (JPC-115)
Chemical Formula: C21H24F3N Molecular Weight: 347.42

This molecule was designed to evaluate the effect of introducing the combination
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and
3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-(3,5Difluorophenethyl)piperidine was reacted with potassium carbonate and 1-(2bromoethyl)-4-fluorobenzene to yield the final product, 4-(3,5-difluorophenethyl)-1-(4fluorophenethyl)piperidine (JPC-115) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.27-1.99 (m, 9H), 2.43-3.01 (m, 8H), 6.63-7.31 (m, 7H)

ppm.
C NMR (100 MHz, DMSO-d6): δ 28.1, 30.95, 31.7, 32.9, 34.9, 51.9, 59.7, 106.8,

13

111.90, 112.0, 113.8, 113.93, 129.7, 161.2, 161.5 ppm.
MS (EI) m/z 347 (M+).
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Figure 3.43 Structure of 1-phenethyl-4-(2,4,5-trimethoxyphenethyl)piperidine
(JPC-068)
Chemical Formula: C24H33NO3 Molecular Weight: 383.52

This molecule was designed to evaluate the effect of introducing 2,4,5-trimethoxy
substituents into the phenyl ring of the phenethyl linker attached to C4 in the piperidine
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Methylpyridine
was subjected to Aldol condensation with 2,4,5-trimethoxybenzaldehyde in refluxing
acetic anhydride to yield (E)-4-(2,4,5-trimethoxystyryl)pyridine (purified via silica gel
column chromatography). Catalytic hydrogenation with Adam’s catalyst (PtO2) and
hydrogen gas afforded 4-(2,4,5-trimethoxyphenethyl)piperidine (purified via silica gel
column chromatography), which was reacted with potassium carbonate and (2bromoethyl)benzene to yield the final product, 1-phenethyl-4-(2,4,5trimethoxyphenethyl)piperidine (JPC-068) after purification via silica gel column
chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.24-1.97 (m, 7H), 2.47-2.98 (m, 10H). 3.72 (s, 3H), 3.77

(s, 3H), 3.80 (s, 3H), 6.44 (s, 1H), 6.62 (s, 1H), 7.12-7.24 (m, 5H) ppm.
C NMR (75 MHz, CDCl3) δ 27.1, 32.6, 34.0, 35.8, 37.5, 54.3, 56.5, 56.7, 61.3, 114.1,

13

126.1, 128.5, 128.8, 140.6, 142.9, 147.6, 151.5 ppm.
MS (EI) m/z 383 (M+).
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A series of 1,4-disubstituted piperidine analogs were prepared with shorter alkane
linker units between the C4 position of the piperidine ring and the phenyl moiety, while
maintaining a substituted phenethyl linker at the N1 position of the piperidine ring, to
determine the ability of the TBZ binding site on VMAT2 to recognize compounds with
shorter linkers and less degrees of freedom of rotation The synthetic route for generating
these compounds is shown in Scheme 3.2, and a total of four compounds were
synthesized via a one-step synthesis.

Scheme 3.2 Synthetic route to the phenethyl substituted 4-benzyl-1-phenethylpiperidine
analogs of lobelane

Starting with 4-benzylpiperidine, which was readily available from Sigma
Aldrich, a simple SN2 reaction with potassium carbonate and the appropriately substituted
(2-bromoethyl)benzene afforded the desired 4-benzyl-1-phenethylpiperidine product,
which was purified by silica gel column chromatography. The four compounds designed
and synthesized in this series, their structures, and analytical data follow in Figures 3.44
through 3.47. NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated)
on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are
reported in ppm relative to either TMS as internal standard or as relative to the solvent
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peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC
incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD.
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Figure 3.44 Structure of 4-benzyl-1-(2-methoxyphenethyl)piperidine (JPC-061)
Chemical Formula: C21H27NO Molecular Weight: 309.45

This molecule was designed to evaluate the effect of incorporating a shorter
methylene linker between the C4 position of the piperidine ring and the phenyl moiety,
while maintaining a 2-methoxyphenethyl unit on the N1 position in the piperidine ring of
the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Benzylpiperidine was
subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-2methoxybenzene to yield the final product 4-benzyl-1-(2-methoxyphenethyl)piperidine
(JPC-061).
1

H NMR (300 MHz, CDCl3): δ 1.30-1.91 (m, 5H), 2.47-2.61 (m, 6H), 2.75-2.78 (m, 4H),

3.82 (s, 3H) 6.74-7.35 (m, 9H) ppm.
MS (EI) m/z 309 (M+).
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Figure 3.45 Structure of 4-benzyl-1-(3-methoxyphenethyl)piperidine (JPC-062)
Chemical Formula: C21H27NO Molecular Weight: 309.45

This molecule was designed to evaluate the effect of incorporating a shorter
methylene linker between the C4 position of the piperidine ring and the phenyl moiety
while, maintaining a 3-methoxyphenethyl unit on the N1 position in the piperidine ring of
the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Benzylpiperidine was
subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-3methoxybenzene to yield the final product, 4-benzyl-1-(3-methoxyphenethyl)piperidine
(JPC-062).
1

H NMR (300 MHz, CDCl3): δ 1.32-1.95 (m, 5H), 2.43-2.60 (m, 6H), 2.77-2.82 (m, 4H),

3.81 (s, 3H) 6.71-7.32 (m, 9H) ppm.
MS (EI) m/z 309 (M+).
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Figure 3.46 Structure of 4-benzyl-1-(3,4-dimethoxyphenethyl)piperidine
(JPC-063) Chemical Formula: C22H29NO2 Molecular Weight: 339.47

This molecule was designed to evaluate the effect of incorporating a shorter
methylene linker between the C4 position of the piperidine ring and the phenyl moiety,
while maintaining a 3,4-dimethoxyphenethyl unit on the N1 position in the piperidine
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Benzylpiperidine
was subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-3,4dimethoxybenzene to yield the final product, 4-benzyl-1-(3,4dimethoxyphenethyl)piperidine (JPC-063).
1

H NMR (300 MHz, CDCl3): δ 1.34-1.87 (m, 5H), 2.41-2.57 (m, 6H), 2.71-2.80 (m, 4H),

3.80 (s, 6H) 6.71-7.30 (m, 8H) ppm.
MS (EI) m/z 339 (M+).
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Figure 3.47 Structure of 4-benzyl-1-(4-methoxyphenethyl)piperidine (JPC-064)
Chemical Formula: C21H27NO Molecular Weight: 309.45

This molecule was designed to evaluate the effect of incorporating a shorter
methylene linker between the C4 position of the piperidine ring and the phenyl moiety,
while maintaining a 4-methoxyphenethyl unit on the N1 position in the piperidine ring of
the 1,4-disubstituted piperidine scaffold on VMAT2 binding. 4-Benzylpiperidine was
subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-4methoxybenzene to yield the final product, 4-benzyl-1-(4-methoxyphenethyl)piperidine
(JPC-064).
1

H NMR (300 MHz, CDCl3): δ 1.28-1.98 (m, 5H), 2.46-2.62 (m, 6H), 2.75-2.84 (m, 4H),

3.82 (s, 3H) 6.75-7.37 (m, 9H) ppm.
MS (EI) m/z 309 (M+).
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A series of 1,4-substituted piperidine analogs with shorter methylene linkers
between the N1 position of the piperidine ring and the substituted phenyl moiety, while
maintaining a substituted phenethyl linker on the C4 position, were prepared to further
analyze the ability of the TBZ binding site on VMAT2 to recognize compounds with
shorter linkers and less degrees of freedom of rotation (one carbon shorter) at the N1
position. The synthetic route for generating these compounds is shown in Scheme 3.3,
and a total of six compounds were synthesized via a one-step synthesis.

Scheme 3.3 Synthetic route to the substituted 1-benzyl-4-phenethylpiperidine
analogs of lobelane.

4-Phenethylpiperidine, which had been previously prepared in earlier syntheses,
was subjected to a reductive amination reaction with an appropriately substituted
benzaldehyde and sodium cyanoborohydride in methanol to yield the appropriate 1benzyl-4-phenethylpiperidine product, which was purified by silica gel column
chromatography. The six compounds designed and synthesized in this series, their
structures, and analytical data follow in Figures 3.48 through 3.53. NMR spectra were
recorded in either CDCl3 or DMSO-d6 (as designated) on one of three Varian instruments
(300 MHz, 400 MHz, or 500 MHz) as indicated are reported in ppm relative to either
172

TMS as internal standard or as relative to the solvent peak present in 13C spectra. GCmass spectra were recorded on an Agilent 6890 GC incorporating an Agilent 7683
autosampler and an Agilent 5973 MSD.
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Figure 3.48 Structure of 1-benzyl-4-phenethylpiperidine (JPC-152)
Chemical Formula: C20H25N Molecular Weight: 279.42

This molecule was designed to evaluate the effect that a shorter methylene linker
(one carbon) between the N1 position on the piperidine ring and the phenyl ring, while
maintaining a phenethyl linker at the C4 position in the piperidine ring of the 1,4disubstituted piperidine scaffold would have on VMAT2 binding. 4-Phenethylpiperidine,
which had been previously prepared in earlier syntheses, was subjected to reductive
amination conditions with benzaldehyde and sodium cyanoborohydride in methanol to
afford the final product 1-benzyl-4-phenethylpiperidine (JPC-152).
1

H NMR (300 MHz, CDCl3): δ 1.05-1.92 (m, 9H), 2.58-2.86 (m, 4H). 3.48 (s, 2H), 7.15-

7.32 (m, 10H) ppm.
C NMR (75 MHz, CDCl3): δ 26.8, 32.6, 33.4, 35.65, 38.7, 54.1, 63.8, 125.7, 127.0,

13

128.25, 128.4, 128.5, 129.4, 138.8, 142.95 ppm.
MS (EI) m/z 279 (M+).
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Figure 3.49 Structure of 1-(2-methoxybenzyl)-4-phenethylpiperidine (JPC-153)
Chemical Formula: C21H27NO Molecular Weight: 309.45

This molecule was designed to evaluate the effect that a shorter methylene linker
(one carbon) between the N1 position of the piperidine ring and a 2-methoxyphenyl ring,
while maintaining a phenethyl linker at the C4 position in the piperidine ring of the 1,4disubstituted piperidine scaffold would have on VMAT2 binding 4-Phenethylpiperidine
was subjected to reductive amination conditions with 2-methoxybenzaldehyde and
sodium cyanoborohydride in methanol to afford the final product 1-(2-methoxybenzyl)-4phenethylpiperidine (JPC-153).
1

H NMR (300 MHz, CDCl3): δ 1.28-2.05 (m, 9H), 2.58-2.94 (m, 4H). 3.55 (s, 2H), 3.81

(s, 3H) 6.84-7.37 (m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 26.8, 32.7, 33.5, 35.6, 38.8, 54.1, 55.7, 56.6, 110.55,

13

120.4, 125.7, 127.9, 128.4, 128.5, 130.7, 157.9 ppm.
MS (EI) m/z 309 (M+).
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Figure 3.50 Structure of 1-(3-methoxybenzyl)-4-phenethylpiperidine (JPC-154)
Chemical Formula: C21H27NO Molecular Weight: 309.45

This molecule was designed to evaluate the effect that a shorter methylene linker
(one carbon) between the N1 position of the piperidine ring and a 3-methoxyphenyl ring,
while maintaining a phenethyl linker at the C4 position in the piperidine ring of the 1,4disubstituted piperidine scaffold would have on VMAT2 binding 4-Phenethylpiperidine
was subjected to reductive amination conditions with 3-methoxybenzaldehyde and
sodium cyanoborohydride in methanol to afford the final product, 1-(3-methoxybenzyl)4-phenethylpiperidine (JPC-154).
1

H NMR (300 MHz, CDCl3): δ 1.28-2.00 (m, 9H), 2.59-2.90 (m, 4H). 3.46 (s, 2H), 3.81

(s, 3H) 6.77-7.29 (m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 32.6, 33.4, 35.6, 38.7, 54.1, 55.5, 63.7, 112.5, 114.8,

13

121.7, 125.7, 128.4, 128.5, 129.2, 141.7, 159.9 ppm.
MS (EI) m/z 309 (M+).
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Figure 3.51 Structure of 1-(4-methoxybenzyl)-4-phenethylpiperidine (JPC-155)
Chemical Formula: C21H27NO Molecular Weight: 309.45

This molecule was designed to evaluate the effect that a shorter methylene linker
(one carbon) between the N1 position of the piperidine ring and a 4-methoxyphenyl ring,
while maintaining a phenethyl linker at the C4 position of the piperidine ring of the 1,4disubstituted piperidine scaffold would have on VMAT2 binding 4-Phenethylpiperidine
was subjected to reductive amination conditions with 4-methoxybenzaldehyde and
sodium cyanoborohydride in methanol to afford the final product 1-(4-methoxybenzyl)-4phenethylpiperidine (JPC-155).
1

H NMR (300 MHz, CDCl3): δ 1.29-1.97 (m, 9H), 2.58-2.90 (m, 4H). 3.44 (s, 2H), 3.80

(s, 3H) 6.83-7.32 (m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 26.8, 32.5, 33.4, 35.6, 38.7, 53.94, 55.51, 63.1, 113.7,

13

125.7, 128.41, 128.44, 130.6, 142.92, 159.5 ppm.
MS (EI) m/z 309 (M+).
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Figure 3.52 Structure of 1-(2-chlorobenzyl)-4-phenethylpiperidine (JPC-156)
Chemical Formula: C20H24ClN Molecular Weight: 313.86

This molecule was designed to evaluate the effect that a shorter methylene linker
(one carbon) between the N1 position of the piperidine ring and a 2-chlorophenyl ring,
while maintaining a phenethyl linker at the C4 position of the piperidine ring of the 1,4disubstituted piperidine scaffold would have on VMAT2 binding. 4-Phenethylpiperidine
was subjected to reductive amination conditions with 2-chlorobenzaldehyde and sodium
cyanoborohydride in methanol to afford the final product, 1-(2-chlorobenzyl)-4phenethylpiperidine (JPC-156).
1

H NMR (300 MHz, CDCl3): δ 1.25-2.01 (m, 9H), 2.58-2.89 (m, 4H). 3.57 (s, 2H), 7.18-

7.57 (m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 32.73, 33.5, 35.6, 38.8, 54.3, 59.8, 125.7, 126.7, 128.0,

13

128.41, 128.44, 129.4, 130.4, 134.2, 136.3, 143.6 ppm.
MS (EI) m/z 313 (M+).
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Figure 3.53 Structure of 1-(4-fluorobenzyl)-4-phenethylpiperidine (JPC-157)
Chemical Formula: C20H24FN Molecular Weight: 297.41

This molecule was designed to evaluate the effect that of a shorter methylene
linker (one carbon) between the N1 position of the piperidine ring and a 4-fluorophenyl
ring, while maintaining a phenethyl linker at the C4 position of the piperidine ring of the
1,4-disubstituted piperidine scaffold of analog would have on VMAT2 binding. 4Phenethylpiperidine was subjected to reductive amination conditions with 4fluorobenzaldehyde and sodium cyanoborohydride in methanol to afford the final product
1-(4-fluorobenzyl)-4-phenethylpiperidine (JPC-157).
1

H NMR (300 MHz, CDCl3): δ 1.05-1.65 (m, 7H), 2.31-2.73 (t, 6H). 3.60 (s, 2H), 7.18-

7.47 (m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 32.4, 32.8, 35.9, 38.3, 52.9, 53.14, 61.3, 114.63, 124.7,

13

127.7, 127.9, 130.45, 132.2, 142.6, 159.9 ppm.
MS (EI) m/z 309 (M+).
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Similarly, another series of 1,4-disubstituted piperidine analogs combined these
factors with shorter linkers between the N1 position of the piperidine ring and the phenyl
moiety, while maintaining a substituted phenethyl linker on the C4 position; or with
shorter linkers between the C4 position of the piperidine ring and the phenyl moiety,
while maintaining a substituted phenethyl linker at the N1 position, were prepared to
further analyze the ability of the TBZ binding site on VMAT2 to recognize compounds
with shorter linkers and less degrees of freedom of rotation (one carbon shorter) at the N1
position. This series of compounds incorporated an alkylbranch in the N1 alkyl linker to
afford a racemic 1-phenylpropan-2-yl moiety attached to N1 of the piperidine ring. The
combined synthetic routes for generating these compounds is shown in Scheme 3.4, and a
total of four compounds were prepared via a one-step synthesis.

Scheme 3.4 Synthesis of the 4-phenethyl-1-(1-phenylpropan-2-yl)piperidine and 4benzyl-1-(1-phenylpropan-2-yl)piperidine series of lobelane analogs
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4-Benzylpiperidine or 4-phenethylpiperidine were each subjected to reductive
amination conditions with the appropriately substituted 1-phenylpropan-2-one and
sodium cyanoborohydride in methanol. This afforded the desired 4-phenethyl-1-(1phenylpropan-2-yl)piperidine and 4-benzyl-1-(1-phenylpropan-2-yl)piperidine scaffolds,
respectively. This synthetic route to these series of molecules also allowed for the
introduction of a bromo substituted phenyl moiety into the scaffold. The final products
were purified via silica gel column chromatography. The structures of four compounds
from this series together with their analytical data are shown in Figures 3.54 through
3.57. NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on one of
three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are reported in
ppm relative to either TMS as internal standard or as relative to the solvent peak present
in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC incorporating an
Agilent 7683 autosampler and an Agilent 5973 MSD.
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Figure 3.54 Structure of racemic 4-benzyl-1-(1-phenylpropan-2-yl)piperidine
(JPC-174) Chemical Formula: C21H27N Molecular Weight: 293.45

4-Benzylpiperidine was subjected to reductive amination conditions with 1phenylpropan-2-one and sodium cyanoborohydride in methanol to afford the final
product, (±)-4-benzyl-1-(1-phenylpropan-2-yl)piperidine (JPC-174).
1

H NMR (300 MHz, CDCl3): δ 0.97 (d, 3H), 1.02-1.88 (m, 5H), 2.21-2.96 (m, 8H). 3.10

(m, 1H), 7.15-7.36 (m, 10H) ppm.
C NMR (75 MHz, CDCl3): δ 14.5, 26.7, 32.8, 33.9, 38.6, 39.4, 43.5, 48.8, 49.5, 53.7,

13

62.0, 125.87, 125.93, 128.2, 128.3, 129.2, 129.4, 139.7, 140.8 ppm.
MS (EI) m/z 293 (M+).
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Figure 3.55 Structure of racemic 4-phenethyl-1-(1-phenylpropan-2-yl)piperidine
(JPC-175) Chemical Formula: C22H29N Molecular Weight: 307.47

4-Phenethylpiperidine was subjected to reductive amination conditions with 1phenylpropan-2-one and sodium cyanoborohydride in methanol to afford the final
product (±)-4-phenethyl-1-(1-phenylpropan-2-yl)piperidine (JPC-175).
1

H NMR (300 MHz, CDCl3): δ 0.96 (d, 3H), 1.22-1.92 (m, 7H), 2.21-2.96 (m, 8H). 3.07

(m, 1H), 7.18-7.34 (m, 10H) ppm.
C NMR (75 MHz, CDCl3): δ 14.6, 33.0, 33.1, 33.4, 36.0, 38.8, 39.5, 48.9, 49.5, 62.0,

13

125.7, 125.9, 128.3, 128.4, 128.43, 128.51, 128.57, 129.4, 141.0, 142.9, 149.8 ppm.
MS (EI) m/z 307 (M+).
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Figure 3.56 Structure of racemic 4-benzyl-1-(1-(4-bromophenyl)propan-2yl)piperidine (JPC-171)
Chemical Formula: C21H26BrN Molecular Weight: 372.34

4-Benzylpiperidine was subjected to reductive amination conditions with 1-(4bromophenyl)propan-2-one and sodium cyanoborohydride in methanol to afford the final
product (±)-4-benzyl-1-(1-(4-bromophenyl)propan-2-yl)piperidine
(JPC-171).
1

H NMR (300 MHz, CDCl3): δ 0.97 (d, 3H), 1.07-1.84 (m, 5H), 2.25-2.99 (m, 8H). 3.15

(m, 1H), 7.15-7.46 (m, 7H), 7.86-7.90 (m, 2H) ppm.
C NMR (75 MHz, CDCl3): δ 14.6, 33.0, 33.1, 33.4, 36.0, 38.8, 39.5, 48.9, 49.5, 62.0,

13

125.7, 125.9, 128.3, 128.4, 128.43, 128.51, 128.57, 129.4, 141.0, 142.9, 149.8 ppm.
MS (EI) m/z 372 (M+).
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Figure 3.57 Structure of racemic 1-(1-(4-bromophenyl)propan-2-yl)-4phenethylpiperidine (JPC-172)
Chemical Formula: C22H28BrN Molecular Weight: 386.37

4-Phenethylpiperidine was subjected to reductive amination conditions with 1-(4bromophenyl)propan-2-one and sodium cyanoborohydride in methanol to afford the final
product, (±)-1-(1-(4-bromophenyl)propan-2-yl)-4-phenethylpiperidine
(JPC-172).
1

H NMR (300 MHz, CDCl3): δ 0.98 (d, 3H), 1.22-1.80 (m, 7H), 2.28-2.94 (m, 8H). 3.13

(m, 1H), 7.24-7.65 (m, 9H) ppm.
C NMR (75 MHz, CDCl3): δ 13.5, 31.2, 33.1, 35.1, 36.8, 37.3, 37.9, 38.5, 47.9, 50.3,

13

53.7, 62.4, 120.3, 124.0, 125.9, 126.3, 128.4, 129.5, 131.1, 131.6, 142.3, 149.7 ppm.
MS (EI) m/z 386 (M+).
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The final series of 1,4-disubstituted piperidine analogs was designed to increase
the water-solubility of the scaffold by replacing the phenyl ring at the N1 phenethyl
linker with saturated heterocyclic moieties, i.e. either piperidine or morpholine, and to
study what effect the introduction of a more polar moiety would have on binding affinity
at the TBZ site of VMAT2. Utilizing synthetic methods similar to those used in Scheme
3.1, 11 analogs were designed and synthesized in this series. The chemistry by which
this series of compounds were generated is shown in Scheme 3.5.

Scheme 3.5 Synthesis of the 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine and 4-(2(4-phenethylpiperidin-1-yl)ethyl)morpholine series of lobelane analogs

The general synthetic scheme to the 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine
and 4-(2-(4-phenethylpiperidin-1-yl)ethyl)morpholine analogs of lobelane utilizes 4186

methylpyridine as the starting material. Similar to chemistry used to construct the 2,6substituted scaffold, 4-methylpyridine was subjected to Aldol condensation with an
appropriately substituted benzaldehyde in refluxing acetic anhydride to afford the
corresponding (E)-4-styrylpyridine intermediate. After purification via silica gel column
chromatography, the conjugated intermediate was then subjected to catalytic
hydrogenation with Adam’s catalyst and hydrogen gas in acetic acid, to afford the
appropriate substituted 4-phenethylpiperidine intermediate. The 4-phenethylpiperidine
intermediate was then subjected to a SN2 reaction with potassium carbonate and either 1(2-chloroethyl)piperidine or 4-(2-chloroethyl)morpholine, to yield respectively the final
products of the 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine and 4-(2-(4phenethylpiperidin-1-yl)ethyl)morpholine series of lobelane analogs. The exact
structures of the above compounds and the analytical data for each compound are shown
in Figures 3.58 through 3.68. NMR spectra were recorded in either CDCl3 or DMSO-d6
(as designated) on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as
indicated are reported in ppm relative to either TMS as internal standard or as relative to
the solvent peak present in 13C spectra. GC-mass spectra were recorded on an Agilent
6890 GC incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD.
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Figure 3.58 Structure of 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine
(JPC-116) Chemical Formula: C20H32N2 Molecular Weight: 300.48

4-Methylpyridine was subjected to Aldol condensation with benzaldehyde in
refluxing acetic anhydride to yield (E)-4-styrylpyridine (purified via silica gel column
chromatography). Subsequent catalytic hydrogenation with Adam’s catalyst (PtO2) and
hydrogen gas afforded 4-phenethylpiperidine (purified via silica gel column
chromatography), which was then reacted with potassium carbonate and 1-(2chloroethyl)piperidine in DMF to yield the final product, 4-phenethyl-1-(2-(piperidin-1yl)ethyl)piperidine (JPC-116) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.43-1.78 (m, 13H), 2.31-2.65 (m, 14H), 7.23-7.43 (m,

5H) ppm.
MS (EI) m/z 300 (M+).
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Figure 3.59 Structure of 4-(2-(4-phenethylpiperidin-1-yl)ethyl)morpholine
(JPC-117) Chemical Formula: C19H30N2O Molecular Weight: 302.45

4-Methylpyridine was subjected to Aldol condensation with benzaldehyde in
refluxing acetic anhydride to yield (E)-4-styrylpyridine (purified via silica gel column
chromatography). Subsequent catalytic hydrogenation with Adam’s catalyst (PtO2) and
hydrogen gas afforded 4-phenethylpiperidine (purified via silica gel column
chromatography), which was reacted with potassium carbonate and 4-(2chloroethyl)morpholine in DMF to yield the final product 4-(2-(4-phenethylpiperidin-1yl)ethyl)morpholine (JPC-117) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.35-1.68 (m, 7H), 2.37-2.70 (m, 14H), 3.43-3.51 (m, 4H)

7.23-7.41 (m, 5H) ppm.
MS (EI) m/z 300 (M+).
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Figure 3.60 Structure of 4-(2-methoxyphenethyl)-1-(2-(piperidin-1yl)ethyl)piperidine (JPC-118)
Chemical Formula: C21H34N2O Molecular Weight: 330.51

4-Methylpyridine was subjected to Aldol condensation with 2methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2methoxystyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield
the final product 4-(2-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-118)
after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.47-1.68 (m, 13H), 2.30-2.67 (m, 14H), 3.82 (s, 3H),

6.81-7.23 (m, 4H) ppm.
MS (EI) m/z 330 (M+).
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Figure 3.61 Structure of 4-(2-(4-(2-methoxyphenethyl)piperidin-1yl)ethyl)morpholine (JPC-119)
Chemical Formula: C20H32N2O2 Molecular Weight: 332.48

4-Methylpyridine was subjected to Aldol condensation with 2methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2methoxystyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield
the final product 4-(2-(4-(2-methoxyphenethyl)piperidin-1-yl)ethyl)morpholine (JPC119) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.32-1.64 (m, 7H), 2.44-2.68 (m, 14H), 3.48-3.58 (m,

4H), 3.81 (s, 3H), 6.81-7.23 (m, 4H) ppm.
MS (EI) m/z 332 (M+).
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Figure 3.62 Structure of 4-(3-methoxyphenethyl)-1-(2-(piperidin-1yl)ethyl)piperidine (JPC-120)
Chemical Formula: C21H34N2O Molecular Weight: 330.51

4-Methylpyridine was subjected to Aldol condensation with 3methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(3methoxystyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(3methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield
the final product, 4-(3-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC120) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.42-1.66 (m, 13H), 2.32-2.64 (m, 14H), 3.81 (s, 3H),

6.83-7.27 (m, 4H) ppm.
MS (EI) m/z 330 (M+).
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Figure 3.63 Structure of 4-(2-(4-(3-methoxyphenethyl)piperidin-1yl)ethyl)morpholine (JPC-121)
Chemical Formula: C20H32N2O2 Molecular Weight: 332.48

4-Methylpyridine was subjected to Aldol condensation with 3methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(3methoxystyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(3methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield
the final product 4-(2-(4-(3-methoxyphenethyl)piperidin-1-yl)ethyl)morpholine (JPC121) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.38-1.67 (m, 7H), 2.44-2.67 (m, 14H), 3.47-3.60 (m,

4H), 3.82 (s, 3H), 6.78-7.19 (m, 4H) ppm.
MS (EI) m/z 332 (M+).
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Figure 3.64 Structure of 4-(4-methoxyphenethyl)-1-(2-(piperidin-1yl)ethyl)piperidine (JPC-122)
Chemical Formula: C21H34N2O Molecular Weight: 330.51

4-Methylpyridine was subjected to Aldol condensation with 4methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(4methoxystyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(4methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield
the final product, 4-(4-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC122) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.35-1.68 (m, 13H), 2.36-2.62 (m, 14H), 3.80 (s, 3H),

6.80-7.22 (m, 4H) ppm.
MS (EI) m/z 330 (M+).
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Figure 3.65 Structure of 4-(2-(4-(4-methoxyphenethyl)piperidin-1yl)ethyl)morpholine (JPC-123)
Chemical Formula: C20H32N2O2 Molecular Weight: 332.48

4-Methylpyridine was subjected to Aldol condensation with 4methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(4methoxystyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(4methoxyphenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield
the final product 4-(2-(4-(4-methoxyphenethyl)piperidin-1-yl)ethyl)morpholine (JPC123) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.31-1.62 (m, 7H), 2.48-2.70 (m, 14H), 3.45-3.62 (m,

4H), 3.84 (s, 3H), 6.73-7.26 (m, 4H) ppm.
MS (EI) m/z 332 (M+).
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Figure 3.66 Structure of 4-(2,4-difluorophenethyl)-1-(2-(piperidin-1yl)ethyl)piperidine (JPC-124)
Chemical Formula: C20H30F2N2 Molecular Weight: 336.46

4-Methylpyridine was subjected to Aldol condensation with 2,4difluorobenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2,4difluorostyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2,4difluorophenethyl)piperidine (purified via silica gel column chromatography), which was
reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield the
final product, 4-(2,4-difluorophenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-124)
after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.38-1.69 (m, 13H), 2.40-2.65 (m, 14H), 6.61-7.27 (m,

3H) ppm.
MS (EI) m/z 336 (M+).
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Figure 3.67 Structure of 4-(2-(4-(2,4-methoxyphenethyl)piperidin-1yl)ethyl)morpholine (JPC-125)
Chemical Formula: C19H28F2N2O Molecular Weight: 338.44

4-methylpyridine was subjected to Aldol condensation with 2,4difluorobenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2,4difluorostyryl)pyridine (purified via silica gel column chromatography). Subsequent
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2,4difluorophenethyl)piperidine (purified via silica gel column chromatography), which was
reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield the
final product 4-(2-(4-(2,4-difluorophenethyl)piperidin-1-yl)ethyl)morpholine (JPC-125)
after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.35-1.63 (m, 7H), 2.38-2.63 (m, 14H), 3.48-3.55 (m, 4H)

6.64-7.23 (m, 3H) ppm.
MS (EI) m/z 338 (M+).
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Figure 3.68 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(2-(piperidin-1yl)ethyl)piperidine (JPC-126)
Chemical Formula: C21H33FN2O Molecular Weight: 348.50

4-Methylpyridine was subjected to Aldol condensation with 2-fluoro-4-methoxy
benzaldehyde in refluxing acetic anhydride to yield (E)-4-(2-fluoro-4-methoxy
styryl)pyridine (purified via silica gel column chromatography). Subsequent catalytic
hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2-fluoro-4methoxy phenethyl)piperidine (purified via silica gel column chromatography), which
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield
the desired 4-(2-fluoro-4-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC126) after purification via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.35-1.62 (m, 13H), 2.37-2.70 (m, 14H), 3.80 (s, 3H)

6.73-7.27 (m, 3H) ppm.
MS (EI) m/z 348 (M+).
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3.3 Summary of the 1,4-disubstituted piperidine analog series

In summary, 68 compounds were designed and synthesized in the 1,4disubstituted piperidine scaffold series as analogs of lobelane utilizing five distinct
chemical schemes. Of the total number of compounds prepared, 43 were of the 1,4substituted scaffold of lobelane, with a large variety of substituent combinations in the
two phenyl rings, that included methoxy, fluoro, and chloro moieties. Another series of
11 compounds belonging to the 1,4-disubstituted piperidine scaffold were designed and
synthesized for the purpose of increasing the water solubility of the scaffold by replacing
the phenyl ring on the N1 phenethyl moiety with saturated heterocyclic moieties, such as
piperidine or morpholine, and to study what effect the introduction of these more polar
moieties would have on binding affinity at the TBZ binding site on VMAT2. The
remaining 14 compounds were of three smaller series of analogs in which a change in the
intramolecular distance between the substituted phenyl rings and the central piperidine
ring was made. The pharmacological assay data for the above 68 compounds from these
different scaffolds are discussed in Chapter 5.

Copyright © John P. Culver 2015
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Chapter 4.
Design and Synthesis of 1,4-disubstituted piperazine and 1,4-diazapane analogs of
lobelane
4.1 Experiments in the 1,4-disubstituted piperazine scaffold
As discussed in Chapter 1, (section 1.8), a series of isomerized lobelane analogs
have been designed and synthesized in which compounds with different attachment
positions of the phenethyl linkers on the central piperidine ring were constructed. Of
these structural modifications, the analogs with the phenethyl linkers in the N1, C4
positions of the piperidine ring showed more promise for optimization and further study
(data shown in Table 1.7), since their binding affinities for VMAT2 were quite similar to
lobelane, while maintaining little to no affinity for α4β2* & α7* nAChRs (data shown in
Table 1.7). The symmetry present in the 1,4-disubstituted scaffold allowed for a
relatively fast and efficient synthesis of a library of compounds with substituents in the
phenyl rings. Several series of compounds were explored in Chapter 3 that possessed a
central piperidine ring, and further studies into a similar scaffold were explored that
inserted an additional nitrogen atom into the central piperidine ring, affording 1,4piperazine and 1,4-diazapane scaffolds. The addition of another nitrogen atom into the
central piperidine ring is predicted to improve the water solubility characteristics of the
scaffold, which is a desirable property in the development of drugs with higher
bioavailability than lobelane, and several series of compounds were designed and
synthesized to explore these possibilities, resulting in the generation of 21 compounds.
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The scheme by which the 1,4-piperazine compounds were synthesized is shown in
Scheme 4.1. The structures of the compounds and the supporting analytical data are
provided in Figures 4.1 through 4.21. The compounds were converted to their
hydrochloride or tartrate salts (di-salts in the case of the piperazine and diazapane
scaffold) prior to being submitted for pharmacological assay, and the assay data is
presented in Chapter 5.

Scheme 4.1 Synthesis of the symmetrical 1,4-substituted piperazine analog scaffold.

A simple one-step reaction was used to generate six initial compounds in the
symmetrical 1,4-substituted piperazine analog series. The starting material for this
reaction was 1.4-piperazine (for ease of handling, the dihydrochloride salt of 1,4piperazine was also used), which was then subjected to SN2 reaction conditions with the
appropriately substituted phenethylbromide and excess potassium carbonate as base in
dimethylformamide as solvent. 2.2 equivalents of the appropriately substituted (2bromoethyl)benzene was added drop-wise into the reaction mixture. The reaction was
then heated to 70-80° Celsius for 12-18 hours until the 1,4-piperazine starting material
was no longer visible by TLC chromatography (visualized with Dragendorff’s reagent).
The reaction was cooled, excess solvent removed under reduced pressure, adsorbed onto
silica gel, and purified via silica gel chromatography to yield the desired 1,4-substituted
piperazine product.
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Figure 4.1 Structure of 1,4-diphenethylpiperazine (JPC-134)
Chemical Formula: C20H26N2 Molecular Weight: 294.43

This compound incorporates a second nitrogen atom into the central ring of the
1,4-piperidine scaffold, while retaining the two phenethyl linkers that were present in
lobelane. 1,4-Piperazine (readily available from Sigma Aldrich Chemical Company) was
reacted via a SN2 reaction with potassium carbonate and 2.2 equivalents of (2bromoethyl)benzene in DMF to yield the desired product, 1,4-diphenethylpiperazine
(JPC-134). The final product was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.59-2.65 (m, 12H), 2.80-2.85 (m, 4H), 7.20-7.32 (m,

10H) ppm.
MS (EI) m/z 294 (M+).
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Figure 4.2 Structure of 1,4-bis(2-methoxyphenethyl)piperazine (JPC-135)
Chemical Formula: C22H30N2O2 Molecular Weight: 354.49

This compound incorporates 2-methoxy substituents into the two phenethyl
linkers that are present in lobelane. 1,4-Piperazine was reacted with potassium carbonate
and 2.2 equivalents of 1-(2-bromoethyl)-2-methoxybenzene in DMF to yield the desired
product, 1,4-bis(2-methoxyphenethyl)piperazine (JPC-135). The final product was
purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.56-2.72 (m, 12H), 2.81-2.87 (m, 4H), 3.82 (s, 6H),

6.83-7.26 (m, 8H) ppm.
C NMR (75 MHz, CDCl3): δ 28.2, 53.4, 55.5, 59.0, 110.4, 120.5, 127.4, 128.8, 130.4,

13

157.5 ppm.
MS (EI) m/z 354 (M+).
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Figure 4.3 Structure of 1,4-bis(3-methoxyphenethyl)piperazine (JPC-137)
Chemical Formula: C22H30N2O2 Molecular Weight: 354.49

This compound incorporates 3-methoxy substituents into the two phenethyl
linkers that are present in lobelane. 1,4-Piperazine was reacted with potassium carbonate
and 2.2 equivalents of 1-(2-bromoethyl)-3-methoxybenzene in DMF to yield the desired
product, 1,4-bis(3-methoxyphenethyl)piperazine (JPC-137). The final product was
purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.59-2.67 (m, 12H), 2.77-2.80 (m, 4H), 3.80 (s, 6H),

6.74-6.82 (m, 6H), 7.18-7.26 (m, 2H) ppm.
MS (EI) m/z 354 (M+).
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Figure 4.4 Structure of 1,4-bis(4-methoxyphenethyl)piperazine (JPC-138)
Chemical Formula: C22H30N2O2 Molecular Weight: 354.49

This compound incorporated 4-methoxy substituents into the two phenethyl
linkers that are present in lobelane. 1,4-Piperazine was reacted with potassium carbonate
and 2.2 equivalents of 1-(2-bromoethyl)-4-methoxybenzene in DMF to yield the desired
product 1,4-bis(4-methoxyphenethyl)piperazine (JPC-138). The final product was
purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.56-2.62 (m, 12H), 2.74-2.81 (m, 4H), 3.79 (s, 6H),

6.82-6.85 (m, 2H), 7.11-7.26 (m, 4H) ppm.
MS (EI) m/z 354 (M+).
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Figure 4.5 Structure of 1,4-bis(2-chlorophenethyl)piperazine (JPC-139)
Chemical Formula: C20H24Cl2N2 Molecular Weight: 363.32

This compound incorporated 2-chloro substituents into the two phenethyl linkers
that are present in lobelane. 1,4-Piperazine was reacted with potassium carbonate and 2.2
equivalents of 1-(2-bromoethyl)-2-chlorobenzene in DMF to yield the desired product,
1,4-bis(2-chlorophenethyl)piperazine (JPC-139). The final product was purified via
silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.61-2.66 (m, 12H), 2.89-2.99 (m, 4H), 7.17-7.33 (m, 8H)

ppm.
MS (EI) m/z 362 (M+).
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Figure 4.6 Structure of 1,4-bis(4-fluorophenethyl)piperazine (JPC-140)
Chemical Formula: C20H24F2N2 Molecular Weight: 330.41

This compound incorporated 4-fluoro substituents into the two phenethyl linkers
that are present in lobelane. 1,4-Piperazine was reacted with potassium carbonate and 2.2
equivalents of 1-(2-bromoethyl)-4-fluorobenzene in DMF to yield the desired product,
1,4-bis(4-fluorophenethyl)piperazine (JPC-140). The final product was purified via silica
gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.57-2.62 (m, 12H), 2.77-2.82 (m, 4H), 6.94-7.00 (m,

4H), 7.17-7.26 (m, 4H) ppm.
MS (EI) m/z 330 (M+).
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After the symmetrical 1,4-piperazine analogs were prepared, the design and
synthesis of asymmetrical 1,4-piperazine analogs was conducted. The synthetic was
slightly more involved than the one step process that generated the symmetrical
compounds in Figures 4.1 through 4.6, since it required a protection step (BOC protection
of one amine functionality) on the 1,4-piperazine ring. The synthetic methodology is
shown in Scheme 4.2.

Scheme 4.2 Synthesis of the asymmetrical 1,4-piperazine scaffold.

The starting material for this series of analogs was again 1,4-piperazine, which
was subjected to BOC (butyloxycarbonyl) protection with di-tert-butyloxy dicarbonate in
acetonitrile and a catalytic amount of DMAP (4-dimethylaminopyridine). This yielded a
mixture of products, with the major product being the desired tert-butyl piperazine-1-
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carboxylate; the other two side products were starting material and the di-protected ditert-butyl piperazine-1,4-dicarboxylate. The desired product was separated via silica gel
column chromatography, and was then subjected to a SN2 reaction with (2bromoethyl)benzene to yield the tert-butyl-4-phenethylpiperazine-1-carboxylate product,
which was purified via silica gel column chromatography. At this point, the BOC
protecting group was removed by subjecting it to a 1:3 trifluoroacetic
acid:dichloromethane reaction mixture. Purification via silica gel column
chromatography afforded the desired 1-phenethylpiperazine, which was utilized as the
common intermediate for the synthesis of five asymmetrical compounds in this series.
The 1-phenethylpiperazine was then subjected to a SN2 reaction with the appropriately
substituted (2-bromoethyl)benzene to yield the desired final products, which were
purified via silica gel column chromatography. The structures and analytical data of the
five compounds generated in this series are shown in Figures 4.7 through 4.11. NMR
spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on one of three
Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are reported in ppm
relative to either TMS as internal standard or as relative to the solvent peak present in
13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC incorporating an
Agilent 7683 autosampler and an Agilent 5973 MSD.
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Figure 4.7 Structure of 1-(2-methoxyphenethyl)-4-phenethylpiperazine (JPC-141)
Chemical Formula: C21H28N2O Molecular Weight: 324.46

This compound incorporates a 2-methoxy substituent into one of the phenethyl
moieties, while retaining the second phenethyl moiety that is present in lobelane.
Synthesis began with 1,4-piperazine, which was subjected to BOC (butoxycarbonyl)
protection via di-tert-butyloxy dicarbonate in acetonitrile and a catalytic amount of
DMAP (4-dimethylaminopyridine). The major product, tert-butyl piperazine-1carboxylate, was separated via silica column chromatography, and reacted with (2bromoethyl)benzene to yield the tert-butyl 4-phenethylpiperazine-1-carboxylate, which
was purified via silica gel column chromatography. Deprotection of the BOC protecting
group was achieved utilizing a trifluoroacetic acid:dichloromethane 1:3 mixture.
Purification of the deprotected product via silica gel column chromatography afforded the
desired 1-phenethylpiperazine, which was then reacted with 1-(2-bromoethyl)-2methoxybenzene to yield the desired final product, 1-(2-methoxyphenethyl)-4phenethylpiperazine (JPC-141) after purification via silica column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.60-2.66 (m, 12H), 2.78-2.86 (m, 4H), 3.82 (s, 3H),

6.81-6.92 (m, 2H), 7.15-7.38 (m, 7H) ppm.
MS (EI) m/z 324 (M+).
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Figure 4.8 Structure of 1-(3-methoxyphenethyl)-4-phenethylpiperazine (JPC-142)
Chemical Formula: C21H28N2O Molecular Weight: 324.46

This compound incorporates a 3-methoxy substituent into one of the phenethyl
moieties, while retaining the second phenethyl moiety that is present in lobelane. 1phenethylpiperazine was reacted with 1-(2-bromoethyl)-3-methoxybenzene to yield the
desired final product 1-(3-methoxyphenethyl)-4-phenethylpiperazine (JPC-142), which
was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.55-2.66 (m, 12H), 2.73-2.83 (m, 4H), 3.81 (s, 3H),

6.84-6.96 (m, 2H), 7.18-7.36 (m, 7H) ppm.
MS (EI) m/z 324 (M+).
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Figure 4.9 Structure of 1-(4-methoxyphenethyl)-4-phenethylpiperazine (JPC-143)
Chemical Formula: C21H28N2O Molecular Weight: 324.46

This compound incorporates a 4-methoxy substituent into one of the phenethyl
moieties, while retaining the second phenethyl moiety that is present in lobelane. 1Phenethylpiperazine was reacted with 1-(2-bromoethyl)-4-methoxybenzene to yield the
desired final product 1-(4-methoxyphenethyl)-4-phenethylpiperazine (JPC-143), which
was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.51-2.70 (m, 12H), 2.75-2.89 (m, 4H), 3.83 (s, 3H),

6.87-6.99 (m, 2H), 7.14-7.38 (m, 7H) ppm.
MS (EI) m/z 324 (M+).
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Figure 4.10 Structure of 1-(2-chlorophenethyl)-4-phenethylpiperazine (JPC-144)
Chemical Formula: C20H25ClN2 Molecular Weight: 328.88

This compound incorporates a 2-chloro substituent into one of the phenethyl
moieties, while retaining the second phenethyl moiety that is present in lobelane. 1Phenethylpiperazine, was reacted with 1-(2-bromoethyl)-2-chlorobenzene to yield the
desired final product 1-(2-chlorophenethyl)-4-phenethylpiperazine (JPC-144), which was
purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.54-2.66 (m, 12H), 2.78-2.87 (m, 4H), 7.19-7.42 (m,

9H) ppm.
MS (EI) m/z 328 (M+).
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Figure 4.11 Structure of 1-(4-fluorophenethyl)-4-phenethylpiperazine (JPC-145)
Chemical Formula: C20H25FN2 Molecular Weight: 312.42

This compound incorporated a 4-fluoro substituent into one of the phenethyl
moieties, while retaining the second phenethyl moiety that is present in lobelane. 1Phenethylpiperazine was ereacted with 1-(2-bromoethyl)-4-fluorobenzene to yield the
desired final product 1-(4-fluorophenethyl)-4-phenethylpiperazine (JPC-145), which was
purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 2.53-2.64 (m, 12H), 2.73-2.84 (m, 4H), 6.96-7.31 (m,

9H) ppm.
MS (EI) m/z 312 (M+).
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After the series of asymmetrical 1,4-piperazine analogs were synthesized, further
modification of the central ring of the 1,4-scaffold was explored. Thus, the central sixmembered 1,4-piperazine ring was expanded to a seven-membered 1,4-diazepane ring.
Six compounds were designed and synthesized in this series. The chemistry utilized to
generate the symmetrical 1,4-diazepane series was very similar to that which afforded the
symmetrical 1,4-piperazine series. The one-step process utilized is outlined in Scheme
4.3.

Scheme 4.3 Synthesis of the symmetrical 1,4-diazepane series of analogs

A simple one-step reaction process was used to generate six compounds in the
symmetrical 1,4-substituted diazepane analog series. The starting material for this
reaction was 1.4-diazapene (readily available from Sigma Aldrich Chemical Company),
which was then subjected to SN2 reaction conditions with appropriately substituted (2bromoethyl)benzene and excess potassium carbonate as base in dimethylformamide as
solvent. Once all materials were dissolved, 2.2 equivalents of the appropriately
substituted (2-bromoethyl)benzene was added drop-wise into the reaction mixture. The
reaction was heated to 70-80° Celsius for 12-18 hours until the 1,4-diazepane starting
material was no longer visible by TLC chromatography (visualized with Dragendorff’s
reagent). The reaction was cooled, excess solvent removed under reduced pressure, and
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the product adsorbed onto silica gel and purified via silica gel chromatography to yield
the desired product in the 1,4-substituted diazepane analog series.
The structures and analytical data of the five compounds generated in this series are
shown in Figures 4.12 through 4.17. NMR spectra were recorded in either CDCl3 or
DMSO-d6 (as designated) on one of three Varian instruments (300 MHz, 400 MHz, or
500 MHz) as indicated are reported in ppm relative to either TMS as internal standard or
as relative to the solvent peak present in 13C spectra. GC-mass spectra were recorded on
an Agilent 6890 GC incorporating an Agilent 7683 autosampler and an Agilent 5973
MSD.
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Figure 4.12 Structure of 1,4-diphenethyl-1,4-diazepane (JPC-146)
Chemical Formula: C21H28N2 Molecular Weight: 308.46

This compound incorporates a second nitrogen atom into the central ring of the
1,4-piperidine scaffold while increasing the ring size from six-membered heterocycle to a
seven-membered heterocycle and retaining the two phenethyl moieties that are present in
lobelane. 1,4-Diazepane (readily available from Sigma Aldrich Chemical Company) was
reacted via a SN2 reaction with potassium carbonate and 2.2 equivalents of (2bromoethyl)benzene in DMF to yield the desired product 1,4-diphenethyl-1,4-diazepane
(JPC-146). The final product was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.76-1.78 (m, 2H) 2.64-3.01 (m, 16H), 7.23-7.39 (m,

10H) ppm.
MS (EI) m/z 308 (M+).
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Figure 4.13 Structure of 1,4-bis(2-methoxyphenethyl)-1,4-diazepane (JPC-147)
Chemical Formula: C23H32N2O2 Molecular Weight: 368.51

This compound incorporates a 2-methoxy substituent into each of the two
phenethyl moieties that are present in lobelane. 1,4-Diazepane was reacted with
potassium carbonate and 2.2 equivalents of 1-(2-bromoethyl)-2-methoxybenzene in DMF
to yield the desired product, 1,4-bis(2-methoxyphenethyl)-1,4-diazepane (JPC-147). The
final product was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.74-1.77 (m, 2H) 2.63-2.99 (m, 16H), 3.81 (s, 6H), 6.83-

7.27 (m, 8H) ppm.
MS (EI) m/z 368 (M+).
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Figure 4.14 Structure of 1,4-bis(3-methoxyphenethyl)-1,4-diazepane (JPC-148)
Chemical Formula: C23H32N2O2 Molecular Weight: 368.51

This compound incorporated a 3-methoxy substituent into each of the two
phenethyl moieties that are present in lobelane. 1,4-Diazepane was reacted with
potassium carbonate and 2.2 equivalents of 1-(2-bromoethyl)-3-methoxybenzene in DMF
to yield the desired product, 1,4-bis(3-methoxyphenethyl)-1,4-diazepane (JPC-148). The
final product was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.74-1.78 (m, 2H) 2.66-3.02 (m, 16H), 3.80 (s, 6H), 6.71-

6.83 (m, 6H), 7.15-7.24 (m, 2H) ppm.
MS (EI) m/z 368 (M+).
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Figure 4.15 Structure of 1,4-bis(4-methoxyphenethyl)-1,4-diazepane (JPC-149)
Chemical Formula: C23H32N2O2 Molecular Weight: 368.51

This compound incorporated a 4-methoxy substituent into each of the two
phenethyl moieties that are present in lobelane. 1,4-Diazepane was reacted with
potassium carbonate and 2.2 equivalents of 1-(2-bromoethyl)-4-methoxybenzene in DMF
to yield the desired product, 1,4-bis(4-methoxyphenethyl)-1,4-diazepane (JPC-149). The
final product was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.72-1.78 (m, 2H) 2.66-3.00 (m, 16H), ), 3.79 (s, 6H),

6.82-6.85 (m, 2H), 7.11-7.26 (m, 4H) ppm.
MS (EI) m/z 368 (M+).
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Figure 4.16 Structure of 1,4-bis(2-chlorophenethyl)-1,4-diazepane (JPC-150)
Chemical Formula: C21H26Cl2N2 Molecular Weight: 377.35

This compound incorporated a 2-chloro substituent into each of the two phenethyl
moieties that are present in lobelane. 1,4-Diazepane was reacted with potassium
carbonate and 2.2 equivalents of 1-(2-bromoethyl)-2-chlorobenzene in DMF to yield the
desired product, 1,4-bis(2-chlorophenethyl)-1,4-diazepane (JPC-150). The final product
was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.71-1.77 (m, 2H) 2.64-2.97 (m, 16H), 7.14-7.31 (m, 8H)

ppm.
MS (EI) m/z 376 (M+).
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Figure 4.17 Structure of 1,4-bis(4-fluorophenethyl)-1,4-diazepane (JPC-151)
Chemical Formula: C21H26F2N2 Molecular Weight: 344.44

This compound incorporates a 2-chloro substituent into each of the two phenethyl
moieties that are present in lobelane. 1,4-Diazepane was reacted with potassium
carbonate and 2.2 equivalents of 1-(2-bromoethyl)-2-chlorobenzene in DMF to yield the
desired product, 1,4-bis(2-chlorophenethyl)-1,4-diazepane (JPC-150). The final product
was purified via silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.73-1.78 (m, 2H) 2.64-2.98 (m, 16H), 6.93-7.00 (m, 4H),

7.14-7.23 (m, 4H) ppm.
MS (EI) m/z 344 (M+).
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Another small series of compounds incorporating two 4-benzylpiperidine moieties
linked together by an N,N’-ethylene bridge was also designed and synthesized, to explore
the possibility that two benzyl piperidine moieties linked by an ethylene chain may be
tolerated by the TBZ site on VMAT2. The synthetic methodology for the generation of
the two compounds in this series is shown in Scheme 4.4.

Scheme 4.4 Synthesis of 1,2-bis(4-benzylpiperidin-1-yl)ethane and 1,2-bis(4phenethylpiperidin-1-yl)ethane

The chemistry for generating the above two molecules is simple and quick. Two
equivalents of the appropriate 4-substituted piperidine starting material was subjected to a
SN2 reaction with one equivalent 1,2-dibromoethane using potassium carbonate as a base
in DMF at 70-80° C. After disappearance of the starting material (TLC monitoring of the
reaction visualized with Dragendorff’s reagent), the reaction material was cooled and
excess solvent removed under reduced pressure. The resulting residue was purified by
silica gel column chromatography to yield the desired final products. The structures of
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the two compounds in this series and the supporting analytical data are shown in Figures
4.18 and 4.19. NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated)
on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are
reported in ppm relative to either TMS as internal standard or as relative to the solvent
peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC
incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD.
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Figure 4.18 Structure of 1,2-bis(4-benzylpiperidin-1-yl)ethane (JPC-132)
Chemical Formula: C26H36N2 Molecular Weight: 376.58

The synthesis began with 4-benzylpiperidine as the starting material. Two
equivalents of 4-benzylpiperidine were reacted with one equivalent 1,2-dibromoethane
using potassium carbonate as a base in DMF at 70-80° C. After disappearance of the
starting material (TLC monitoring and visualization with Dragendorff’s reagent) the
reaction material was cooled and excess solvent removed under reduced pressure. The
residue was purified via silica gel column chromatography to yield the desired
compound, 1,2-bis(4-benzylpiperidin-1-yl)ethane (JPC-132).
1

H NMR (300 MHz, CDCl3): δ 1.17-1.82 (m, 10H) 2.06-2.78 (m, 16H), 7.06-7.23 (m,

10H) ppm.
C NMR (75 MHz, CDCl3): δ 32.6, 37.7, 43.5, 46.7, 56.2, 125.9, 128.3, 129.3, 140.9

13

ppm.
MS (EI) m/z 376 (M+).
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Figure 4.19 Structure of 1,2-bis(4-phenethylpiperidin-1-yl)ethane (JPC-133)
Chemical Formula: C28H40N2 Molecular Weight: 404.32

Two equivalents of 4-benzylpiperidine were reacted with one equivalent of 1,2dibromoethane using potassium carbonate as a base in DMF at 70-80° C. After
disappearance of the starting material (monitored by TLC and visualized with
Dragendorff’s reagent) the reaction material was cooled, and excess solvent removed
under reduced pressure. The residue was purified via silica gel column chromatography
to yield the desired 1,2-bis(4-benzylpiperidin-1-yl)ethane (JPC-132).
1

H NMR (300 MHz, CDCl3): δ 1.23-1.76 (m, 14H) 2.26-2.73 (m, 16H), 7.10-7.28 (m,

10H) ppm.
MS (EI) m/z 404 (M+).
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One final set of two compounds were designed and synthesized to evaluate
analogs that possessed a branched alkyl linker unit between one of the piperazine Natoms and the phenyl moiety, to afford a racemic 1-phenylpropan-2-yl moiety attached to
N1 of the piperazine ring, while maintaining the phenethyl linker on N4 of the piperazine
ring. One of the compounds in this set also incorporated a 4-bromo substituent in the
phenyl ring attached to the N1 position of the piperazine ring. The synthetic pathway for
these two compounds is shown in Scheme 4.5.

Scheme 4.5 Synthesis of the 1-phenethyl-4-(1-phenylpropan-2-yl)piperazine set of
compounds

Starting from 1-phenethylpiperazine, a reductive amination was carried out
utilizing the appropriately substituted 1-phenylpropan-2-one to yield the two racemic 1phenethyl-4-(1-phenylpropan-2-yl)piperazines. The structures of the two compounds in
this series and the analytical data supporting their structures are shown in Figures 4.20
and 4.21. NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on
one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are
reported in ppm relative to either TMS as internal standard or as relative to the solvent
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peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC
incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD.
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Figure 4.20 Structure of racemic 1-phenethyl-4-(1-phenylpropan-2-yl)piperazine
(JPC-176) Chemical Formula: C21H28N2 Molecular Weight: 308.46

1-Phenethylpiperazine was reacted with 1-phenylpropan-2-one under reductive
amination conditions with sodium cyanoborohydride in methanol to afford the final
product, (±)-1-phenethyl-4-(1-phenylpropan-2-yl)piperazine (JPC-176), which was
purified by silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 1.01-1.03 (d, 3H), 2.43-3.18 (m, 15H), 7.22-7.34 (m,

10H) ppm.
C NMR (75 MHz, CDCl3): δ 14.64, 33.9, 39.5, 48.5, 53.8, 60.8, 61.5, 125.9, 126.1,

13

128.3, 128.4, 128.7, 129.3, 140.60, 140.64 ppm.
MS (EI) m/z 308 (M+).
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Figure 4.21 Structure of racemic 1-(1-(4-bromophenyl)propan-2-yl)-4phenethylpiperazine (JPC-173)
Chemical Formula: C21H27BrN2 Molecular Weight: 387.36

1-Phenethylpiperazine was reacted with 1-(4-bromophenyl)propan-2-one in
methanol via reductive amination with sodium cyanoborohydride to afforded the final
product, (±)- 1-(1-(4-bromophenyl)propan-2-yl)-4-phenethylpiperazine (JPC-173), which
was purified by silica gel column chromatography.
1

H NMR (300 MHz, CDCl3): δ 0.96-0.98 (d, 3H), 2.35-3.05 (m, 15H), 7.06-7.43 (m, 9H)

ppm.
C NMR (75 MHz, CDCl3): δ 14.64, 33.9, 39.0, 48.55, 53.7, 53.8, 60.9, 61.3, 119.7,

13

126.9, 128.5, 128.8, 131.1, 131.4, 139.7, 140.4 ppm.
MS (EI) m/z 387 (M+).
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4.2 Summary of the 1,4-disubstituted piperazine analog series

In summary, 21 compounds were designed and synthesized in the 1,4disubstituted piperidine scaffold series by utilizing four distinct chemical approaches. Of
the total number of compounds prepared, 11 were 1,4-disubstituted piperazine analogs
containing a variety of aromatic substituents in each of the two phenyl rings, including
methoxy, fluoro, and chloro substituents. Another series of six 1,4-disubstituted
diazepane analogs were designed and synthesized to determine if an increase in the size
of the central heterocyclic (1,4-piperazine) ring from six membered ring to a seven
membered would improve affinity for VMAT2. Another small series of compounds were
designed and synthesized to determine if two benzyl piperidine rings linked together by
an ethylene chain would be tolerated by the TBZ binding site on VMAT2. The
remaining two compounds were analogs that possessed a branched N1 alkyl linker in the
form of a racemic 1-phenylpropan-2-yl moiety attached to N1 of the piperazine ring, as
well as a phenethyl moiety at N4 of the piperazine ring. This set of compounds also
included an analog containing a 4-bromophenyl moiety at the N1 position of the
piperazine ring. The pharmacological assay data for these 21 compounds are discussed in
Chapter 5.

Copyright © John P. Culver 2015
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Chapter 5
Pharmacology Assays and Data

5.1 [3H] Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay
Background
Pharmacology (from Greek pharmakon, "poison" in classic Greek; "drug" in
modern Greek; and -λογία, -logia "study of", "knowledge of") is the extension and
cohesion of medicine and biology concerned with the study of drug action (De Jong et
al., 2005). Just as organic and medicinal chemistry is vital to the invention and discovery
of new drug molecules, pharmacology is a cornerstone of the drug discovery process.
While it is the medicinal chemist that designs and synthesizes the candidate drug
compound, the pharmacologist is the one who tests it for physiologic activity. A
promising compound will be investigated by many other scientists to include
toxicologists, microbiologists, and medical clinicians, but the initial discovery of the
potential therapeutic effect by the pharmacologist must always come first. Well prior to
being studied in humans, candidate drug molecules must first be studied either “in vitro”
or “in vivo” in animal models. In vivo (Latin for "within the living") (Merriam-Webster,
2013) is experimentation using a whole, living organism as opposed to a partial or dead
organism which is an in vitro (Latin for "within the glass", for example in a test tube or
petri dish) (Merriam-Webster, 2013) within a more controlled environment.
The assays used to analyze the effectiveness of the 107 compounds described in
Chapters 2 through 4 are of the “in vitro” variety and are described as the [3H]
Dihydrotetrabenazine Binding Assay and [3H] Dopamine Vesicular Uptake Assay.
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The [3H] Dihydrotetrabenazine Binding Assay was used to determine the affinity
of the analogs in the synthesized compound library for the TBZ binding site on VMAT2.
Potency of a compound in binding to the TBZ site of VMAT2 does not directly correlate
into inhibition of VMAT2 function. It was therefore necessary to evaluate the ability of
the compounds to inhibit [3H]DA uptake into synaptic vesicles as well (Nickell et al.,
2010).
In the [3H] Dihydrotetrabenazine Binding Assay and the [3H] Dopamine Vesicular
Uptake Assay, the following materials and methods were used (Nickell et al., 2010).
Assays were conducted by J. Nickell and G. Deaciuc in the laboratories of Dr. Linda
Dwoskin. Methodology was developed and used in those laboratories and is shown here
in original format.

Animals. Male Sprague-Dawley rats (200–250 g upon arrival) were purchased from
Harlan (Indianapolis, IN). Rats were housed in the Division of Laboratory Animal
Resources at the College of Pharmacy at the University of Kentucky (Lexington, KY)
and had ad libitum access to food and water. Experimental protocols involving the
animals were in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee at the University of Kentucky.
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Materials. [3H]DA (specific activity, 28.0 Ci/mmol) was purchased from PerkinElmer
Life and Analytical Sciences (Boston, MA). [3H]DTBZ (specific activity, 79.0 Ci/mmol)
was a gift from Dr. Michael R. Kilbourn (Department of Internal Medicine and
Neurology, University of Michigan, Ann Arbor, MI). Bovine serum albumin, EDTA,
EGTA, L-(-)-tartaric acid, sucrose, magnesium sulfate, polyethyleneimine, adenosine 5triphosphate magnesium salt, HEPES, S(-)-nicotine ditartrate (nicotine), 3hydroxytyramine (dopamine, DA), DOPAC, d-methamphetamine hydrochloride
(methamphetamine), sodium chloride, magnesium sulfate and ascorbate oxidase were
purchased from Sigma-Aldrich (St. Louis, MO). (-)-D-Glucose, L-ascorbic acid, and
monobasic potassium phosphate were purchased from Aldrich Chemical Co.
(Milwaukee, WI), AnalaR-BHD Ltd. (Poole, UK), and Mallinckrodt (St. Louis, MO),
respectively. Perchloric acid (70%) was purchased from Mallinckrodt Baker
(Phillipsburg, NJ). Ro4-1284 was obtained from Hoffman-La Roche Ltd. (Basel,
Switzerland). All other commercial chemicals were purchased from Fisher Scientific Co.
(Pittsburgh, PA) (Nickell et al., 2010).

[3H]DTBZ Binding Assay. Analog-induced inhibition of [3H]DTBZ binding was
determined by use of modifications of a method described previously (Teng et al., 1998).
Rat whole brain (excluding cerebellum) or striatum was homogenized in 20 ml of icecold 0.32 M sucrose solution with seven up-and-down strokes of a Teflon pestle
homogenizer (clearance ~ 0.003 inch). Homogenates were centrifuged at 1000g for 12
min at 4°C, and the resulting supernatants were again centrifuged at 22,000g for 10 min
at 4°C. Resulting pellets were incubated in 18 ml of ice-cold water for 5 min, and 2 ml of
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HEPES (25 mM) and potassium tartrate (100 mM) solution were subsequently added.
Samples were centrifuged (20,000g for 20 min at 4°C), and 20 µl of MgSO4 (1 mM)
solution was then added to the supernatants. Solutions were centrifuged
(100,000g for 45 min at 4°C) and pellets resuspended in ice-cold assay buffer (25 mM
HEPES, 100 mM potassium tartrate, 5 mM MgSO4, 0.1 mM EDTA, and 0.05 mM
EGTA, pH 7.5). Assays were performed in duplicate by use of 96-well plates. Aliquots of
vesicular suspension (15 µg of protein in 100 µl) were added to wells containing 5 nM
[3H]DTBZ, 50 µl of analog (1 nM to 1 mM), and 50 µl of buffer. Nonspecific binding
was determined in the presence of Ro4-1284 (20 µM). Reactions were terminated by
filtration (Packard Filtermate harvester; PerkinElmer Life and Analytical Sciences) onto
Unifilter-96 GF/B filter plates (presoaked in 0.5% polyethyleneimine). Filters were
subsequently washed five times with 350 µl of ice-cold buffer (25 mM HEPES, 100 mM
potassium tartrate, 5 mM MgSO4, and 10 mM NaCl, pH 7.5). Filter plates were dried and
bottom-sealed, and each well was filled with 40 µl of scintillation cocktail (MicroScint
20; PerkinElmer Life and Analytical Sciences). Radioactivity on the filters was
determined by liquid β-scintillation spectrometry (TopCount NXT; PerkinElmer Life and
Analytical Sciences). Inhibition curves will be analyzed by non-linear regression and
IC50 values used to yield Ki values (Teng, et al., 1997; Teng et al., 1998; Cheng-Prusoff,
1973; Nickell et al., 2010).
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Vesicular [3H]DA Uptake Assay. Inhibition of [3H]DA uptake was conducted by use of
a preparation of isolated synaptic vesicles as described previously (Teng et al., 1997). In
brief, rat striata were homogenized with 10 up-and-down strokes of a Teflon pestle
homogenizer (clearance ~ 0.003 inch) in 14 ml of 0.32 M sucrose solution. Homogenates
were centrifuged (2000g for 10 min at 4°C), and the resulting supernatants were
centrifuged again (10,000g for 30 min at 4°C). Pellets were resuspended in 2 ml of 0.32
M sucrose solution and subjected to osmotic shock by adding 7 ml of ice-cold water to
the preparation, followed by the immediate restoration of osmolarity by adding 900 µl of
0.25 M HEPES buffer and 900 µl of 1.0 M potassium tartrate solution. Samples were
centrifuged (20,000g for 20 min at 4°C), and the resulting supernatants were centrifuged
again (55,000g for 1 h at 4°C), followed by the addition of 100 µl of 10 mM MgSO4, 100
µl of 0.25 M HEPES, and 100 µl of 1.0 M potassium tartrate solution before the final
centrifugation (100,000g for 45 min at 4°C). Final pellets were resuspended in 2.4 ml of
assay buffer (25 mM HEPES, 100 mM potassium tartrate, 50 µM EGTA, 100 µM EDTA,
1.7 mM ascorbic acid, 2 mM ATP-Mg2+, pH 7.4). Aliquots of the vesicular suspension
(100 µl) were added to tubes containing assay buffer, various concentrations of analog
(0.1 nM to 10 mM) and 0.1 µM [3H]DA to produce a final volume of 500 µl. Nonspecific
uptake was determined in the presence of Ro4-1284 (10 µM). Reactions were terminated
by filtration, and radioactivity retained by the filters was determined as described
previously (Nickell et al., 2010).
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5.2 [3H] Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay
Results
The structures of 107 JPC compounds designed and synthesized as relayed in
Chapters 2-4 are presented in Tables 5.1 (18 compounds), 5.2 (68 compounds), and 5.3
(21 compounds) along with their corresponding Ki values in the [3H]
Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay. The structures
and corresponding Ki values in the [3H] Dihydrotetrabenazine Binding Assay and [3H]
Dopamine Uptake Assay for lobeline and lobelane are included in each table for
comparison convenience.
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Compound
Code

Structure

VMAT2
[ H]DTBZ
Binding
Assay;
Ki ± SEM
(µM)

VMAT2
[3H]DA
Uptake;
Ki ± SEM
(µM)

Lobeline

2.04 ± 0.64

0.47 ± 0.045

lobelane

0.97 ± 0.19

0.045 ± 0.002

JPC-001

5.24 ± 1.81

0.043 ± 0.0034

JPC-011

0.29 ± 0.03

0.156 ± 0.0323

JPC-002

3.88 ± 0.43

*

JPC-008

30.6

*

JPC-003

5.09 ± 1.37

0.084 ± 0.0071

JPC-007

3.09 ± 0.60

0.19 ± 0.025

JPC-130A

2.24 ± 0.15

0.056 ± 0.026

3

Table 5.1 (continued)
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JPC-130B

0.43 ± 0.050

0.030 ± 0.0017

JPC-004

2.57 ± 0.48

0.30 ± 0.080

JPC-010

2.87 ± 0.83

0.23 ± 0.023

JPC-033

29.0 ± 5.0

0.58 ± 0.096

JPC-034

5.93 ± 1.40

0.99 ± 0.079

JPC-035

2.08 ± 0.098

0.23 ± 0.065

JPC-036

0.62 ± 0.020

0.30 ± 0.077

JPC-041

2.70 ± 0.70

0.14 ± 0.033

JPC-042

0.56 ± 0.082

0.13 ± 0.0087

Table 5.1 (continued)
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JPC-161B

2.25 ± 0.28

0.032 ± 0.0022

JPC-161C

0.35 ± 0.042

0.036 ± 0.010

Table 5.1 [3H] Dihydrotetrabenazine Binding Assay Data and [3H] Dopamine Uptake
Assay Data for JPC compounds in the 2,6-substituted piperidine analog scaffold of
lobelane

Compound
Code

Structure

VMAT2
[ H]DTBZ
Binding
Assay;
Ki ± SEM
(µM)

VMAT2
[3H]DA
Uptake;
Ki ± SEM
(µM)

Lobeline

2.04 ± 0.64

0.47 ± 0.045

lobelane

0.97 ± 0.19

0.045 ± 0.002

JPC-057

0.255 ± 0.026

0.030 ± 0.0020

JPC-058

2.80 ± 0.11

0.056 ± 0.009

3

Table 5.2 (continued)
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JPC-059

0.265 ± 0.038

0.022 ± 0.00087

JPC-060

1.62 ± 0.19

0.046 ± 0.0037

JPC-072

0.38 ± 0.0058

0.047 ± 0.0063

JPC-073

1.82 ± 0.0058

0.032 ± 0.0038

JPC-078

0.69 ± 0.050

0.022± 0.0028

JPC-077

0.19 ± 0.0088

0.0093 ± 0.0006

JPC-094

0.15 ± 0.0058

0.013 ± 0.0015

JPC-095

0.50 ± 0.10

0.043 ± 0.0028

JPC-096

0.19 ± 0.020

0.020 ± 0.0030

Table 5.2 (continued)
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JPC-097

0.40 ± 0.097

0.013 ± 0.0021

JPC-079

0.32 ± 0.015

0.056 ± 0.0086

JPC-080

0.32 ± 0.055

0.040 ±0.0075

JPC-081

0.23 ± 0.019

0.085 ± 0.010

JPC-082

0.45 ± 0.13

0.13 ± 0.023

JPC-083

0.46 ± 0.098

0.42 ± 0.049

JPC-084

0.96 ± 0.047

0.069 ± 0.004

JPC-085

0.51 ± 0.087

0.11 ± 0.007

JPC-086

0.42 ± 0.019

0.083 ± 0.009

Table 5.2 (continued)
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JPC-087

0.23 ± 0.047

0.075 ± 0.004

JPC-088

2.47 ± 0.27

0.16 ± 0.012

JPC-089

0.23 ± 0.020

0.040 ± 0.007

JPC-090

0.47 ± 0.067

0.060 ± 0.005

JPC-098

0.53 ± 0.11

0.053 ± 0.0055

JPC-099

0.35 ± 0.048

0.041 ±0.012

JPC-100

0.27 ± 0.015

0.029 ± 0.0055

JPC-101

1.30 ± 0.17

0.070 ± 0.0051

JPC-102

0.24 ± 0.038

0.11 ± 0.019

Table 5.2 (continued)
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JPC-103

1.45 ± 0.24

0.043 ± 0.014

JPC-104

0.29 ± 0.064

0.12 ± 0.0085

JPC-105

0.33 ± 0.018

0.076 ± 0.010

JPC-106

0.19 ± 0.009

0.083 ± 0.0038

JPC-107

1.61 ± 0.078

0.044 ± 0.0033

JPC-108

0.23 ± 0.015

0.067 ± 0.021

JPC-109

0.60 ± 0.075

0.060 ± 0.0082

JPC-110

1.10 ± 0.087

0.051 ± 0.0035

Table 5.2 (continued)
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JPC-111

0.41 ± 0.038

0.034 ± 0.0039

JPC-112

0.25 ± 0.003

0.028 ± 0.0027

JPC-113

2.03 ± 0.13

0.12 ± 0.028

JPC-114

0.66 ± 0.058

0.18 ± 0.068

JPC-115

1.43 ± 0.28

0.068 ± 0.016

JPC-068

0.38 ± 0.049

0.094 ± 0.0096

JPC-061

2.76 ± 0.31

0.13 ± 0.015

Table 5.2 (continued)
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JPC-062

1.53 ± 0.10

0.077 ± 0.0098

JPC-063

2.99 ± 0.17

0.24 ± 0.034

JPC-064

1.94 ± 0.43

0.18 ± 0.011

JPC-152

21.7 ± 2.08

0.19 ± 0.63

JPC-153

9.36 ± 1.32

0.070 ± 0.0075

JPC-154

12.7 ± 4.28

0.19 ± 0.020

JPC-155

6.23 ± 0.56

0.25 ± 0.027

Table 5.2 (continued)
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JPC-156

44.5 ± 17.8

0.27 ± 0.042

JPC-157

10.1 ± 0.58

0.21 ± 0.012

JPC-174

*

0.020 ± 0.0082

JPC-175

2.32 ± 0.26

0.073 ± 0.0008

JPC-171

2.56 ± 0.34

0.21 ± 0.052

JPC-172

0.257 ± 0.37

0.30 ± 0.032

Table 5.2 (continued)
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JPC-116

30.3 ± 5.97

2.32 ± 0.50

JPC-117

>100

6.28 ± 0.39

JPC-118

11.5 ± 0.80

2.19 ± 0.37

JPC-119

>100

3.74 ± 1.03

JPC-120

9.26 ± 1.27

1.18 ± 0.12

JPC-121

>100

2.90 ± 0.36

JPC-122

14.1 ± 2.36

0.36 ± 0.050

JPC-123

22.0 ± 4.48

1.12 ± 0.19

Table 5.2 (continued)
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JPC-124

19.7 ± 4.40

0.60 ± 0.11

JPC-125

22.9 ± 1.9

2.00 ± 0.32

JPC-126

6.27 ± 0.22

0.42 ± 0.04

Table 5.2 [3H] Dihydrotetrabenazine Binding Assay Data and [3H] Dopamine Uptake
Assay Data for JPC compounds in the 1,4-substituted piperidine analog scaffold of
lobelane

Compound
Code

Structure

VMAT2
[3H]DTBZ
Binding
Assay;
Ki ± SEM
(µM)

VMAT2
[3H]DA
Uptake;
Ki ± SEM
(µM)

Lobeline

2.04 ± 0.64

0.47 ± 0.045

lobelane

0.97 ± 0.19

0.045 ± 0.002

Table 5.3 (continued)
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JPC-134

3.05 ± 0.64

0.11 ± 0.012

JPC-135

1.17 ± 0.13

0.035 ±
0.0012

JPC-137

1.05 ± 0.087

0.060 ± 0.004

JPC-138

6.63 ± 0.84

0.41 ± 0.005

JPC-139

0.37 ± 0.038

0.048 ± 0.003

JPC-140

3.71 ± 0.48

0.058 ± 0.012

JPC-141

1.07 ± 0.25

0.037 ±
0.0005

JPC-142

1.30 ± 0.33

0.098 ± 0.016

Table 5.3 (continued)
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JPC-143

4.63 ± 1.31

0.10 ± 0.011

JPC-144

1.59 ± 0.26

0.063 ±
0.0069

JPC-145

3.86 ± 1.01

0.088 ±
0.0069

JPC-146

3.17 ± 0.55

0.17 ± 0.017

JPC-147

2.02 ± 0.11

0.18 ± 0.011

JPC-148

2.24 ± 0.53

0.10 ± 0.010

JPC-149

2.88 ± 0.25

0.25 ± 0.015

JPC-150

0.93 ± 0.021

0.17 ± 0.025

Table 5.3 (continued)
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JPC-151

5.05 ± 0.77

0.085 ±
0.0052

JPC-132

0.82 ± 0.19

0.26 ± 0.019

JPC-133

3.42 ± 0.34

0.11 ± 0.0087

JPC-176

13.3 ± 1.10

0.15 ± 0.015

JPC-173

4.55 ± 0.94

0.31 ± 0.005

Table 5.3 [3H] Dihydrotetrabenazine Binding Assay Data and [3H] Dopamine Uptake
Assay Data for JPC compounds in the 1,4-substituted piperazine and diazepane analog
scaffolds of lobelane and similar compounds
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5.3 [3H] Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay
Results Discussion
The 107 JPC compounds designed, synthesized, and assayed for activity and function
at VMAT2 can and have been assigned to one of three groups based on structure. These
groups are 1) the 2,6-substituted piperidine analog scaffold of lobelane, 2) the 1,4substituted piperidine analog scaffold of lobelane, and 3) the 1,4-substituted piperazine
and diazepane analog scaffolds of lobelane. Groups 2 and 3 can be divided further into
subgroups based on structure to allow later SAR discussions to better describe trends. In
order for a compound to be selected for further testing in the whole animal model, it must
meet two requirements: 1) be among the most potent compounds if not the most potent
compound among a designated series or scaffold of compounds and 2) have a potency in
the functional [3H] Dopamine Uptake Assay of better than 100 nM. Compounds that
have been selected from the 107 JPC compounds that were designed and synthesized
have been marked in bold face font within the tables present in Chapter 5.
The 2,6-substituted piperidine analog scaffold of lobelane contained 18 compounds
that are similar in scaffold structure to remain in one group without further division. The
compounds differed in their [3H]DTBZ affinities by as much as two orders of magnitude,
with the best compound (JPC-011) having an affinity for the TBZ binding site on
VMAT2 of 0.29 µM and the least effective compound (JPC-008) having a binding
affinity for the TBZ binding site on VMAT2 of 30.6 µM. The compounds that did not
possess a N-methyl substituent (nor-compounds) were generally 10-fold less potent than
their N-methyl containing counterparts, a trend that is in line with previous data collected
in our laboratories with other compounds in the 2,6-substituted piperidine analog
scaffold. The two compounds that possessed completely saturated cyclohexyl moieties in
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place of the phenyl rings found in lobelane (JPC-003 and JPC-007) had 3-5 fold less
affinity for the TBZ site on VMAT2, so again the presence of two hydrophobic phenyl
rings is shown to be necessary for the TBZ site of VMAT2 to recognize a ligand
molecule.
The analogs that possessed two substituents in each of the phenyl rings showed
interesting binding characteristics. Compounds JPC-011 and JPC-130B that contained
two very electronegative (and therefore electron withdrawing) fluoro moieties (3,5difluoro and 2,4-difluoro respectively), had the best affinities for the TBZ binding site on
VMAT2 with Ki values of 0.29 µM (JPC-011) and 0.43 µM (JPC-130B). Analogs that
possess less localized electron density present in the phenyl rings appears to bind slightly
better to VMAT2. The analogs that possess dimethoxy functionalities in the phenyl rings
showed large differences in affinity depending on the attachment point of the methoxy
groups. The analog that has methoxy functionalities in the 3,5-positions of the phenyl
rings (JPC-010) had approximately 2.5 fold less affinity for VMAT2 (Ki = 2.57 µM) than
lobelane (0.97 µM), and when the methoxy moieties were moved to the 3,4-positions of
the phenyl rings (JPC-034), the affinity decreased 6-fold (Ki = 5.93 µM) compared to
lobelane. Analogs that contain methoxy functionalities in the 2,3-positions of the phenyl
rings (JPC-036) and in the 2,5-positions of the phenyl rings (JPC-042) had affinities (Ki
= 0.62 µM and Ki = 0.56 µM), for the TBZ binding site on VMAT2 similar to lobelane,
if not slightly stronger. It is postulated that when the methoxy groups are in the 3,5 and
3,4 positions of the phenyl rings, a steric effect must be occurring in the binding site that
does not allow those analogs to bind as tightly, while when methoxy substituents are
located in the 2,3 and 2,5 positions of the phenyl rings, the steric issues can be avoided.
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The analog containing both a methoxy functionality and a fluoro functionality (JPC161C) supports this idea, as the methoxy group is in the meta (3) position of the phenyl
rings and the fluoro is in the para (4) position of the phenyl rings (same 3,4-substitution
pattern as JPC-034), and the binding affinity was almost 17-fold greater for JPC-161C
(Ki = 0.35) than for JPC-034 (Ki = 5.93).
In comparison to compounds previously generated that contained monosubstituted phenyl rings, the compounds that contain two functionalities in each phenyl
ring met with mixed results in reference to affinity at VMAT2. Compounds that
possessed two methoxy moieties were comparable to their mono-methoxy substituted
counterparts, as two methoxy substitution patterns (2,3 and 2,5) on the phenyl rings
yielded analogs with comparable to equal affinities, while two substitution patterns on the
phenyl rings (3,4 and 3,5) yielded analogs with moderately less affinity for the TBZ site
on VMAT2. Compounds that possessed two fluoro substituents or one fluoro and one
methoxy substituents in the phenyl rings displayed affinities for VMAT2 that were equal
to slightly (2-4 fold) better than their mono-substituted counterparts synthesized
previously.
The best compound in the 2,6-substituted piperidine analog scaffold with respect
to the DTBZ binding assay was JPC-011. None of the compounds within the 2,6substituted piperidine analog series showed tremendous potency with respect to the
functional vesicular [3H]DA uptake assay and therefore none have yet been selected for
further study in the whole animal model. While half of the dimethoxy substituted
analogs faired reasonably well in the [3H]DTBZ binding assay, all of the dimethoxy
substituted compounds were equal in functional potency when compared to lobelane, as
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most of them were an order of magnitude less potent in the functional vesicular [3H]DA
uptake assay. Compounds JPC-001, JPC-130A, JPC-130B, JPC-161B, and JPC-161C
were similar in potency to lobelane.
The second group of compounds to be discussed are those within 1,4-substituted
piperidine analog scaffold of lobelane. This series, which consists of 68 compounds, will
be divided into subgroups for discussion: 1) the 1,4-substituted isomeric analogs of
lobelane, 2) the 4-benzyl-1-phenethylpiperidine and 1-benzyl-4-phenethylpiperidine
analogs, 3) the 4-phenethyl-1-(1-phenylpropan-2-yl)piperidine and 4-benzyl-1-(1phenylpropan-2-yl)piperidine analogs, and 4) the 4-phenethyl-1-(2-(piperidin-1yl)ethyl)piperidine and 4-(2-(4-phenethylpiperidin-1-yl)ethyl)morpholine analogs.
The 43 designed and synthesized 1,4-substituted isomeric analogs of lobelane
ranged from 5-fold greater affinity to 2.5-fold less affinity for the TBZ site on VMAT2
when compared to lobelane. The six compounds that began the series possessed a
phenethyl linker attached to the C4 position of the piperidine ring and a substituted
phenethyl linker attached to the N1 position of the piperidine ring. Compounds JPC-057
and JPC-059 contain methoxy functionalities in the ortho (2) and meta (3) positions of
the phenethyl linker attached to the N1 position of the piperidine ring, respectively.
These two compounds displayed affinities 4-fold stronger than lobelane, with JPC-057
displaying a Ki = 0.255 µM and JPC-059 displaying a Ki = 0.265 µM. Both JPC-057 and
JPC-059 displayed potencies in the functional vesicular [3H]DA uptake assay slightly
better than lobelane. Again, as was seen in the 2,6-substituted piperazine series,
compounds containing a methoxy moiety in the ortho or meta position of the phenyl ring
appear to be recognized by the TBZ site on VMAT2 better than compounds without
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substituents or with methoxy substituents in the para position. Addition of a 2-chloro
substitutent (JPC-072) did improve affinity in the [3H]DTBZ binding assay (Ki = 0.38
µM) by 3-fold compared to lobelane, and had nearly identical potency in the functional
vesicular [3H]DA uptake assay (Ki = 0.047 µM). Three of the six compounds had
slightly less affinity at the TBZ site on VMAT2 when compared to lobelane (JPC-058,
JPC-060, and JPC-073) with affinities of Ki = 2.80 µM, Ki = 1.62 µM, Ki = 1.82 µM
respectively. These compounds did, however, have comparable affinities in the
functional vesicular [3H]DA uptake assay with Ki = 0.056 µM, Ki = 0.046 µM, Ki = 0.032
µM, correspondingly.
The next subseries of compounds possessed a 2-methoxy moiety in the phenyl
ring of the phenyethyl linker attached to the C4 position of the piperidine ring. This
entire group of six compounds had stronger affinity for the TBZ site on VMAT2, so
placing a methoxy group in the ortho position of the phenyl ring attached to the linker at
C4 is beneficial to the recognition of the molecule at the binding site. These six analogs
have Ki’s in the [3H]DTBZ binding assay ranging from 0.15 µM to 0.69 µM. The most
potent three compounds in this subseries are JPC-077, JPC-094, and JPC-096 with nearly
identical affinity values in [3H]DTBZ binding assay (Ki’s = 0.19 µM, Ki = 0.15 µM, Ki =
0.19 µM, respectively). It should be noted that the three moieties in the phenethyl
substitutents attached at the N1 position that continue to give the highest affinities in each
subseries are 2-methoxy, 3-methoxy, and 2-chloro. The same three compounds that were
most potent in binding to the TBZ site on VMAT2 were among the best in their ability to
inhibit DA uptake into the vesicle, with functional vesicular [3H]DA uptake assay values
of Ki = 0.0093 µM, Ki = 0.013 µM, Ki = 0.020 µM, correspondingly. JPC-077 was the
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most potent compound in the entire 43 designed and synthesized 1,4-substituted isomeric
analogs in inhibiting DA uptake into the vesicle, with potency nearly 5-fold stronger than
lobelane.
The next subseries of compounds possessed a 3-methoxy moiety in the phenyl
ring of the phenyethyl linker attached to the C4 position of the piperidine ring. Again,
this entire group of six compounds had stronger affinity for the TBZ site on VMAT2, so
placing a methoxy group in the meta position of the phenyl ring attached to the linker at
C4 is also beneficial to the recognition of the molecule at the binding site. These six
analogs have Ki’s in the [3H]DTBZ binding assay ranging from 0.15 µM to 0.69 µM.
The most potent three compounds in this subseries are JPC-079, JPC-080, and JPC-081
with nearly identical affinity values in [3H]DTBZ binding assay (Ki’s = 0.32 µM, Ki =
0.32 µM, Ki = 0.23 µM, respectively). Again, the best two compounds possessed a 2methoxy or 3-methoxy moiety in the phenyl ring of the phenethyl linker attached to the
N1 position of the piperidine ring. A significant trend is seen developing, as molecules
containing 2-methoxy and 3-methoxy moieties in either one or both phenyl rings are
continuing to be recognized better by the TBZ binding site on VMAT2. This series of six
compounds did not fare as well in the functional assay, with potencies comparable to
lobelane if not slightly inferior.
The next subseries of compounds possessed a 4-methoxy moiety in the phenyl
ring of the phenyethyl linker attached to the C4 position of the piperidine ring, and
displayed similar trends. Five analogs in this group of six compounds had stronger
affinity than lobelane for the TBZ site on VMAT2, so placing a methoxy group in the
para position of the phenyl ring attached to the linker at C4 is also beneficial to the
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recognition of the molecule at the binding site, but it can be said that compounds
containing 4-methoxy substitutents in both phenyl rings is not as well tolerated, as JPC088 has this feature, and has a Ki = 2.47 µM, which is 2.5-fold less potent than the parent
compound with just two unsubstituted phenyl rings as well as 2.5-fold less potent than
lobelane, and JPC-088 is 5-10 fold less potent than the other compounds in this subseries.
It should be again be noted that the three moieties in the phenethyl substitutents attached
at the N1 position that continue to give the highest affinities in each subseries are 2methoxy, 3-methoxy, and 2-chloro (Ki’s = 0.42 µM, Ki = 0.23 µM, Ki = 0.23 µM,
respectively). The same three compounds that were most potent in binding to the TBZ
site on VMAT2 were also the best in their ability to inhibit DA uptake into the vesicle,
with functional vesicular [3H]DA uptake assay values of Ki = 0.083 µM, Ki = 0.075 µM,
Ki = 0.040 µM, correspondingly, which is comparable to lobelane.
The next subseries of compounds possessed 2,4-fluoro substituents in the phenyl
ring of the phenyethyl linker attached to the C4 position of the piperidine ring, and
displayed similar trends. Four analogs in this group of six compounds had stronger
affinity than lobelane for the TBZ site on VMAT2, with the other two comparable to
lobelane, so placing 2,4-fluoro substituents the phenyl ring attached to the linker at C4 is
also beneficial to the recognition of the molecule at the binding site. Again, it should be
noted that the three moieties in the phenethyl substitutents attached at the N1 position that
continue to give the highest affinities in each subseries are 2-methoxy (JPC-099), 3methoxy (JPC-100), and 2-chloro (JPC-102), with affinities in the [3H]DTBZ binding
assay ranging from 0.24 µM to 0.35 µM (Ki’s = 0.35 µM, Ki = 0.27 µM, Ki = 0.24 µM,
respectively). Analogs JPC-100 and JPC-101 were again the most potent in the
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functional vesicular [3H]DA uptake assay values of Ki = 0.041 µM, Ki = 0.029 µM,
correspondingly, which is comparable to lobelane (slightly more potent) and continues
the trend.
The next subseries of compounds possessed 2-fluoro, 4-methoxy substituents in
the phenyl ring of the phenyethyl linker attached to the C4 position of the piperidine ring,
and displayed similar trends. Five analogs in this group of six compounds had stronger
affinity than lobelane for the TBZ site on VMAT2, with the other comparable to
lobelane, so placing 2-fluoro, 4-methoxy substituents the phenyl ring attached to the
linker at C4 is also beneficial to the recognition of the molecule at the binding site. Once
again, the three moieties in the phenethyl substitutents attached at the N1 position that
continue to give the highest affinities in each subseries are 2-methoxy (JPC-105), 3methoxy (JPC-106), and 2-chloro (JPC-108), with affinities in the [3H]DTBZ binding
assay ranging from 0.19 µM to 0.33 µM (Ki’s = 0.33 µM, Ki = 0.19 µM, Ki = 0.23 µM,
respectively). Compound JPC-108 is the first analog that possessed the combination of
three different moieties in the two phenyl rings. All compounds in this subseries
displayed similar potencies in the functional vesicular [3H]DA uptake assay comparable
to lobelane.
The next subseries of compounds possessed 3,5-difluoro substituents in the
phenyl ring of the phenyethyl linker attached to the C4 position of the piperidine ring,
and displayed similar trends. Four analogs in this group of six compounds had stronger
affinity than lobelane for the TBZ site on VMAT2, with the other comparable to
lobelane, so placing 3,5-difluoro substituents the phenyl ring attached to the linker at C4
is also beneficial to the recognition of the molecule at the binding site. Once again, the
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three moieties in the phenethyl substitutents attached at the N1 position that continue to
give the highest affinities in each subseries are 2-methoxy (JPC-111), 3-methoxy (JPC112), and 2-chloro (JPC-114), with affinities in the [3H]DTBZ binding assay ranging
from 0.25 µM to 0.66 µM (Ki’s = 0.41 µM, Ki = 0.25 µM, Ki = 0.66 µM, respectively).
Analogs JPC-111 and JPC-112 were again the most potent in the functional vesicular
[3H]DA uptake assay values of Ki = 0.034 µM, Ki = 0.028 µM, correspondingly, which is
comparable to lobelane (slightly more potent) and continues the trend.
The final compound in this group of 43 among the 1,4-substituted piperidine
analog scaffold of lobelane is JPC-068. This analog contains a 2,4,5-trimethoxy
substituent in the phenyl ring of the phenyethyl linker attached to the C4 position of the
piperidine ring, and an unsubstituted phenethyl linker attached to the N1 position.
Previously, in the 2,6-substituted piperidine series, compounds with multiple methoxy
groups present in the meta and para positions in both phenyl rings were 5-6 fold less
potent in the [3H]DTBZ binding assay, and this was postulated to be due to steric issues.
This compound had only one phenyl ring substituted with multiple methoxy substituents,
and has an affinity for the TBZ site on VMAT2 3-fold more potent than lobelane. It
appears that if steric hindrance is the issue for earlier compounds not being able to bind
as strongly, it is only on one portion of the binding site, as this compound was tolerated
quite well. Despite having a 3-fold better binding affinity at the TBZ binding site, JPC068 did not improve upon lobelane in the functional vesicular [3H]DA uptake assay, with
values comparable but not enhanced.
The next series of series of 1,4-substituted piperidine analogs was designed and
synthesized with shorter linkers between the C4 position of the piperidine ring while
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maintaining a substituted phenethyl linker on the N1 position were prepared to further
analyze the ability of the TBZ binding site on VMAT2 to recognize compounds with
shorter linkers and less degrees of freedom of rotation (one carbon shorter on the C4
attached linker. Four compounds were generated in this series and all had weaker affinity
than lobelane for the TBZ site on VMAT2, with the other comparable to lobelane, so
placing shorter linkers between the C4 position of the piperidine ring is not beneficial to
the recognition of the molecule at the binding site. The most appealing compound among
the four in the series is JPC-062, which has a 3-methoxy substituent in the phenyl ring
attached to the N1 position of the piperidine ring. Affinity at the TBZ site of VMAT2
was comparable (Ki = 1.53 µM) to lobelane, and effectiveness in the functional vesicular
[3H]DA uptake assay was comparable (Ki = 0.077 µM), but was not enhanced.
A series of 1,4-substituted piperidine analogs with shorter linkers between the N1
position of the piperidine ring while maintaining a substituted phenethyl linker on the C4
position were prepared to further analyze the ability of the TBZ binding site on VMAT2
to recognize compounds with shorter linkers and less degrees of freedom of rotation (one
carbon shorter) on the N1 attached linker. The entire series of six compounds had less
affinity for the TBZ site on VMAT2 with Ki values ranging from 6.23 µM to 44.5 µM.
One analog, JPC-153, containing a 2-methoxy substituent in the phenyl ring attached by a
one carbon linker to the N1 position of the piperidine ring did have effectiveness in the
functional vesicular [3H]DA uptake assay was comparable (Ki = 0.070 µM), but all others
were 4-6 fold less potent than lobelane. It is clear that reducing the length of the linker
between the N1 position of the piperidine ring and the phenyl ring is not beneficial, and
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has a detrimental effect on how the TBZ binding site on VMAT2 recognizes the
molecule.
Similarly, another series of 1,4-substituted piperidine analogs combined these
factors with shorter linkers between the N1 position of the piperidine ring while
maintaining a substituted phenethyl linker on the C4 position or with shorter linkers
between the C4 position of the piperidine ring while maintaining a substituted phenethyl
linker on the N1 position were prepared to further analyze the ability of the TBZ binding
site on VMAT2 to recognize compounds with shorter linkers and less degrees of freedom
of rotation (one carbon shorter) on the N1 attached linker. This series of compounds was
designed to possess a branch in the N1 alkyl linker in the form of a racemic 1phenylpropan-2-yl functionality attached to N1 of the piperidine ring. Four compounds
were generated in this series, and had similar affinities as lobelane for the TBZ site on
VMAT2 with one exception. JPC-172, containing a 4-bromo substituent on the phenyl
ring of the 1-phenylpropan-2-yl linker attached to the N1 position of the piperidine ring
displayed a Ki = 0.257 µM in the [3H]DTBZ binding assay, approximately 4-fold more
potent than lobelane. JPC-174 and JPC-175 exhibited effectiveness in the functional
vesicular [3H]DA uptake assay was comparable (Ki = 0.073 µM and Ki = 0.073 µM,
respectively) to lobelane.
The final series of compounds of 1,4-substituted piperidine analogs was designed
to increase the water solubility of the scaffold by replacing the phenyl ring on the N1
phenethyl linker with saturated heterocyclic moieties, either piperidine or morpholine and
to study what effect the introduction of a more polar moiety would have on binding
affinity at the TBZ site of VMAT2. Of the 11 compounds generated in this series, all had
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much lower affinity in the [3H]DTBZ binding assay than compounds possessing two
phenyl rings. Values in the [3H]DTBZ binding assay ranged from Ki = 6.27 µM to >100
µM. Effectiveness in the functional vesicular [3H]DA uptake assay was also greatly
diminished with Ki’s ranging from 0.36 to 6.28 µM. Clearly, attempting to increase
water solubility by replacing one of the phenyl rings with a piperidine or morpholine
moiety is not effective. The next series of compounds attempted to maintain the two
phenyl rings while increasing the water solubility characteristics of the analogs by
placing a second amino moiety inside the central saturated ring.
The series of 1,4-piperazine and 1,4-diazepane analogs were designed and
synthesized to add the second amino functionality into the central ring of the lobelane
scaffold. The addition of another polar functionality into the central ring will increase the
water solubilizing characteristics of the scaffold, which is desirable in development of
drugs with higher bioavailability than lobelane, and several series of compounds were
designed and synthesized to explore these possibilities, resulting in the generation of 21
compounds.
The first series of six compounds consisted of symmetrical 1,4-piperazine
analogs. Of these six compounds, all had affinities for the TBZ site on VMAT2 similar
to that possessed by lobelane, ranging from slightly better (Ki = 0.37 µM) to slightly
worse (6.63 µM). Considering that this series of compounds should be at least 2-3 times
as soluble in water as their piperidine counterparts, these affinities are remarkably
effective, especially when one considers the large loss of affinity found when replacing
one of the phenyl rings of the piperidine scaffold with a water solubilizing piperidine or
morpholine moiety. It was not surprising, however, that the three most potent analogs in
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both the [3H]DTBZ binding assay and the functional vesicular [3H]DA uptake assay
maintained the same trend as seen before. Analogs that possessed a 2-methoxy (JPC135), a 3-methoxy (JPC-137), or a 2-chloro (JPC-139) functionality in both of the two
phenyl rings had the strongest affinity for the TBZ site on VMAT2 with Ki’s of 1.17 µM,
1.05 µM, and 0.37 µM, respectively. In the functional vesicular [3H]DA uptake assay the
same three analogs displayed Ki’s of 0.035 µM, 0.060 µM, and 0.048 µM, respectively,
which were all quite similar to lobelane.
The second series of five compounds were asymmetrical 1,4-piperazine analogs
containing an unsubstituted phenethyl linker attached to N4 position of the piperazine
ring, and a substituted phenethyl linker attached to the N1 position of the piperazine ring.
Of these five compounds, all had affinities for the TBZ site on VMAT2 similar to that
possessed by lobelane, ranging from the same (Ki = 1.07 µM) to slightly worse (4.63
µM). As is nearly standard by this point, the three compounds that have the best affinity
for the TBZ site on VMAT2 were those that that possessed a 2-methoxy (JPC-141), a 3methoxy (JPC-142), or a 2-chloro (JPC-144) functionality in the phenyl ring attached to
the N1 position of the piperazine ring, Ki’s of 1.07 µM, 1.30 µM, and 1.59 µM,
respectively. In the functional vesicular [3H]DA uptake assay the same three analogs
displayed Ki’s of 0.037 µM, 0.098 µM, and 0.063 µM, respectively, which were all quite
similar to lobelane.
After the series of asymmetrical 1,4-piperazine analogs were synthesized, further
modification of the central ring of the 1,4-scaffold was desired. Enlarging the central sixmembered piperazine ring to a seven-membered 1,4-diazepane ring was explored, with
six compounds designed and synthesized to explore this series. All analogs in this series
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displayed affinities for the TBZ site on VMAT2 similar to that possessed by lobelane,
ranging from the same (Ki = 0.93 µM) to slightly worse (5.05 µM). These compounds
did not fare as well as the 1,4-piperazine analogs in the functional vesicular [3H]DA
uptake assay, ranging from 2-5 fold less potent than lobelane.
The next small series of compounds, JPC-132 and JPC-133, contain two amine
moieties central to the molecule and were designed and synthesized to explore the idea
that two piperidine rings linked by ethylene chain may be tolerated by the TBZ site on
VMAT2. While JPC-132 displayed an affinity in the [3H]DTBZ binding assay slightly
better (Ki = 0.82 µM) than lobelane, it had less potency in the functional vesicular
[3H]DA uptake assay (Ki = 0.26 µM), or 5-fold less potent than lobelane.
The final series of compounds in the library consisted of two compounds were
designed and synthesized to evaluate analogs that possess a branch in the N1 alkyl linker
in the form of a racemic 1-phenylpropan-2-yl functionality attached to N1 of the
piperazine ring, while maintaining the phenethyl linker on N4 of the piperazine ring.
This series also explored the addition of a 4-bromo moiety in the phenyl ring attached to
the N1 position of the piperazine ring. This mirrored a similar series generated in the
piperidine scaffold, and the results in the assays were of a similar nature. JPC-176 had
10-fold less affinity for the TBZ site on VMAT2 than lobelane, and JPC-173, which
contained the 4-bromo substituent, was 5-fold less potent than lobelane.
Of the 107 compounds generated in the library, many showed improved affinity
in the [3H]DTBZ binding and the functional vesicular [3H]DA uptake assay when
compared to the first and second generation analogs that were prepared previously. The
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compounds selected for further evaluation are: JPC-077, JPC-078, JPC-089, JPC-141,
JPC-142, and JPC-143, and these improved compounds were chosen to undergo further
in vivo evaluation in rat models of behavior. These experiments are still ongoing, but
preliminary results look quite promising. JPC-077 has displayed the ability to inhibit
METH self-administration in the rat model as well as the ability to prevent METH
induced locomotor response in rats. JPC-078 also shows potential, as it has shown the
ability to prevent METH induced locomotor response in rats. JPC-141, a 1,4-piperazine
analog, has also displayed the capability to prevent METH induced locomotor response
in the rat model. The other three compounds are still in the process of evaluation.

Copyright © John P. Culver 2015
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Chapter 6
Ligand based pharmacophore modeling of the VMAT2 binding site

6.1 Background of computational modeling
Modern SAR efforts require the use of computational resources and programs that
use mathematical models of the drug molecule and target. This part of the drug discovery
pathway has become more and more complex as it evolves. Entire research groups are
dedicated to the “virtual synthesis” and “virtual screening” of molecules and drug targets.
These virtual efforts go hand in hand with traditional drug discovery procedures, and are
mainly used to support the continuing synthetic efforts to make more and more efficient
drug candidates. By taking advantage of the information gleaned from prior synthetic
efforts and biological experimentation, computational SAR can uncover the required
molecular features of the lead compounds from past generations of synthesis and provide
direction and novel ideas for structural chemical modification.
The computational methods for SAR differ depending on the circumstances and
information at hand. The different methods are described as: 1.) development of ligandreceptor models (also known as docking models), and these are used specifically for
situations where the receptor or biomolecular target structure has been previously
identified through methods such as x-ray crystallography, or 2.) development of a
pharmacophore-based model, also known as a ligand based model, which consists of
SAR modeling based on certain molecular features of the ligand molecules from the
constructed compound library; these methods used in situations where little information
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is known about the drug target, or when the critical molecular structural features of the
target are not well defined, as in this case with VMAT2.
6.2 Model Methods of automatic pharmacophore modeling of VMAT2 inhibitors.
Computational pharmacophore modeling has emerged as one of the major
computational techniques in pharmaceutical drug design, especially in the absence of a
protein 3D structure. For instance, when active compounds are available, chemists use
the geometric and electronic structures of the chemical compounds to naturally define a
chemical model of how a particular ligand or a series of structurally related ligands
interact with the receptor, and/or to deduce structure-activity relationships.
In the current study, pharmacophore modeling has been performed using the small
molecule ligands that have been discovered to bind to the TBZ site on VMAT2 by
conventional screening procedures. The discovered compounds demonstrated what can
be considered strong inhibitory activity in the [3H]DTBZ binding assay and the functional
vesicular [3H]DA uptake assay. In order to understand the specific chemical features that
are responsible for the activity of the compounds, the elucidation of the pharmacophore
has been performed.
MOE software was utilized extensively for the pharmacophore modeling. Two
kinds of pharmacophore modeling can be performed, 1.) manual pharmacophore
generation, and 2.) automatic pharmacophore generation. Briefly, manual pharmacophore
modeling can be performed by using each of the most active compounds from the current
series of compounds. Automatic pharmacophore generation can be performed when one
or more active compounds with a similar binding mode at the targeted binding site are
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available in the library of compounds. Since the compounds reported in this study are all
analogs of similar structural scaffolds, and since the binding modes of the compounds
cannot be generated due to the absence of a defined binding site structure, for now, we
must assume that all the inhibitors bind in a similar binding mode.
The three major steps involved in automatic pharmacophore modeling are:
1. Conformation generation
2. Alignment
3. Pharmacophore query elucidation.

Prior to running the pharmacophore application in MOE, all the compounds have
to be imported into the MOE database along with the [3H]DTBZ binding and the
functional vesicular [3H]DA uptake assay data. Briefly, the input database must contain
in one field molecules either in 2D or 3D format. The pharmacophore elucidator in MOE
only works with 3D conformations, and if the 2D structures are provided, MOE can
automatically convert the 2D structures to 3D conformations, or the conformations of the
compounds can be generated with any other method or software and imported into the
MOE database. For the current work, the internal MOE conformation generator was used
on the library of compounds (which were all protonated and charged at biological pH)
utilizing a Stochastic search. In general, it is best to use the same method for generating
conformations as is used for preparing the 3D search databases. The generated
conformations per compound were stored in the molecule field of the database. In the
second field, the activity data (biological assay data) is provided. If no limit of activity is
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specified, the MOE elucidator will assume all the compounds to be active, therefore, in
the current study, all the compounds with affinities in the [3H]DTBZ binding assay that
were less than 1.0 µM were treated as active and all compounds with affinities > 1.0 µM
were treated as inactive compounds. After the input database is prepared, the next step is
to specify a scheme. In MOE the modeling of H-donor and H-acceptor features depends
on the selected pharmacophore scheme. There are six schemes supplied with MOE: PCH,
PCHD, PCH_All, PPCH, PPCH_All, and CHD. The default CHD scheme was selected
for use in the current work. Finally, before generation of the pharmacophore queries,
molecular geometric alignments from the collection of input conformations was done by
considering all possible discrete geometries and all possible combinations of feature
query expressions. The default CHD contains a feature limit of 5, which means the
pharmacophore with a maximum of 5 features are generated, and this is due to the
preliminary nature of this study. Pharmacophore queries with higher numbers of features
to be matched predictably tend to match fewer molecules outside the input database,
which would be less useful in this early process.

6.3 Results of automatic pharmacophore modeling of VMAT2 inhibitors.
A total of 177 different pharmacophore models (queries) were generated by using
the CHD scheme and the above mentioned method. The best pharmacophore is displayed
and discussed further. The pharmacophore query resulting from the MOE pharmacophore
elucidator is shown in Figure 6.1 and Figure 6.2. The statistics of the pharmacophore
model are shown in Table 6.1, with descriptions below to describe the different
categorical results. The model was developed based on the input that all compounds with
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affinities for the TBZ site on VMAT2 >1 µM are treated as inactive and all others as
active compounds.

Query

Cover

Overlap

Accuracy

acc1

No. of features

HHH+

10

7.3009

1.0

1.0

4

Table 6.1 Statistics of best pharmacophore model query obtained by using the MOE
pharmacophore elucidator (automatic pharmacophore modeling).
Cover: The number of active molecules that match the query.
Overlap: The score of the alignment. This number varies between [0,n] where n is the
number of active molecules, therefore the larger this number, the better the alignments.
Accuracy: The accuracy of the query in separating actives and inactives. A value of 1.0
(the value actually obtained) signifies that the query matched all active compounds, and
did not match any inactive compounds. The accuracy is measured on clustered
conformations.
acc1: The accuracy of the query in matching the active compounds. The value of 1.0 (the
value actually obtained) signifies that all actives were matched, while a value 0.0 would
mean that none were matched. The accuracy is measured on clustered conformations.

The best pharmacophore generated by this method is shown in Figure 6.1. The
quality of the pharmacophore query or model depends on the hit rate, which in other
words can be defined as number of active compounds (true positives) that were captured
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leaving behind the inactive compounds. The pharmacophore model shown in Figure 6.1
retrieves the known active compounds with an accuracy of 100.0% (see Table 6.1).

Figure 6.1 The most reliable pharmacophore model generated by automatic
pharmacophore model generation in the MOE pharmacophore elucidator. The spheres in
green represent the hydrophobic features and the blue sphere represents the central cation
feature.
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Figure 6.2 The most reliable pharmacophore model generated by automatic
pharmacophore model generation in the MOE pharmacophore elucidator with all active
compounds aligned in their best fit to the pharmacophore model.
The pharmacophore query produced by the MOE pharmacophore elucidator
contains three hydrophobic features and a cation feature. The query has an overlap of 7.3
and accuracy of 100% which means the query could match all the 10 active compounds
which were used as input. When we run the query against the 66 compound input
database with active compounds, this query was able to retrieve 61 out of 66 compounds
of input database, which suggests that the query describes the chemical features with
huge significance.
In addition to running the pharmacophore model against the known active
compounds, the query was used to run on an external database of 1000 random
compounds from NCI, which resulted in 74 hits being retrieved from the NCI database.
In summary, the pharmacophore query resulting from the MOE pharmacophore
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elucidator suggests that hydrophobic features in the middle of the compounds and two
hydrophobic features one each on either side of the central hydrophobic feature and one
cation feature to the bottom of the central hydrophobic feature are necessary for the
biological activity of the compounds. These observations can be used in further designing
and synthesizing the similar analogs to the current series of compounds.

6.4 Model Methods of manual pharmacophore modeling of VMAT2 inhibitors.
In the manual pharmacophore modeling, two compounds with best inhibitory
activity were selected. The conformations of all the compounds were generated in the
same way as conformations generated by automatic pharmacophore modeling (stochastic
method). The conformations with lowest energy were finally utilized as input for the
pharmacophore modeling. Manual pharmacophore modeling was performed with each
compound separately, therefore, two pharmacophore queries were generated.
In the first step, JPC-077 has been manually imported into the MOE environment
and used to create the pharmacophore. MOE’s pharmacophore query editor detected the
pharmacophore features automatically and quickly generated four features which best
describe the compound for biological activity. One hydrophobic and one cation and
donor feature were created in the center of the compound (JPC-077) and two
hydrophobic but slightly anionic features, one at either end of the compound (due to the
aromatic methoxy functionalities). The compound JPC-077 with its manually created
pharmacophoric query is shown in Figure 6.3. Likewise, the pharmacophore query of an
active compound from the library, namely lobelane was created and shown in Figures
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6.4. Finally, a manual pharmacophore model of lobeline was completed and is shown in
Figure 6.5. Briefly, the pharmacophore models for lobeline and cis- contain three
hydrophobic features and a cation and donor feature at different locations in the structure
of the compounds and with different speherical volume.

Figure 6.3 Pharmacophoric features derived manually using compound JPC-077. The
four pharmacophore features are displayed in red (anionic/acceptor), green
(hydrophobic), and purple (cationic/donor) colored spheres.

276

Figure 6.4 Pharmacophoric features derived manually using lobelane. The four
pharmacophore features are displayed in green (hydrophobic) and purple (cationic/donor)
colored spheres.
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Figure 6.5 Pharmacophoric features derived manually using the compound lobeline. The
four pharmacophore features are displayed in yellow (hydrophobic), green (hydrophobic)
and purple (cationic/donor) colored spheres.

6.5 Results of manual pharmacophore modeling of VMAT2 inhibitors.
All the three above mentioned queries differs from each other in several
significant ways. Only the hydrophobic feature at the center of molecule and the cationic
and donor features are features that are considered common among all the queries, and
even then, each one differs by the spherical volume. Also, the anionic features of JPC077 were not included in the other two queries; instead, hydrophobic features on either
side of the central hydrophobic feature are used. All four of the pharmacophore queries
were able to retrieve approximately 50 compounds (varying by only one or two hits) of
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the 66 active compounds of the current library. The pharmacophore queries suggest that
the presence of a hydrophobic feature in the center of the molecule, a cationic and donor
feature, and another two hydrophobic features on either side of the central hydrophobic
feature, and possibly an anionic feature at the terminal aromatic methoxy group
containing phenyl rings, are responsible for the biological activity of the compounds.
In perspective, following the initial pharmacophore modeling, much more could
be done in the future. Possible next steps in molecular modeling to include building a
homology model of VMAT2, which is as close to an actual crystal structure as possible
with this trans-membrane transporter (Vardy et al., 2004). This step would be followed
by docking and molecular dynamics simulation to provide insights into the interaction
between the inhibitors and the protein structure, and finally, this would be followed by
virtual screening, using the pharmacophore query and docking for discovering possible
new inhibitors.

Copyright © John P. Culver 2015
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Chapter 7
Review and Discussion

Psychostimulant abuse has become a severe worldwide problem that has shown
no sign of lessening the hold that it has on much of mainstream society. There exists an
ongoing need for new therapies and medications that can provide efficacy in the
treatment of psychostimulant abuse. METH especially is identified as an addictive and
increasingly popular psychostimulant drug, and there are no effective, Food and Drug
Administration (FDA) approved pharmacological treatments available for the addicts
who wish to quit. This project has been designed to address the needs of those people
who currently abuse psychostimulants such as METH, and who need an effective therapy
that will help them break away from their addiction. The design and synthesis of a library
of analogs similar to lobelane has been completed, with structural alterations designed
into the molecules to make them more potent at the target protein: VMAT2. The
overriding goal of this study was to provide one or multiple potential drug candidates that
could ultimately become a treatment for psychostimulant abuse for that part of the
population that currently abuses psychostimulants but wishes to quit.
Three distinct scaffolds were designed and synthesized. The first scaffold was
based directly on lobelane. Further optimization and study was needed to ascertain if
addition of different aromatic substituents into the phenyl rings would enhance binding
affinity at VMAT2. Addition of two aromatic substituents into each of the two phenyl
rings was also explored in order to determine if multiple substituents could also improve
affinity. Eighteen compounds in this series were designed and synthesized. JPC-011 was
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found to be the most potent compound within this series in the [3H]DTBZ binding assay
(was 4-fold more potent than lobelane), but was disappointing in potency in the
functional vesicular [3H]DA uptake assay, which better predicts how it will effect METH
self-administration in the rat model and correspondingly the human model. In the
second scaffold, further optimization and study was needed to ascertain if the addition of
different aromatic substituents into the phenyl rings of the 1,4-substituted lobelane
scaffold would enhance binding affinity at VMAT2. Addition of multiple aromatic
substituents into the phenyl rings was also explored. 43 compounds in this series were
designed and synthesized, and of those 43 analogs, 32 had improved affinity for the TBZ
site on VMAT2 when compared to lobelane, with some compounds exhibiting as much
as 5-fold improvement compared to lobelane and 13 compounds exhibited significant
improvement in the functional vesicular [3H]DA uptake assay compared to lobelane, with
JPC-077 displaying a 5-fold enhancement over lobelane.
The third scaffold was designed to increase the water-solubility of the analogs
while maintaining, if not improving the compound’s affinity and function at VMAT2.
The addition of another N-atom into the central heterocyclic piperidine ring was
predicted to improve the water solubilizing characteristics of the scaffold, which is
desirable property in the development of drugs that have a higher bioavailability than
lobelane, and several series of compounds were designed and synthesized to explore
these possibilities, resulting in the generation of 21 novel compounds. Of these 21
analogs, seven displayed affinities for the TBZ site on VMAT2 that either maintained the
affinity exhibited by lobelane, or improved it by as much as 3-fold (JPC-139). Six
compounds had comparable potency in the functional vesicular [3H]DA uptake assay
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when compared to lobelane. Considering that these analogs have at least 2-3 fold
improved water solubility compared to lobelane and other related analogs in the
piperidine series of compounds, these results are encouraging, and may lead to clinical
candidates with greater oral bioavailability.
In summary, of the 107 compounds generated in the current library, many showed
improved affinity in both the [3H]DTBZ binding assay, and the functional vesicular
[3H]DA uptake assay, when compared to the first and second generation analogs that
were prepared earlier. The compounds selected for further evaluation are: JPC-077, JPC078, JPC-089, JPC-141, JPC-142, and JPC-143, and these improved compounds were
chosen to undergo further in vivo evaluation in rat models of behavior. These
experiments are still ongoing, but preliminary results look quite promising. JPC-077 has
displayed the ability to inhibit METH self-administration in a rat model of METH
addiction, as well as the ability to prevent METH- induced locomotor responses in rats.
JPC-078 also shows potential as a clinical candidate, since it has been shown to prevent
METH-induced locomotor responses in rats. JPC-141, a 1,4-piperazine analog, is also
able to prevent METH-induced locomotor responses in the rat model. The other three
JPC compounds are still in the process of evaluation.
A preliminary ligand-based pharmacophore model has been generated utilizing
the SAR data accumulated from the library of compounds and their evaluation in the
binding and functional assays. It proved to be very accurate in retrieval of the active
compounds from the library.
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This study involved three central hypotheses. One hypothesis of this work was that
structural analogs of lobelane that maintain the 2,6-disubstitued piperidine scaffold, but
incorporated preferred aromatic substituents into the two phenyl rings present in the
lobelane structure, can improve binding affinity at the Vesicular Monoamine Transporter2 (VMAT2), and can also improve functional inhibition of VMAT2. A second hypothesis
of this work was that structural analogs of lobelane in which the phenethyl moieties
present in the C2 and C6 positions of the piperidine ring can be structurally modified to
afford analogs in which these moieties are located on the N1 and C4 positions of the
piperidine ring, and these 1,4-disubstuted analogs have increased affinity for VMAT2
and increased potency as functional inhibitors of VMAT2. A third hypothesis of this
work was that introduction of an additional N-atom into the piperidine ring of the
lobelane scaffold will increase water-solubility while maintaining similar binding affinity
and functional inhibition potency for VMAT2 when compared to lobelane.
As a summary of the results pertaining to the three initial hypotheses, the first
hypothesis was valid in part: examples are present where structural analogs of lobelane
that maintain the 2,6-disubstitued piperidine scaffold, but incorporated preferred aromatic
substituents into the two phenyl rings present in the lobelane structure improved binding
affinity at the Vesicular Monoamine Transporter-2 (VMAT2), but were not shown to also
improve functional inhibition of VMAT2. The second and third hypotheses were shown
to be valid, in that several examples from each series of compounds in the study
displayed both greater affinity for the TBZ site on VMAT2 and greater potency as
functional inhibitors at VMAT2 when compared to lobelane.
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The data presented in this work have further demonstrated that VMAT2 is a valid
target for the treatment of methamphetamine abuse, and should continue to strengthen
that argument as the data from the whole animal model studies are revealed. With in-vivo
studies currently underway and initial results for several compounds generated within this
library looking promising, the primary three hypotheses of the study were addressed
through well designed and executed experiments and initiative. The experiments detailed
here have successfully expanded our knowledge and understanding of the properties of
these novel compounds, as they relate to their binding and functional inhibition of
VMAT2, and several JPC compounds are currently being evaluated as potential
candidates for the treatment of METH abuse. It is highly possible that several of the
compounds were presented in this manuscript and were designed and synthesized by this
author will go into human clinical trials for the treatment of methamphetamine abuse, and
if one proves effective in the human, this work will have not only verified that VMAT2 is
an excellent target for the treatment of methamphetamine abuse, but will also have made
available a pharmacological treatment for the addicts who wish to quit.

Copyright © John P. Culver 2015
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